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ABSTRACT
The number of people with dementia due to Alzheimer’s disease (AD) is
increasing worldwide. Although AD pathology begins well before clinical
symptoms are apparent, identifying individuals at risk of developing AD to
provide early interventions is still a challenge. Brain-derived neurotrophic factor
(BDNF) is produced by neurons and glial cells and has complex interactions with
AD pathology. BDNF also crosses the blood-brain barrier and can be measured
in serum or plasma. In this dissertation, I investigated the biomarker potential of
serum BDNF for AD using post mortem human samples, an aged rat model of
cognitive impairment, and blood samples from cognitively healthy older adults. In
the first part of my dissertation, I investigated the relationship between CSF,
serum, and brain tissue levels of BDNF and AD-related pathology using post
mortem human brain tissue samples. In these studies, I demonstrated, for the
first time, that serum proBDNF levels reflect brain BDNF levels and that low brain
BDNF levels are associated with increased accumulation of pTau and amyloid in
the hippocampus. In the next part of my dissertation, I investigated whether
serum BDNF levels were altered in an aged rat model exposed to a combination
of the locus coeruleus selective neurotoxin and inflammation caused by
lipopolysaccharides (LPS). I found that serum BDNF levels have an inverse
relationship with inflammatory markers, and BDNF levels increase at two weeks
Page xiii

post LPS injection, suggesting a compensatory increase. Finally, in the last part
of my dissertation, I investigated whether serum BDNF levels can predict early
changes in neuropsychological performance and neuroimaging measures
associated with AD in cognitively healthy older adults. In this cohort of older
adults, we found significant differences between women and men. Women had
higher serum BDNF levels than men, the changes of neuropsychological
performance over time were different in women and men, and higher baseline
BDNF levels were associated with greater declines in hippocampal volume and
limbic FA in men but not in women. Overall, results from this dissertation indicate
that serum BDNF levels correlate with brain BDNF levels, are reduced by
neurodegeneration and inflammation, and may reflect clinically-relevant changes
in older adults and, therefore, should be considered for inclusion in routine blood
workup in a clinical setting.
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CHAPTER 1. GENERAL INTRODUCTION

CHAPTER 1.

GENERAL INTRODUCTION

Page 1

1.1 Dementia: An emerging health crisis
The older adult population, defined as those aged 65 and over, is growing
at an unprecedented rate in the western world, and the United States (U.S.)
Census Bureau has projected that the world older adult population will double to
a total of 1.6 billion between 2025 and 2050 (He et al. 2016). As the ratio of older
adults to younger adults increase, the health care system will need to adapt to
address the unique health challenges the elderly population face, including
dementia.
Dementia is a syndrome characterized by a significant and progressive
decline in two or more modalities of cognition (including aphasia, inability to plan
and initiate complex behavior, attention, executive function, language, learning
and memory, perceptual-motor, or social cognition) that interferes with daily
function and independence. Dementia is associated with several diseases
including Alzheimer’s disease (AD), Dementia with Lewy bodies (LBD),
Frontotemporal dementia (FTD), Huntington’s disease (HD), Parkinson’s disease
(PD), and Vascular dementia (VaD) (Association 2018). In low- and middleincome countries, dementia is the leading cause of disability and dependence in
older adults (Prince et al. 2015). Total Medicaid cost for care related to dementia
is projected to exceed $47 billion dollars in 2018 (Association 2018). Alzheimer’s
disease accounts for approximately 60 to 80 percent of dementia cases, and the
number of older adults aged 65 years or older with AD in the United States is
expected to more than double by 2050 and exceed 13.8 million people
(Association 2018).
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1.2 Biological Causes of Alzheimer’s disease
AD was described more than a century ago by Dr. Alois Alzheimer in his
accounts of a 51-year-old woman, Auguste D, who showed progressive
impairment in comprehension and memory as well as aphasia, disorientation,
paranoia, and psychosocial impairment already in her 50s (Alzheimer 1907,
Maurer et al. 1997). After the death of Auguste D, Dr. Alzheimer noted in
Auguste D’s brain that “in the centre of an otherwise almost normal cell there
stands out one or several fibrils due to their characteristic thickness and peculiar
impregnability” and that “[n]umerous small miliary foci are found in the superior
layers” (Maurer et al. 1997). The latter is now known as plaques and the former
as neurofibrillary tangles (NFT). In addition to plaques and NFTs, hippocampal
atrophy, cortical thinning, and ventricle enlargement were also noted in AD brains
(Figure 1-1). The eponym Alzheimer was introduced by German psychiatrist Dr.
Emil Kraepelin several years later after prominent medical scientists made similar
reports on other patients. Currently, the only way to definitively diagnosis AD is
through post mortem analysis of the brain, even though evidence indicates that
the underlying pathology of AD begins decades before clinical symptoms
manifest themselves (Dubois et al. 2007, Jack and Holtzman 2013, Jack et al.
2013). A probable AD diagnosis is clinically determined for patients who show
impairment in at least two cognitive domains (learning and memory, reasoning
and judgment, visuospatial, language, or behavior and comportment) with a
decline in functioning overtime that disrupts their activities of daily living
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(McKhann et al. 2011). Additionally, these clinical features must have an
insidious onset, have a clear-cut history of worsening, and not be explained by
vitamin B12 deficiency, delirium, medications or another major psychiatric
disorder. The clinical diagnosis of probable AD is confirmed through
histopathologic examination of amyloid plaques and NFT post mortem (Hyman et
al. 2012, Montine et al. 2012). The etiology of AD is highly debated, and the
following is a review of several of the prevailing biological mechanisms proposed.

1.2.1 Amyloid cascade hypothesis
The primary components of AD plaques are neurotoxic amyloid β (Aβ)
peptides. These Aβ peptides are created through sequential cleavage of the
amyloid precursor protein (APP) by β-secretase and γ-secretase (Figure 1-1D)
and comprise of 40-42 amino acids (amyloidogenic pathway). The 42 amino acid
form of Aβ (Aβ42) is considered to be the more toxic form of Aβ when compared
with the 40 amino acid form (Aβ40) due to its higher propensity to oligomerize,
form fibrils, and resist degradation (Walsh and Selkoe 2004, Baranello et al.
2015). Alternatively, APP can be cleaved by α-secretase and γ-secretase to
produce a smaller fragment named P3 (non-amyloidogenic pathway) which does
not oligomerize or have toxic properties (Dulin et al. 2008, Han et al. 2011). The
compartmentalization of these processing events is critical in APP regulation,
and, while α-secretase cleaving of APP occurs either in the secretory pathway or
at the cell surface, β-secretase cleaving of APP occurs in endocytic vesicles at
an optimum acid pH (Baranello et al. 2015). Aβ plaques are proposed by Thal et
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al. (2002) to be deposited throughout the brain in five phases: 1st in the
neocortex, 2nd in allocortical brain regions, 3rd in the diencephalic nuclei, striatum,
and basal forebrain, 4th in the brainstem, and 5th in the cerebellum.
The APP gene resides on chromosome 21, and the risk to develop the
clinical and histopathological features of AD are increased in those who have
trisomy 21 (Down syndrome; Egensperger et al. 1999, Head et al. 2016). The
population with DS develops AD with near complete penetrance in their 4th or 5th
decade. Genetic mutations of APP, presenilin 1 (PSEN1), or presenilin 2
(PSEN1) genes are associated with increased production of Aβ plaques and the
development of early-onset AD (EOAD), which is defined as AD where
symptoms begins before the patient is 65 years old (Bekris et al. 2010). These
mutations are autosomal dominant and account for fewer than 10% of all AD
cases. The majority of AD cases are considered to be late-onset AD (LOAD) and
occur in adults who are 65 years old or older. Although no causative gene is
associated with LOAD, older adults with the ε4 allele of the apolipoprotein E
(APOE) gene are more likely to develop sporadic LOAD (Bekris et al. 2010). In
mouse models that express human apoE protein, researchers found that apoE
protein isoforms do not alter APP processing or increase Aβ synthesis; instead,
the APOE genotype differentially modulates clearance. The ε4 allele is
associated with lower Aβ clearance when compared with ε3 and ε2 (Castellano
et al. 2011).
These genetic associations between Aβ formation and AD largely support
the amyloid cascade hypothesis which asserts that Aβ production and
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accumulation is the critical step that initiates a cascade characterized by
activated microglia and astrocytes, NFT formation, damaged neurons, and
ultimately dementia and death (Karran et al. 2011). Accordingly, several
therapeutic agents such as inhibitors targeting β- and γ-secretase or antibodies
targeting Aβ were developed to either impede Aβ production or facilitate Aβ
clearance (Baranello et al. 2015). Unfortunately, several Aβ-targeted Phase III
clinical trials have been discontinued due to adverse outcomes or poor efficacy
(Karran et al. 2011, Hung and Fu 2017). One of the challenges of testing AD
drugs is identifying potential candidates for therapy early enough in the disease
course to maximize therapeutic benefit (Sperling et al. 2011).

1.2.2 The tau hypothesis
Intracellular

neurofibrillary

tangles

(NFTs)

are

composed

of

hyperphosphorylated, microtubule-associated protein tau (Grundke-Iqbal 1986).
Microtubules are a critical component of the neuronal cytoskeleton that regulates
transport along the axon, dendrites, and spines. The tau protein has six isoforms
with varying repeats and lengths (Buee et al. 2000). The hyperphosphorylation of
tau by kinases causes the tau protein to disassociate from the microtubule which
destabilizes the microtubule and interferes with the neuron’s ability to transport
material between the cell body and dendrites (Billingsley and Kincaid 1997).
These free-floating hyperphosphorylated tau aggregate to form insoluble paired
helical fragments (PHFs). Paired helical fragments then self-assemble to form
intracellular NFT inclusions. Both the formation of intracellular NFT inclusions
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and malfunctioning microtubules ultimately cause the neuron to die and leave
behind an extracellular NFT, or a so-called ghost tangle (Augustinack et al. 2001,
Andorfer et al. 2003, Ballatore et al. 2007). Neurofibrillary tangle deposits in the
brain have been shown to sequentially spread from the transentorhinal cortex in
early stages to the isocortex in late stages (Braak and Braak 1991).
The notion that dysfunction of tau is a primary event in AD is highly
debated but is supported by the finding that NFT burden better correlates with
cognitive decline than amyloid burden (Nelson et al. 2012) and by the finding of
NFTs in patients with mild dementia without plaques (Crary et al. 2014). In
addition, abnormal tau can act as a “seed,” be transferred to healthy cells, and
can promote further abnormal tau formation and aggregation (Lewis and Dickson
2016), suggesting a prion-like propagation mechanism for spreading AD
pathology throughout the brain. Alternatively, AD cases with NFT and without
amyloid plaque formation, so-called “tangle-prominent AD,” have been proposed
to be a distinct pathological category by themselves with a potentially different
etiology than AD (Crary et al. 2014, Crary 2016).
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Figure 1-1. Alzheimer’s disease pathology. Cortical thinning, enlarged
ventricles, deeper sulci, and hippocampal atrophy are apparent in the AD brain
compared to a normal brain (A). Histopathological examination of AD brains
reveals numerous plaques (Amylo-Glo; B) and tangles (AT8; C) in the
hippocampus. Nuclei were stained for using EtBr or DAPI. Plaques are made up
of amyloid-beta (Aβ) protein which is produced by the sequential cleavage of the
amyloid precursor protein (APP) by β-secretase and γ-secretase (D).
Alternatively, APP can be sequentially cleaved by α-secretase and γ-secretase to
form P3. Tangles are made up of tau proteins which disassociate from and
destabilize microtubules when hyperphosphorylated (E).
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1.2.3 Inflammation hypothesis
Alzheimer’s disease has been shown to be strongly associated with
chronic inflammation characterized by microglia proliferation and increased
production of proinflammatory cytokines in the periphery and brain (Franceschi et
al. 2006, Holmes 2013, Amor et al. 2014, Heneka et al. 2015, Heppner et al.
2015). In in vitro models of AD, both plaques and NFTs are shown to activate
microglia which in turn release proinflammatory cytokines and can cause cell
death and propagate plaque and tangle pathology (Combs et al. 2001, Sondag et
al. 2009, Morales et al. 2013). In patients with dementia, in vivo positron
emission tomography (PET) have shown increased microglial activation (Cagnin
et al. 2001), and post mortem studies on AD brains have shown increased levels
of proinflammatory cytokines compared to controls (Griffin et al. 1989, Morimoto
et al. 2011). Furthermore, in mice, Chen et al. (2016) showed that NFTs
stimulate microglia phagocytic activity to promote the clearance of plaques.
These and other results suggest that on the one hand, microglia proliferation
facilitates the clearance of plaques through phagocytosis and may instead help
ameliorate AD pathology (Lai and McLaurin 2012, Heneka et al. 2015). On the
other hand, the unregulated release of proinflammatory cytokines from microglia
without a proper resolution can facilitate neurodegeneration and cognitive decline
(Wang et al. 2015).
Neuroinflammation was traditionally viewed to only occur at the late
stages of AD; however, several clinical and epidemiological studies suggested
that pro-inflammatory cytokines can increase the susceptibility to cognitive
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impairment in older adults (Perry 2010, Simen et al. 2011, Holmes 2013), and
experimental studies in mice and rats from our group and others have suggested
that immune challenges can trigger and even drive development of AD-like
pathophysiology (Krstic et al. 2012, Bharani et al. 2017). Interestingly, a post
mortem study on patients without a clinical history of dementia but with sufficient
plaques and NFTs to qualify for an AD diagnosis (a.k.a. High Pathology Controls
or HPC) shown that measures of inflammation (i.e., C5b-9 and LN3
immunoreactivity) were significantly reduced in HPC compared to AD cases and
that HPC inflammatory status was similar to normal control cases (Lue et al.
1996). These results have fueled the hypothesis that the immune process plays
an important role in AD pathogenesis and that interventions that modulate the
immune system are crucial to prevent or arrest the progression of AD pathology
(McGeer and McGeer 2007, Zotova et al. 2010).

1.2.4 Cholinergic hypothesis
Degeneration of the basal forebrain cholinergic neurons and the
subsequent damage to cholinergic neurotransmission was one of the earliest
theories of AD (Perry et al. 1977, Bartus et al. 1982, Whitehouse et al. 1982,
Francis et al. 1999, Mufson et al. 2008, Ferreira-Vieira et al. 2016). This theory
was supported by early post mortem studies which found reductions in the
neurotransmitter acetylcholine (Bowen and Davison 1980), reductions in the
major enzyme responsible for the synthesis of acetylcholine - choline
acetyltransferase (Perry et al. 1977, Sims et al. 1983), reductions in uptake of the
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acetylcholine precursor protein - choline (Rylett et al. 1983), and loss of basal
forebrain cholinergic neurons in the nucleus basalis of Meynert (Davies and
Maloney 1976, Whitehouse et al. 1982, Mufson et al. 2008) in AD brains
compared to controls. The cholinergic hypothesis for AD suggests that
degeneration of basal forebrain cholinergic neurons contributes to development
and spread of AD pathology as well as the memory and attention deficits
exhibited by AD patients (Whitehouse et al. 1982, Muir et al. 1992, Rogers and
Kesner 2004, Ferreira-Vieira et al. 2016). Currently, three US Food and Drug
Administration (FDA) approved drugs for AD are cholinesterase inhibitors
(donepezil, galantamine, rivastigmine). Cholinesterase inhibitors effectively
increase access to acetylcholine in the synaptic cleft by inhibiting the enzyme
that degrades acetylcholine. Although these drugs do not stop the progression of
AD, they do ameliorate some cognitive symptoms, enhance quality of life,
diminish caregiver burden, and delay alterations in ADL (Mufson et al. 2008,
Raina 2008, Sun et al. 2008, Howard et al. 2012, Hager et al. 2014, FerreiraVieira et al. 2016). There are still many research groups who focus on the
cholinergic hypothesis, and cholinergic cell loss in AD still warrants investigation
based on the close relationship between cholinergic degeneration and memory
loss in AD.

1.2.5 Noradrenergic hypothesis
Degeneration of the nucleus locus coeruleus (LC) results in decreased
norepinephrine (NE) levels throughout the brain (Kelly et al. 2017). With age, LCPage 11

NE neurons degenerate, and to a greater extent, in the presence of AD
pathology (Zarow et al. 2003, Marien et al. 2004, Lockrow et al. 2011). The LCNE neurons project throughout the brain and spinal cord but densely innervate
the hippocampus and neocortex where NE acts on adrenergic receptors on
neurons, endothelial cells, and glia to impart potent anti-inflammatory, antioxidant, neurotrophic, and neuroprotective effects and to facilitate learning and
memory processes (Sara 2009, O'Donnell et al. 2012, Braun et al. 2014,
Uematsu et al. 2015, Kelly et al. 2017). Neurofibrillary tangle formation has been
found in the LC in early stages of AD including amnestic mild cognitive
impairment (MCI), preceding amyloid deposition (Grudzien et al. 2007, Braak and
Del Tredici 2011) as well as NFT accumulation in other brain regions.
Furthermore, lesions of the LC in mouse models of AD lead to increased
inflammation, neuronal damage, and plaque burden (Kalinin et al. 2007, Lockrow
et al. 2011). Converging evidence from animal models and clinical and preclinical
data demonstrate the importance of the LC-NE preservation to ameliorate AD
development and highlight the disease-modifying potential of pharmaceutical
modification of NE (Chalermpalanupap et al. 2013, Braun et al. 2014). Several
NE pharmacotherapies are FDA-approved to treat attention-deficit disorder,
depression, and hypotension, and investigations of these drugs on individuals
with preclinical or early clinical stages of AD are highly anticipated. The
importance of LC-NE loss for memory function and neuroinflammation will
be examined in Aim 2 of this dissertation, using an aged rat model of age-
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related cognitive impairment with LC-NE degeneration combined with the
injection of lipopolysaccharide (LPS).

1.3 Diagnosing Alzheimer’s disease
Currently, a definitive diagnosis of AD can only be achieved through a
post mortem histopathologic examination of the brain (Braak and Braak 1991,
Beach et al. 2012, Hyman et al. 2012, Jack et al. 2018, Wolk and Dickerson
2018). Clinical criteria for an ante mortem probable AD dementia diagnosis have
been established by the National Institute on Aging and the Alzheimer’s
Association (NIA-AA; McKhann et al. 2011, Wolk and Dickerson 2018). Using
data from 919 subjects from the National Alzheimer’s Coordinating Center
Uniform Data Set (NACC-UDS), Beach et al. (2012) concluded that the sensitivity
ranged from 70.9% to 87.3% and the specificity ranged from 44.3% to 70.8% for
ante mortem AD diagnosis in relation to post mortem AD diagnosis. The
Diagnostic and Statistical Manual of Mental Disorders (DSM) is also commonly
used for the ante mortem diagnosis of AD, and the DSM-IV criteria have been
shown to have similar accuracy to the NIA-AA criteria (Knopman et al. 2001).
The accuracy for the latest DSM-V criteria for dementia, now named major
neurocognitive disorder due to AD and including expanded consideration for
other cognitive domains compared to DSM-IV (Association 2013), has not been
tested yet. This room for improvement in clinical diagnostic accuracy in AD has
fueled the search for new AD biomarkers to better identify and categorize AD.
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Part of the challenge of treating AD is identifying patients early in the
disease course to maximize therapeutic potential of pharmacological intervention
(Sperling et al. 2011). Amnestic mild cognitive impairment (MCI) is a diagnosis
given to those who exhibit progressive memory impairment, but intact cognitive
and social functions to live independently without assistance (Petersen et al.
2001, Petersen et al. 2009, Albert et al. 2011). Amnestic MCI is considered to be
an early stage of AD, but a meta-analysis of 41 MCI cohort studies found that the
adjusted annual conversion rate for amnestic MCI convert to AD was 10 to 15
percent with some never converting to AD (Mitchell and Shiri-Feshki 2009).
Accordingly, several investigations into biomarkers to better predict the
conversion of MCI to AD have been undertaken. These studies have found that
the presence of APOE ε4 genotype, increased brain atrophy on magnetic
resonance imaging (MRI), and low amyloid levels and high tau levels in
cerebrospinal fluid (CSF) increase the risk of conversion from MCI to AD
(Petersen et al. 1995, Davatzikos et al. 2011, Gomar et al. 2011, van Maurik et
al. 2017). These biomarkers do not predict the conversion from MCI to AD
perfectly, but efforts to incorporate these biomarkers in a prognostic model to
support clinical decisions have been promising with the overall goal to assess the
individual risk of conversion and to intervene accordingly (van Maurik et al.
2017). In addition to predicting the conversion from MCI to AD, the major quest in
this field is to detect the mechanistic shift from healthy brain aging to
neurodegeneration (i.e., from normal control to MCI) in order to halt the disease
course before any permanent damage has occurred (Jack and Holtzman 2013,
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Jack et al. 2013, Fjell et al. 2014, Dubois et al. 2016). In Aim 3, we investigated
a blood-based biomarker in normal older adults in relation with both
neuropsychological performance and neuroimaging measures.

1.3.1 Modeling AD biomarkers
A hypothetical model of biomarker changes in AD suggests that the AD
phenotype follows a temporal sequence with abnormal changes first occurring in
Aβ regulation and then followed by tau phosphorylation (pTau), neuronal survival,
memory function, and finally clinical function (Jack and Holtzman 2013, Jack et
al. 2013). It is also suggested that AD pathology begins in one area of the brain
and progresses to other brain regions via a prion-like process (Braak and Braak
1991, Malkki 2015). In fact, current neuropathological staging is based on
progression of both NFTs and amyloid to involve progressively more brain
regions (Montine et al. 2012). Although this amyloid-first hypothesis is well
supported, to accommodate the alternative hypothesis that tau may precede
amyloid formation but is difficult to detect based on limitations of current
technologies, a detection threshold was added to the current AD disease
progression model (Figure 1-2). The amyloid-first hypothesis model best mimics
what is seen in the clinical AD population and is accurately described above this
detection threshold. Below the detection threshold, the model suggests that pTau
abnormalities may precede Aβ dysfunction, but Aβ levels increase and
accumulate faster than pTau and are detected earlier. Neurodegeneration
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ensues after Aβ and pTau pathological accumulation and subsequently leads to
memory dysfunction.
Figure 1-2
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Aβ levels
pTau levels
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Cognitively Healthy
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Figure 1-2. Temporal model of changes in AD phenotype. The vertical axis
represents severity from low to high, and the horizontal axis represents time and
progression from cognitively normal to MCI to AD. The detection threshold is
signified by a horizontal gray area and represents the limit of current technology
to detect pathophysiological changes. Above the detection threshold, biomarkers
detect dysfunction in Aβ first and then pTau, brain structure, memory function,
and finally overall health and independence (clinical function). Patients gradually
deteriorate when the elevation of AD biomarkers have reached a plateau. Below
the detection threshold, pTau is hypothesized to precede Aβ dysfunction but
accumulate slower than Aβ pathology. Adapted from Jack et al. (2013).

1.3.2 AD Research Framework
In an attempt to better incorporate biomarkers into AD research, an
initiative by the NIA-AA led to the development of a research framework to
identify AD patients for use in observational and interventional research (Jack et
al. 2018). This framework defines AD by its neuropathological hallmarks (i.e.,
accumulation of Aβ and pTau) and proposes an AT(N) biomarker system to
classify research participants by biomarkers identified in fluid or through
neuroimaging. The AT(N) biomarker system describes the biomarker presence
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(+) or absence (-) of Aβ plaque (labeled “A”), fibrillary tau (labeled “T”), and
neurodegeneration or neuronal injury (labeled “N”) in order to build eight different
AT(N) biomarker profiles to better individually categorize patients. Although this
framework was largely built with the modified amyloid cascade hypothesis in
mind, it is flexible enough to incorporate other AD hypotheses, including the tau
hypothesis and hypotheses implicating an upstream pathological process that
preceeds and causes Aβ plaque and NFT formation, such as chronic
inflammation. A major focus of my dissertation (all three aims) is to assess
the biomarker potential of brain-derived neurotrophic factor (BDNF) for AD
in the context of this framework.

1.4 Brain-derived neurotrophic factor
Neurotrophic factors support neuronal survival and function (Kazim and
Iqbal 2016) and are being actively investigated for their therapeutic potential to
mitigate AD neuropathology (Nagahara and Tuszynski 2011). The neurotrophin
family of growth factors consists of nerve growth factor (NGF), neurotrophin-4/5,
as well as BDNF (Nockher and Renz 2005). BDNF is expressed by both glial
cells and neurons in the brain, and has significant beneficial effects for both
development and maintenance of many neuronal populations (Gonzalez et al.
2016). BDNF has been shown to have a dose-dependent protective effect
against amyloid toxicity in AD mouse models (Arancibia et al. 2008), and
reduction in BDNF levels has been correlated with the accumulation of neuritic
amyloid plaques in AD human brain tissues (Lee et al. 2005) and in rat
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hippocampal cell cultures (Matrone et al. 2008). In addition, BDNF crosses the
blood-brain barrier (BBB) through a high-capacity, saturable transport system
(Poduslo and Curran 1996, Pan et al. 1998). In animal and human studies, both
blood and brain BDNF levels have been shown to be sensitive to neurological
insults (Connor et al. 1997, Murer et al. 2001, Song et al. 2015, Bharani et al.
2017), suggesting that monitoring blood BDNF levels could be useful for early
detection of neuropathological changes.

1.4.1 BDNF production and function
The BDNF gene is located on chromosome 11, and a single nucleotide
polymorphism Val66Met has been linked to the development of various
neuropsychiatric and neurodegenerative disorders (Vepsalainen et al. 2005,
Verhagen et al. 2010, Molendijk et al. 2012). Specifically, the presence of a
Val66Met allele has been associated with lower activity-dependent secretion of
BDNF, memory impairment, and abnormal hippocampal activity during memory
processing in contrast to the BDNF Val homozygote (Egan et al. 2003, Lim et al.
2016). BDNF is synthesized as a precursor pre-proBDNF protein in cortical
neurons and is anterogradely transported in dense-core vesicles to target areas
(Altar et al. 1997). Pre-proBDNF is then proteolytically cleaved to produce the 32kDa proBDNF protein. ProBDNF can subsequently be either proteolytically
cleaved intracellularly by furin or pro-convertases or extracellularly by plasmin or
metalloproteinases to produce the 14-kDa mature BDNF protein (Lessmann et al.
2003, Cunha et al. 2010). Both proBDNF and mature BDNF are stored in prePage 18

and postsynaptic compartments and can undergo retrograde and anterograde
transport, and can be secreted by an activity-dependent secretory pathway
(Murer et al. 2001, Kohman et al. 2007, Cunha et al. 2010).
Mature BDNF binds to the tropomyosin-related kinase B (TrkB) receptor, a
member of the tyrosine kinase family, to induce receptor dimerization and
autophosphorylation on multiple tyrosine residues

(Figure 1-3). These

phosphorylated tyrosine residues become binding sites for SH2 domains of
various intracellular target proteins and can activate intracellular signaling
cascades such as the phosphoinositide 3-kinase (PI3K) cascade, the Rasmitogen-activated protein kinase (Ras-MAPK) cascade, and the phospholipase C
cascade (PLC). Through these pathways, BDNF can regulate CREB and
mammalian target of rapamycin (mTOR) to increase gene expression and protein
translation,

respectively,

and

facilitate

neuronal

survival

and

synaptic

strengthening (Binder and Scharfman 2004). ProBDNF can oppose the effects of
mature BDNF by acting on the p75 receptor (p75NTR), a low-affinity panneurotrophin receptor, to initiate programmed cell death (apoptosis) via JNK
signaling pathway (Teng et al. 2005). Alternatively, proBDNF can synergize with
mature BDNF by acting on p75NTR to promote cell survival via NF-kB transcription
factor (Mandel et al. 2009).
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Figure 1-3
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Figure 1-3. BDNF and proBDNF receptors. ProBDNF can be cleaved
intracellularly by furin or convertase and extracellularly by plasmin or
metalloproteinase into mature BDNF. Mature BDNF acts on the TrkB receptor
which autophosphorylates and activates the intracellular signaling cascades
phosphoinositide 3-kinase (PI3K), Ras-mitogen-activated protein kinase (RasMAPK), and phospholipase C cascade (PLC) to promote cell survival,
proliferation, and synaptic plasticity. ProBDNF binds to the p75NTR receptor and
can activate NF-κB to promote cell survival or JNK to initiate programmed cell
death (apoptosis).
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In addition to BDNF’s role to promote proliferation and neuronal survival,
BDNF is important for hippocampal learning and memory processes. Long-term
depression (LTD) and long-term potentiation (LTP) are two models of synaptic
plasticity underlying learning and memory. While LTD can inactivate an
associative memory (i.e., a memory of a relationship between unrelated items),
LTP can reactivate the same memory (Nabavi et al. 2014). BDNF can act on the
TrkB receptor to induce LTP, and proBDNF can act on the p75 NTR receptor to
modify the NMDA receptor and induce LTD (Bliss and Cooke 2011). Alonso et al.
(2002) showed that neutralizing endogenous BDNF in the hippocampus using an
anti-BDNF antibody blocked short-term and long-term memory formation in rat
and infusion of recombinant human BDNF into the hippocampus strongly
facilitated short-term and long-term memory formation. These results suggest
that BDNF is necessary for hippocampal-mediated learning. In Aim 2 of this
dissertation, I investigated the interplay between LC-NE degeneration and
BDNF levels in an aged rat model.

1.4.2 Detecting BDNF
Several methods are employed to detect BDNF in various sample
matrixes. Enzyme-linked immunosorbent assays (ELISAs) and western blots are
the most commonly used techniques to detect BDNF in biological fluids and
tissue homogenates. Both of these techniques depend on using an antibody that
is specific for BDNF. BDNF ELISAs are commonly used to quantify BDNF levels
in serum and tissue homogenates due to their commercial availability from
Page 21

several providers, their high sensitivity to BDNF levels, and their relatively
straight-forward protocol that can be automated. Commercial ELISAs also have
the added benefit of being validated by the manufacturing company to have low
interassay variability; however, this interassay variation declared by the
manufacturer has been reported to be higher in practical use by several research
groups (Lim et al. 2015, Polacchini et al. 2015). In addition, an ELISA specificity
is limited by the specificity of the antibody used to detect the antigen of interest,
and, while ELISAs have low detection limits, commercial BDNF ELISA kits
specificity to mature BDNF is questioned due to their antibody cross-reactivity to
proBDNF (Fahnestock et al. 2002, Yoshida 2012, Lim et al. 2015, Polacchini et
al. 2015). Western blots can distinguish mature BDNF (14 kDa) from proBDNF
(36 kDa) by their molecular weight (Fahnestock et al. 2002) and have high
specificity but low sensitivity compared to ELISAs. In addition, the western blot
protocol is relatively labor intensive compared to the ELISA protocol, and there
may be high interassay variability between blots due to variations in gel
composition and transfer procedure used. Western blot interassay variability is
reduced through standardizations in materials and user technique as well as
internal controls. Chapter 2 Section 2.4 will further explore the strengths and
limitations of ELISAs and western blot techniques in detecting BDNF.

1.4.3 BDNF and aging
BDNF is crucial for healthy development and aging. The majority of BDNF
homozygous knockout (–/–) mice die postnatally due to cardiorespiratory defects
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and those that do survive only live for up to 3 weeks and show severe
hypomyelination (Huang and Reichardt 2001, Binder and Scharfman 2004, Xiao
et al. 2010). BDNF heterozygous knockout (+/–) mice are viable and live normal
life spans, but these mice display hypomyelination, develop obesity, exhibit
aggressiveness, and have impaired learning at an early age (Linnarsson et al.
1997, Lyons et al. 1999, Xiao et al. 2010). Petzold et al. (2015) further showed
that the spatial learning impairment found in BDNF heterozygous knockout (+/–)
mice increases with age despite having stable BDNF and TrkB protein levels
over time. These results suggest that chronically low BDNF levels influence brain
structure and function over time, and these accumulating changes can result in
learning deficits at an older age. In rat studies, aging is associated with reduced
BDNF protein levels, reduced BDNF mRNA expression, synaptic loss in the
dentate gyrus, and a decline in spatial memory (Geinisman et al. 1992, Schaaf et
al. 2001). In both rat and mouse studies, brain protein levels of the BDNF
receptor TrkB also decline with age (Rage et al. 2007, Petzold et al. 2015).
These animal studies highlight the importance of BDNF for proper brain and
behavior development and suggest that early deficits in BDNF levels may have
consequences at later ages. However, it is not known whether serum BDNF
levels are correlated with amyloid or pTau pathology or underlie
neurodegenerative changes associated with AD. This will be explored in
Aim 1 of this dissertation.
Normal aging in humans is generally associated with cortical and
hippocampal degeneration, white matter degeneration, and cognitive decline,
Page 23

including decline in executive function and memory (Falangola et al. 2008,
Harada et al. 2013). Several studies, but not all, have shown that circulating
BDNF levels in the blood decrease with increasing age (Lommatzsch et al. 2005,
Ziegenhorn et al. 2007, Gunstad et al. 2008, Erickson et al. 2010), and a
carefully performed mediation analysis on serum BDNF and hippocampal volume
in adults aged 59-81 years further found that age-related decline in BDNF levels
partially contributes to the age-related volumetric shrinkage of the hippocampus
(Erickson et al. 2012). While this finding highlights the importance of serum
BDNF in age-related hippocampal volume decay in a cross-sectional study, the
longitudinal relationship between serum BDNF and neuropsychological
performance and neuroimaging measures have not been reported, and
studying this relationship was one of the goals for Aim 3 in this
dissertation.

1.5 BDNF and AD
Abnormal BDNF levels in the brain and blood have been linked to the
development of depression and schizophrenia (Angelucci et al. 2005, Yoshida et
al. 2012), and a growing body of literature has implicated disruption of BDNF
biosynthesis in the pathogenesis of AD (Diniz and Teixeira 2011, Laske et al.
2011). Although it is unknown whether the observed loss of BDNF in AD is a
primary or secondary pathological event, the interaction between BDNF and AD
pathology is complex, and the loss of neuroprotection normally conferred by
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BDNF may contribute to the progression of AD (Arancibia et al. 2008, TapiaArancibia et al. 2008, Wang et al. 2011, Zhang et al. 2012).

1.5.1 BDNF and AD pathology
Interestingly, BDNF functioning and APP processing to produce amyloid
are linked by γ-secretase, and γ-secretase inhibitors have been shown to disrupt
BDNF trafficking and signaling while also reducing the amount of Aβ produced
(Weissmiller 2015). In post mortem analysis of AD brains, the BDNF receptor
TrkB was found to be trapped in senile plaques (Connor et al. 1996) and
increasing plaque load correlated with the loss of BDNF (Lee et al. 2005),
suggesting that amyloid can contribute to loss of BDNF neuroprotection. While
mature BDNF has been shown to protect cells from plaque toxicity, proBDNF
synergizes with Aβ toxicity and induces more cell death than Aβ alone in SHSY5Y human neuroblastoma cell cultures (Lim et al. 2015). Overall, these results
indicate that mature BDNF mitigates amyloid toxicity while proBDNF promotes
amyloid production and toxicity. BDNF may also protect against tangle toxicity;
neurons immunoreactive for BDNF protein did not have NFTs in post mortem
evaluation of human AD brain samples (Murer et al. 1999). This result was
supported by in vitro studies where BDNF stimulation of the TrkB receptor in
neuronally differentiated P19 mouse embryonic carcinoma cells resulted in a
rapid decrease in tau phosphorylation (Elliott et al. 2005).
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1.5.2 BDNF and inflammation
Inflammation further complicates the relationship between BDNF and AD
pathology. Both plaques and tangles are shown to activate microglia which in
turn release proinflammatory cytokines (Combs et al. 2001, Sondag et al. 2009,
Morales et al. 2013). Pro-inflammatory cytokines such as IL-1β can inhibit the
synthesis and function of BDNF in vivo and in vitro (Barrientos et al. 2004,
Calabrese et al. 2014, Di Benedetto et al. 2017) while anti-inflammatory
cytokines such as IL-10 has been shown to stimulate BDNF production in vitro
(Zhu et al. 2015). However, microglia also secrete BDNF, and mice depleted of
BDNF produced by microglia showed deficits in multiple learning tasks and a
significant reduction in motor-learning-dependent synapse formation, suggesting
that BDNF secreted from microglia has an important role in learning and memory
(Parkhurst

et

al.

2013).

BDNF

can

also

reduce

inflammation,

and

intracerebroventricular delivery of BDNF in rats with pneumococcal meningitis
resulted in downregulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and
upregulation of anti-inflammatory cytokine (IL-10) in the hippocampus and cortex
(Xu et al. 2017).
These results suggest that BDNF can mitigate AD pathology directly
through interactions with plaques and tangles or indirectly through its antiinflammatory properties. However, high levels of AD pathology and inflammation
can

suppress

BDNF

production

and

function

and

ultimately

facilitate

neurodegeneration by blocking the neuroprotective actions of BDNF (Figure 14). The link between deterioration of BDNF function and AD pathology is
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scientifically interesting and deserves attention based on the lack of coherent
data either in patients or in post mortem tissue or animal models to date.
Figure 1-4
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Figure 1-4. Interactions between AD pathology, BDNF, and inflammation.
AD pathology including Aβ plaques and tau tangles aggravate inflammation and
can ultimately interfere with BDNF production and function. The loss of
neuroprotection from BDNF may further contribute to the progression of AD.

1.6 BDNF as a biomarker
BDNF and TrkB protein and mRNA are expressed predominantly in the
CNS with particularly high protein expression in the hippocampus (Connor et al.
1996, Connor et al. 1997, Yan et al. 1997, Murer et al. 1999, Durany et al. 2000,
Murer et al. 2001). The ability of BDNF to cross the blood-brain barrier and be
detected in venous blood has led to several investigations of blood BDNF levels
as a biomarker for normal and pathological aging in older adults. However, BDNF
is also produced peripherally in leucocytes, macrophages, muscles, and
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endothelial cells and is stored in blood platelets, and blood BDNF levels do not
only reflect BDNF secreted from the brain (Fujimura et al. 2002, Phillips et al.
2014). Although a positive relationship between brain and blood BDNF
levels has been demonstrated in several animal models (Karege et al. 2002,
Sartorius et al. 2009, Klein et al. 2011), the relationship between blood
BDNF levels and brain BDNF levels in humans has yet to be reported and
was one of the goals for Aim 1 in my dissertation.

1.6.1 Serum BDNF levels in AD
Although BDNF can be readily detected in serum, plasma, and whole
blood, this dissertation will be focused on BDNF levels in serum. This decision
was made for several reasons. First, serum BDNF is considered to be a more
reliable source of BDNF since plasma BDNF levels are commonly affected by
choice of incubation time and anti-coagulant (Tsuchimine et al. 2014, Polacchini
et al. 2015, Polyakova et al. 2017). Second, serum BDNF levels have been
shown to be 100 times higher than plasma BDNF due to the release of BDNF
from platelets during the clotting process (Radka et al. 1996). In plasma, platelet
degranulation is difficult to control for and can occur from simple shearing force
during blood collection or even due to inherent platelet instability from increasing
age or pharmacological intervention (Elfving et al. 2010). Third, serum BDNF
levels have comparable BDNF levels to whole blood and have been shown to be
identical to BDNF levels in washed platelet lysates (Fujimura et al. 2002). Thus
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serum BDNF levels represent BDNF stored in platelets and reflect total
circulating BDNF produced by both the brain and peripheral organs.
Table 1-1 summarizes findings from studies on serum BDNF levels in AD
and controls completed by groups around the world. Details on these studies can
be found in Appendix 1. Most of these studies used commercially available
ELISA kits from a variety of suppliers. Although the majority of studies report
lower serum BDNF levels in AD compared to controls, several studies have
found higher serum BDNF levels in AD compared to control or have failed to find
a difference in serum BDNF levels between AD and controls. One of the possible
reasons for this discrepancy is the different stages of AD that were studied.
Laske et al. (2006) found that serum BDNF levels were increased during early
AD (MMSE scores ≥ 21) when compared to late AD (MMSE scores < 21).
Similarly, Konukoglu et al. (2012) found that although serum BDNF levels in the
AD group (n=22) as a whole was not significantly different from the controls
(n=20), AD patients with early dementia (n=12; MMSE scores ≥ 21) had
significantly higher serum BDNF levels than both the controls and AD patients
with late dementia (n=10; MMSE scores < 21). Overall these results suggest that
BDNF levels may vary with disease severity and that a protective compensatory
increase in BDNF may exist in early stages of AD and MCI to mitigate AD
toxicity. When this compensation fails, lower BDNF levels persist, and a decline
in cognition and clinical status to AD may occur. In Aim 2 of my dissertation, I
investigated how BDNF levels fluctuate with mild cognitive impairment in a
rat model of aging.
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Table 1-1

Table 1-1. Summary of studies on brain BDNF levels in AD. AD = Alzheimer's
disease, ELISA = Enzyme-linked immunosorbent assay, MCI = Mild Cognitive
Impairment
# of
Studies

Result

Origin

Decreased
BDNF levels
in AD
compared
to Control

Brazil, China,
Germany, Italy,
Japan, Korea,
Turkey, USA,

17

Increased
BDNF levels
in AD
compared
to Control

Germany,
India, Italy,
Turkey

4

No
difference
Germany,
in BDNF
Spain, Turkey,
levels
USA
between AD
and Control

6

Total AD
Participants

Total Control
Participants

Method

907

2890

ELISA
(Abexa,
Chemikine,
Promega,
R&D, Raybio)

179

120

ELISA
(Promega,
R&D, Raybio)

429

ELISA
(Promega,
R&D, Rule
Based
Medicine)

607

1.6.2 Brain BDNF levels in AD
Several groups have investigated changes in BDNF protein levels in AD
and control brains and have reported mixed results (Table 1-2, Appendix 2).
The discrepancy between studies may be due to post mortem interval (PMI);
however, PMI and handling of post mortem samples is often limited by the
management of the brain bank (Ferrer et al. 2008). Storage and handling of brain
material may also influence BDNF levels in human brains, and BDNF levels have
been shown to decay up to 15% in rat brains when stored at 4oC for 24 hours
(Ferrer et al. 1999). Alternatively, certain ante mortem clinical features that
influence BDNF levels such as medication, depression, lifestyle (e.g., smoking,
alcohol, exercise), and pathological staging are rarely reported in ante mortem
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studies (Balietti et al. 2018), let alone in post mortem studies where such
information may not be easily obtained.
Nevertheless, post mortem assessment of BDNF levels in AD and control
human brain tissue have concluded that lower BDNF levels are found in certain
regions of the AD brain. Generally, in AD brains compared to controls, there have
been more reports of lower BDNF levels in the hippocampus, parietal cortex, and
temporal cortex. BDNF levels in the basal forebrain, basal ganglia, cerebellum,
frontal cortex, occipital cortex, putamen, and thalamus have generally not been
found to be different between AD and control. Two studies have reported
increased brain BDNF levels in AD. Durany et al. (2000) used the BDNF Emax®
ImmunoAssay System from Promega to measure free BDNF and found
increased BDNF levels in AD compared to control in the hippocampus and
parietal cortex. Lim et al. (2015) used western blotting methods to distinguish
proBDNF from mature BDNF and found increased proBDNF in AD hippocampus.
Considering that the Promega BDNF ELISA used by Durany et al. (2000) does
not distinguish between proBDNF and mature BDNF, it is possible that the
increased BDNF reported by Durany et al. (2000) reflects increased proBDNF
levels similar to results from Lim et al. (2015). Increased proBDNF levels in AD
brain makes conceptual sense considering the toxic synergistic relationship
found between proBDNF and Aβ plaques. Overall, BDNF levels are expected to
be lower in AD brains compared to control and be related AD pathology. In Aim
1 of my dissertation, I measured BDNF levels in human brain samples by
both ELISA and western blotting methods to better understand the
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relationship between total BDNF, mature BDNF, and proBDNF and AD
histopathology.
Table 1-2

Table 1-2. Summary of studies on brain BDNF levels in AD. AD = Alzheimer's
disease, BA = Brodmann Area, BF = Basal forebrain, BG = Basal Ganglia, CBL =
Cerebellar cortex, CG = Cingulate gyrus, Con = Control, DG = Dentate gyrus,
ELISA = Enzyme-linked immunosorbent assay, ENT = Entorhinal cortex, FC =
Frontal cortex, HIP = Hippocampus, IHC = Immunohistochemistry, MC = Motor
Cortex, MCI = Mild Cognitive Impairment, OC = Occipital cortex, PC = Parietal
cortex, PUT = Putamen, TC = Temporal cortex, THL = Thalamus, WB = Western
Blot.
Result

Region

# of
Studies

Total AD
Participants

Total Control
Participants

Method

Decreased
BDNF levels DG, ENT, FC,
in AD
HIP, MC, PC,
compared
TC
to Con

9

178

137

ELISA
(Promega,
R&D, Abexa),
IHC, WB

Increased
BDNF levels
in AD
compared
to Con

2

21

18

ELISA
(Promega),
WB

7

235

144

ELISA
(Promega,
R&D), WB

HIP, PC

No
difference BF, BG, CBL,
in BDNF
CG, FC, HIP,
levels
OC, PC, PUT,
between AD
TC, THL
and Con

1.6.3 CSF BDNF levels in AD
Measurement of brain portien in CSF is thought to be a more direct
measure of brain tissue levels. However, several studies have reported difficulty
in measuring BDNF in CSF using commercial ELISAs (Blasko et al. 2006, Laske
et al. 2006, Laske et al. 2007, Jiao et al. 2016). Laske et al. (2006) was not able
to detect BDNF in CSF in any of their samples using an R&D ELISA with a limit
of detection (LOD) of 15 pg/ml. Using a more sensitive fluorescent ELISA with a
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LOD of 0.1 pg/ml, Laske et al. (2007) was only able to detect CSF BDNF levels
in 8/27 AD and 5/10 older adult controls. Similarly, Blasko et al. (2006) was only
able to detect CSF BDNF levels in 2/14 AD and 0/12 older adult controls using
an R&D ELISA (LOD 15 pg/ml), and Jiao et al. (2016) was only able to detect
BDNF in CSF in about 7/28 AD and 11/22 older adult controls using an Abbexa
BDNF ELISA (LOD 31.2 pg/ml). Although Laske et al. (2007) and Jiao et al.
(2016) were not able to detect BDNF in their entire cohort, they both report that
the detection rate (i.e., the number of cases with measurable BDNF divided by
the total number of cases) of BDNF in CSF was lower in AD. Laske et al. (2007)
further reported that BDNF in CSF did not correlate with BDNF in serum and that
there were no differences in serum BDNF levels between participants with and
without detectable BDNF in CSF. In studies that did detect BDNF in CSF, CSF
BDNF levels were significantly lower in AD compared to healthy controls (Zhang
et al. 2008, Li et al. 2009, Forlenza et al. 2015). BDNF investigations of CSF
have thus far been limited to ante mortem lumbar puncture samples, and
BDNF levels in post mortem cranial CSF are unknown to date. In addition,
the relationship between BDNF in CSF and the brains has not been
reported and is part of the goals for Aim 1 in this dissertation.

1.6 Purpose of this study
In this dissertation, I investigated the biomarker potential of BDNF in AD
using post mortem human samples, an aged rat model with LC-NE degeneration,
and blood samples from cognitively healthy older adults. BDNF, AD pathology,
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and inflammation are highly interconnected (see Figure 1-4), and the balance
between all three was taken into consideration across all three of my Aims. My
goal was to determine whether human serum BDNF levels were related to
human brain BDNF levels and AD pathology (Aim 1; Chapter 3), whether serum
BDNF levels reflected acute neurological insults related to age-related memory
impairment (Aim 2; Chapter 4), and whether serum BDNF levels could predict
changes in neuropsychological performance or neuroimaging measures over
time in healthy older adults (Aim 3; Chapter 5). My overall hypothesis is that
BDNF fluctuates with disease course with high levels of BDNF in early stages of
the disease course and low levels of BDNF in late stages of AD. This overall
hypothesis is depicted in Figure 1-5 where the hypothetical changes in BDNF
and inflammation over time are plotted together with the previously proposed AD
biomarker theory shown in Figure 1-2. In Chapter 3 (Aim 1), I assessed the
relationship between serum BDNF levels, brain BDNF levels (hippocampus,
entorhinal cortex, and prefrontal cortex), CSF BDNF levels, AD pathology
(plaques and tangles), and inflammation (cytokines, astroglia, microglia, and
oligodendrocytes) in post mortem samples from AD and control cases. The
different forms of BDNF (mature BDNF and proBDNF) as well as the stage of AD
(high or low pathology) were taken into account as we assessed whether a)
serum BDNF levels were correlated with brain BDNF levels, b) serum BDNF
levels were correlated with brain pathology (plaques, pTau, and inflammation)
and c) brain BDNF levels were related to brain pathology. In Chapter 4 (Aim 2), I
assessed the relationship between serum BDNF levels, brain BDNF levels
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(frontal cortex and hippocampus), and inflammation (cytokines, astroglia, and
microglia) in aged rats with LC neurodegeneration and an acute systemic
inflammation challenge. This aged rat model is a well-recognized model for
aging-related memory loss and degeneration. Assessment of serum and brain
BDNF in this model allowed us to make inferences on whether a) serum and
brain BDNF decreased during an inflammatory challenge and b) a compensatory
increase in serum and brain BDNF occurred after the challenge. In Chapter 5
(Aim 3), I assessed serum BDNF and cytokine levels in cognitively normal adults
who have completed neuropsychological testing, structural MRI scans, and blood
draws in two visits approximately 15 months apart to determine whether baseline
BDNF levels can predict

abnormal changes in a)

neuropsychological

performance (executive function and memory) and b) neuroimaging measures
(dorsolateral prefrontal cortex thickness, hippocampal volume, and white matter
microstructure of limbic system). Overall, these studies were designed to
evaluate the ability of serum BDNF levels to reflect brain BDNF levels and/or
neuropathophysiological changes related to AD in cognitively healthy older
adults, aged rats with memory loss, and AD.
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Figure 1-5

Biomarker Abnormality

High

Low

Aim 3

Aim 2

Aim 1

Longitudinal

Experimental

Cross-sectional

Aβ levels
pTau levels
Brain Structure
Memory Function
Clinical Function
Inflammation
BDNF Levels

Detection
Threshold

Cognitively Healthy

MCI

AD

Can BDNF levels
predict cognitive or
neurodegenerative
decline in healthy
older adults?

How do BDNF
levels fluctuate with
inflammation in an
aged rat model with
mild cognitive
impairment?

What is the
relationship
between serum
BDNF levels, brain
BDNF levels, and
AD pathology?

Figure 1-5. Framework of major dissertation questions. Hypothetical changes
in BDNF and inflammation over time and clinical diagnosis are added to the
model in Figure 1-2. The vertical axis represents biomarker severity from low to
high, and the horizontal axis represents time and progression from cognitively
healthy to cognitively impaired to AD. BDNF can be detected in serum at young
ages and is always above the detection threshold. An inverse relationship
between inflammation and BDNF is depicted with a compensatory increase in
BDNF occurring after peak inflammatory activity. Failure of BDNF compensation
over time is hypothesized to facilitate the progression to AD and increasing
inflammation.
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2.1 Study population
All studies involving humans or animals were reviewed and approved by
MUSC’s Institutional Review Board (IRB) or Institutional Animal Care and Use
Committee (IACUC), respectively, to ensure compliance with ethical guidelines
set by the NIH. Aim 1 was conducted using post mortem human brain tissue and
fluids obtained from the Carroll A. Campbell, Jr. Neuropathology Laboratory at
MUSC. The IRB and MUSC’s Office of Research Integrity determined that this
study met the Not Human Research (NHR) criteria set forth by the Code of
Federal Regulations (45CFR46). All samples were obtained post mortem from
donors whose next of kin provided consent, and donor identity was kept
anonymous with an assigned random identifier. Aim 2 was conducted using
twenty-month-old male Fischer 344 (F344) rats from the aging colony at the
Charles River laboratories. These rats were pair-housed in an Association for
Assessment and Accreditation of Laboratory Animal Care (AAALAC) accredited
animal care facility at MUSC, were maintained on a 12-h light/dark cycle, and
received food and water ad libitum according to the National Institute of Aging
(NIA) guidelines for aged rats. Aim 3 was conducted on cognitively healthy older
adults recruited for the MR Imaging of Neurodegeneration (MIND) study. All
participants

gave

written

informed

consent

to

participate

in

annual

neuropsychological tests, MRI scans, and a fasting blood draw. Sample numbers
and demographics for each study population are detailed in each Aim’s
respective chapter. Benefits and limitations of using different study designs and
population for each Aim can be found in Table 2-1 below.
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Table 2-1

Table 2-1. Benefits and limitations of different study designs and
population types in Aims 1-3.
Aim

Aim 1

Aim 2

Aim 3

Study
Type

Study
Benefits
Population

Limitations

Crosssectional

Post
Mortem
Human
Samples

 Cross-sectional
 Potential recruiting
bias

Interventional
CrossAged Rats
sectional

Longitudinal

 Direct assessment
and relevance to
disease pathology

 Able to control for
multiple confounders  May not accurately
model all
 Can perform more
invasive procedures
symptoms found in
a clinical
 Excellent model for
population with AD
aging-related
cognitive impairment

 Clinically relevant
Healthy
 Can suggest a
Older Adults cause-and-effect
relationship

 Risk of drop out
over time
 Costly
 Potential recruiting
bias

2.2 Serum collection
Aim 1 post mortem human blood and Aim 2 rat blood from cardiac
puncture was collected into BD Vacutainer Serum Separator Tubes® and
allowed to clot for 60 minutes at room temperature (RT) before being centrifuged
for 20 minutes at 1,500 x g. Serum was then carefully collected, aliquoted, and
stored in a -80oC freezer until further analysis. Aim 3 ante mortem blood was
collected into serum separator tubes, inverted five times to mix with clot activator,
and allowed to clot for 30 minutes at room temperature (RT). After being
centrifuged for 10 minutes at 3000 rpm at 4oC, serum was then carefully
aliquoted into 0.5 ml aliquots and stored at -80oC.
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2.2.1 Glass vs. plastic tubes
The collection of blood has been traditionally done in glass tubes;
however, plastic tubes, which are cheaper and less likely to break, have become
more ubiquitous. Most studies show that the use of glass vs plastic tubes does
not affect analyte concentration in serum (Hill et al. 1992, Preissner et al. 2004).
Although Smets et al. (2004) reported a small but statistically significant
difference (p<0.05) in some hormones in blood collected in glass versus plastic
test tubes, this difference was not clinically significant. The effect of glass vs
plastic test tubes on BDNF concentration in serum has not been reported and
may be relevant based on the proposed “stickiness” of this protein, likely due to
its abundance of positively charged moieties (Waterhouse and Xu 2009). To test
the effects of glass or plastic test tubes on BDNF levels in the same assay, the
BDNF Emax® ImmunoAssay System (G7610, Promega, Madison, WI) was used
to measure BDNF in standards and human brain (HB) tissue processed in either
glass or plastic pipettes. We found no significant difference in optical density
(OD) values from the BDNF assay in different concentrations of the BDNF
standard diluted in manufacturer provided Block & Sample buffer between glass
or plastic processing (Figure 2-1A). Similarly, we did not find a significant
difference in OD from the BDNF assay in three human brain sample
homogenates between glass- or plastic-based processing, strongly suggesting
that this particular issue does not affect the outcome of experiments, either in
serum or in brain tissue samples (Figure 2-1B).
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Figure 2-1
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Figure 2-1. Glass vs. plastic effects on optical density (OD) from a BDNF
immunoassay. Buffer with differing concentrations of BDNF (A) and three
different human brain (HB) homogenates (B) were processed through a glass or
plastic pipette before being run on the BDNF Emax® ImmunoAssay System
(G7610, Promega, Madison, WI). OD values from this assay indicate that BDNF
levels in buffer and HB homogenates were not significantly altered from
processing in glass or plastic pipette.

2.3 Procurement of human brain tissue and homogenization
2.3.1 Human samples
In Aim 1, the left hemisphere of the brain from human donors was cut into
1 cm coronal slabs and photographed. Frozen pieces of human middle frontal
gyrus (Brodmann area 46; BA46), the entorhinal cortex (ENT), and the
hippocampus (HIP) were isolated from the left hemisphere and stored at -80oC
until homogenization.

2.3.2 Rat samples
In Aim 2, rats were anesthetized deeply with isoflurane before the right
frontal cortex and right hippocampus were isolated, snap frozen on dry ice, and
stored at -80oC until homogenization.
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2.3.3 Homogenization protocol
The final homogenization protocol for brain tissues used in Aim 1 and Aim
2 has been published previously (Bharani et al. 2017). Briefly, 200-500 mg of
brain tissue were homogenized for 20 seconds using a battery-powered pestle
mixer (Argos Technologies) with 1:10 w/v homogenization buffer (20 mM TrisHCl, 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 10%
glycerol, 1% NP-40) and cOmplete™ Protease Inhibitor Cocktail (Roche
Diagnostics, Ltd., Mannheim, Germany). Samples were then incubated on ice for
30 minutes before the suspension was centrifuged at 10,000 x g for 20 minutes
at 4˚C. The pellet was then re-homogenized with 1:5 w/v homogenization buffer
for 20 seconds, incubated on ice for 30 minutes, and centrifuged at 10,000 x g for
20 minutes at 4˚C. The supernatants were combined, aliquoted, and stored in a 80˚C freezer prior to use. Protein quantification was determined using a
bicinchoninic acid (BCA) protein assay (Thermo Scientific, Rockford, IL, USA).

2.3.4 Buffer optimization
Several different lysis buffers have been used for BDNF extraction from
human and rat brain tissue in past literature (Ferrer et al. 1999, Lee et al. 2005,
Angelucci et al. 2010, Elfving et al. 2010), but optimization of the lysis buffer for
extraction of protein and BDNF from brain tissue has not been previously done in
the Granholm lab. Radioimmunoprecipitation assay buffer (RIPA buffer) is
commonly used to solubilize all membranes but interferes with antibody binding
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in commercially-available ELISAs. Accordingly, homogenization buffers with
milder, nonionic detergents, such as NP-40 or Triton-X 100 were considered and
compared. Promega (Madison, WI) recommended the detergent NP-40 for use in
their BDNF Emax® ImmunoAssay System (G7610, Promega, Madison, WI) while
several investigators used varying concentrations of the detergent Triton-X 100
instead of NP-40 (Ferrer et al. 1999, Lee et al. 2005, Elfving et al. 2010). To
ensure optimal protein extraction, protein was extracted from human brain using
homogenate buffer (20 mM Tris-HCl, 137 mM NaCl, 2.7 mM KCl, 8.1 mM
Na2HPO4, 1.5 mM KH2PO4, 10% glycerol) with cOmplete™ Protease Inhibitor
Cocktail (Roche Diagnostics, Ltd., Mannheim, Germany) containing either 1%
NP-40 or 0.1% Triton-X 100. Protein quantification from these two homogenates
was assessed using a BCA protein assay (Thermo Scientific, Rockford, IL, USA).
Less variability and approximately 13% more protein were observed using 1%
NP-40 compared to 0.1% Triton-X 100 (Figure 2-2A). Therefore, 1% NP-40 was
used instead of 0.1% Triton-X 100 in the extraction of BDNF from human and rat
brain tissue. This buffer will be referenced to as Lab buffer from here on forward.

2.3.5 Buffer comparison
Neuronal Protein Extract Reagent (N-PER) is a proprietary cell lysis
reagent from Thermo Scientific that is optimized for efficient extraction of protein
from neuronal tissue. To test whether the Lab buffer was as potent in protein
extraction as N-PER, frozen parietal cortices from two young rats were
homogenized using the Lab buffer or N-PER, and protein was quantified using a
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BCA protein assay. Protein extraction from two rat brain samples was found to
be similar between the homogenization protocols using Lab buffer or N-PER
(Figure 2-2B).

2.3.6 Protocol optimization
The resultant pellet after one round of homogenization and centrifugation
may still have protein, and the effects of combining two rounds of
homogenization, one on the tissue and one on the pellet, has not been tested
previously. To test whether homogenization of the pellet will extract more protein,
frozen parietal cortices from two young rats were first homogenized using the
Lab buffer, incubated on ice for 30 minutes, and centrifuged at 10,000 x g for 20
minutes at 4˚C. The subsequent pellet was then re-homogenized with 1:5 w/v
homogenization buffer for 20 seconds, incubated on ice for 30 minutes, and
centrifuged at 10,000 x g for 20 minutes at 4˚C. Protein quantification of
homogenates from both steps and their combination suggested that a higher
amount of protein was extracted per mg of tissue (Figure 2-2C) when combining
homogenates from both steps.
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Figure 2-2
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Figure 2-2.
Homogenization buffer and
protocol optimization.
Protein levels (mean ± SD),
measured by BCA assay, of
human brain tissue
homogenized with 1% NP-40
or 0.1% Triton-X 100 show
that use of 1% NP-40
extracted more protein than
0.1% Triton-X 100 (A).
Comparison between
homogenization with Lab
buffer vs N-PER buffer
showed that the buffers
extract equivalent amounts
of protein from two rat brain
samples (B). In two rat brain
samples, we show that the
first homogenization step
extracts the most protein per
tissue but more protein can
be extracted through a
second homogenization of
the pellet from the first step.
The combination of
supernatants from both the
first and second
homogenization steps yields
the most protein per tissue
(C).

2.4 BDNF quantification
2.4.1 BDNF ELISA optimization
In general, an ELISA involves the quantitative detection of an analyte in a
liquid sample using antibodies specific to the analyte and a linked enzyme that
undergo an optical change which can be quantitatively measured by
spectrophotometry. A sandwich ELISA is a type of ELISA in which the analyte of
interest is captured by two specific antibodies, one that is bound to the plate
(capture antibody) and one that is added after nonspecific binding sites are
blocked (primary antibody). After the analyte is effectively ‘sandwiched’ between
these two antibodies, an enzyme-linked secondary antibody is added to bind
specifically to the primary antibody. The enzyme-substrate is then added to be
converted by the enzyme to produce a colored or fluorescent product that can be
detected by spectrophotometry and related to the concentration of the analyte of
interest.
A large number of research groups have quantified BDNF in human whole
blood, serum, and plasma using the commercially available Human Free BDNF
Quantikine ELISA Kit (DBD00, R&D Systems, Minneapolis, USA). This kit (R&D
BDNF

ELISA

kit),

although

validated

for

use

on

human

and

rat

blood/serum/plasma, was not validated for use on human or rat tissue. To
validate and assess the accuracy of this R&D BDNF ELISA on human and rat
brain homogenates, a spike-and-recovery and linearity-of-dilution experiment
was performed using the Spike, Recovery, and Linearity Protocol for Validating
Untested Samples in R&D Systems ELISA provided by R&D Systems support. A
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spike-and-recovery experiment involves adding a known amount of analyte
(BDNF) to the sample matrix (human or rat brain homogenate) and to a standard
diluent. A linearity-of-dilution experiment involves preparing dilutions of the
sample matrix with the addition of a known amount of analyte (known as a
‘spike’). If the quantification of the spike in the sample diluent is not identical to
the spike in the sample matrix, or, if the spike does not exhibit a linear dilution,
then there is something in the sample matrix that is interfering with the ELISA.
The R&D BDNF ELISA kit comes with two different calibrator diluents:
animal serum (RD6P) with preservatives for use with serum/plasma samples and
buffered protein base with preservatives (RD5K) for cell culture supernatant. We
ran a spike-and-recovery and a linearity-of-dilution experiment on human brain
and rat brain homogenate diluted with either RD6P or RD5K. A spike was
created using the standard BDNF protein provided by the R&D BDNF ELISA kit,
and brain homogenates were spiked with 4000 pg/ml of BDNF. Spiked and
unspiked brain homogenates were then serially diluted with either RD6P or
RD5K to 1:2, 1:4, and 1:8. BDNF levels were then quantified using the R&D
BDNF ELISA standard curve. Percent Recovery (%Recovery) of the spiked
sample was calculated using the 1:2 dilution of the spiked and unspiked samples
as follows: %Recovery = 100 x (Spiked – Unspiked)/2000. Percent Linearity
(%Linearity) was calculated for the 1:4 and 1:8 dilutions as follows and averaged
together: %Linearity 1:4 = 100 x [1:4 Spiked/(1:2 Spiked/2)] and %Linearity 1:8 =
100 x [1:4 Spiked/(1:2 Spiked/4)]. Percent recovery and linearity for HB and rat
brain (RB) homogenates diluted in either RD6P or RD6K are plotted in Figure 2Page 48

3. The acceptable range for %Recovery and %Linearity is 80-120%. Only RB
diluted in RD6P had acceptable %Recovery and %Linearity for the R&D BDNF
ELISA, and my results indicate that the R&D BDNF ELISA kit should not be used
to measure BDNF levels in human brain homogenates without additional
optimization such as protein purification.
Figure 2-3
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Figure 2-3. Percent recovery and linearity for the R&D BDNF ELISA kit
using human brain (HB) and rat brain (RB) homogenates. Spike-andrecovery and linearity-of-dilution studies done on HB and RB homogenates with
R&D diluents RD6P and RD5K demonstrate that the R&D Human Free BDNF
Quantikine ELISA kit can accurately measure BDNF levels in RB homogenates
using the diluent RD6P but not in HB homogenates regardless of diluent used.
The acceptable range for %Recovery and %Linearity is 80-120% and is noted on
the graphs by dotted horizontal lines.
The R&D BDNF ELISA kit is claimed by the manufacturer to be specific for
mature BDNF with some cross-reactivity to proBDNF. To investigate this crossreactivity further, we ran increasing concentrations of proBDNF protein
(Alomone, B-245) with the manufacturer provided mature BDNF standard
(Figure 2-4). Results from this experiment indicate that the R&D BDNF ELISA is
sensitive to mature BDNF with a limit of detection of less than 62.5 pg/ml but
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does detect proBDNF at levels greater than 500 pg/ml. This result somewhat
conflicts with Polacchini et al. (2015) where the R&D BDNF ELISA antibody was
found to be very reactive to proBDNF in line blots. Nonetheless, this crossreactivity with proBDNF is important to consider when quantifying BDNF levels in
biological samples with high levels of proBDNF compared to mature BDNF. For
example, proBDNF levels have been reported to be more than 10-fold higher
than mature BDNF levels in healthy Jewish subjects and not in in Japanese
subjects (Levin et al. 2015, Hashimoto 2016, Hashimoto 2016). Measurement of
mature BDNF levels in these subjects using the R&D BDNF ELISA would result
in an artificially high result due to the high levels of proBDNF levels. To avoid
such an erroneous conclusion, BDNF levels quantified by ELISA will be referred
to as total BDNF levels.
Figure 2-4

R & D B D N F E L IS A S p e c if ic it y
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Figure 2-4. Specificity of the R&D BDNF ELISA kit to BDNF isoforms.
Different concentrations of mature BDNF and proBDNF protein were measured
using the R&D Human Free BDNF Quantikine ELISA kit. The primary antibody
used in this kit is specific for mature BDNF but exhibits some cross-reactivity to
proBDNF. Only high concentrations of proBDNF are detected by this ELISA kit.
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Accordingly, total BDNF levels in undiluted cranial CSF (CSF-C), undiluted
lumbar CSF (CSF-L), and serum samples (diluted 1:20 with the manufacturer’s
provided diluent, RD6P) and rat brain homogenates were measured in duplicates
using the R&D BDNF ELISA. Total BDNF levels in brain homogenates (BA46,
ENT, HIP; each diluted 1:2 with manufacturer-provided Block & Sample buffer)
were measured in duplicate using the manufacture validated BDNF Emax®
ImmunoAssay System (G7610, Promega, Madison, WI; Promega BDNF ELISA).
Comparison of these two ELISA kits can be found in Table 2-2.

2.4.2 R&D BDNF ELISA protocol
The R&D BDNF ELISA was run according to the manufacturer’s
instructions as previously described (Bharani et al. 2017, Hakansson et al. 2017).
The sensitivity of this R&D BDNF ELISA was 20 pg/mL (Polacchini et al. 2015).
Briefly, the manufacturer-provided 96-well plate was pre-coated with a
monoclonal antibody specific for the human free BDNF. These plates were then
incubated with 1) Assay Diluent RD1S for 1 hour at RT; 2) diluted serum samples
and BDNF standards for 2 hours at RT; and 3) a buffer containing monoclonal
antibody specific for human free BDNF conjugated to horseradish peroxidase for
1 hour at RT. After the wells were washed with the manufacturer-provided buffer,
a

color

reaction

was

produced

by

incubating

the

plate

with

a

tetramethylbenzidine solution. This reaction was stopped with the addition of 2N
sulfuric acid, and the absorbance was read by an automated microplate reader
(BioTek Synergy H1) at 450 nm with wavelength corrections set to 540 nm within
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30 minutes. BDNF concentration in test samples was extrapolated from a 4parameter logistic curve fit calculated from the manufacturer-provided standards.
BDNF levels in serum samples were measured twice in duplicate, and all four
measurements were averaged together to one value which was used in
subsequent analyses.

2.4.3 Promega BDNF ELISA protocol
The Promega BDNF ELISA was run according to the manufacturer’s
instructions. The Promega BDNF ELISA has been previously validated for use on
human brain samples, is comparable to the R&D BDNF kit, and has a sensitivity
of 15.6 pg/ml (Yoshida 2012, Polacchini et al. 2015). Briefly, Costar 96-well flatbottom EIA plates (Costar #2240096) were coated with anti-BDNF monoclonal
antibody diluted in carbonate buffer (25 mM sodium bicarbonate, 25 mM sodium
carbonate, pH 9.7) overnight at 4oC. The next day, plates were incubated with 1)
Block & Sample buffer for 1 hour at RT; 2) diluted brain samples and BDNF
standards for 2 hours at RT with agitation; 3) Block & Sample buffer containing
anti-Human BDNF polyclonal antibody for 2 hours at RT with agitation; and 4)
Block & Sample buffer containing anti-IgY antibody conjugated with horseradish
peroxidase for 1 hour at RT with agitation. Each step was followed by washing as
recommended by the manufacturer. A color reaction was produced by incubating
the plate with a tetramethylbenzidine solution. This reaction was stopped with the
addition of 1N hydrochloric acid, and the absorbance at 450 nm was read by an
automated microplate reader within 30 minutes. BDNF concentration in test
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samples was extrapolated from a 4-parameter logistic curve fit calculated from
the manufacturer-provided standards.
Table 2-2

Table 2-2. Manufacture Declared Properties of BDNF ELISA kits. Table
content modified from Polacchini et al. (2015) and Yoshida (2012). NA = Not
Applicable.
Company

R&D System

Promega

Kit Name (Cat #)

Quantikine ®
(DBD00)

BDNF Emax®
Immuno-Assay System
(G7610)

Sandwich ELISA

Sandwich ELISA

Sensitivity (pg/ml)

20

15.6

Range of Detection
(pg/ml)

62.5 - 4000

7.8 - 5000

BDNF Standard

Human recombinant

Type not declared

Coating/Capture
Antibody

anti-BDNF
(mouse monoclonal)

anti-BDNF
(mouse monoclonal)

Primary Antibody

anti-BDNF
(mouse monoclonal)
HRP conjugated

anti-BDNF
(chicken polyclonal)

NA

anti-IgY
HRP conjugated

Species
Cross-Reactivity

Only human

Not specified

ProBDNF
Cross-Reactivity

13%†

NA‡

Type of Assay

Secondary Antibody

Processing Time
4–5 hours
23–24 hours
† The R&D BDNF ELISA declared cross-reactivity with proBDNF is 13%;
however, labs have reported cross-reactivity with proBDNF up to 30% (Lim et al.
2015).
‡ Although the cross-reactivity with proBDNF has not been quantified, the
Promega BDNF ELISA kit is based on an antibody that targets the carboxyl
terminal of BDNF and recognizes both the proBDNF and mature BDNF (Yoshida
2012, Lim et al. 2015).
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2.4.4 BDNF western blot optimization
Western blotting separates protein by molecular weight from a fluid
through denaturing gel electrophoresis. Protein from the gel is then transferred or
‘blotted’ to a membrane. The membrane is then blocked with a buffer to prevent
nonspecific binding of an antibody to the membrane. Then the membrane is
incubated with a primary antibody specific for the protein of interest. A
fluorophore-linked or enzyme-linked secondary antibody directed to the primary
antibody is then added and detected with an appropriate spectrophotometer.
Independent studies have shown that the antibodies used in the R&D
Systems-Quantikine® and the Promega-Emax® ELISA are specific for mature
BDNF (mBDNF) but also cross-react with proBDNF up to 30% (Lim et al. 2015,
Polacchini et al. 2015). Accordingly, BDNF levels measured from ELISAs will be
referred to as total BDNF (tBDNF). Western blotting was used to differentiate
further and quantify mBDNF (14-16 kDa) and proBDNF (28-32 kDa) band
intensities normalized to internal control proteins (ICP) for serum (transferrin; 77
kDa) and brain homogenate (β-actin; 42 kDa). Information on antibodies used for
western blotting can be found in Table 2-3. Strengths and limitations of ELISAs
and western blotting can be found in Table 2-4.
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Table 2-3

Table 2-3. Antibodies used for western blotting.
Target

Host

Dilution

Source

Identifier

β-actin

Mouse

1:200,000

Sigma-Aldrich

A5441

mBDNF

Rabbit

1:1,000

Alomone

ANT-010

ProBDNF

Rabbit

1:1,000

Alomone

ANT-006

Transferrin

Rabbit

1:2,000

Abcam

ab109503

Ms IgG (H+L)

Goat

1:10,000

LI-COR

IRDye® 680RD
925-68070

Rb IgG (H+L)

Goat

1:10,000

LI-COR

IRDye® 800CW
925-32210

To assess ICP saturation in HB homogenates and human serum, dilutions
of HB homogenate from 40 to 1 µg and dilutions of human serum from 125-3.9
µg were run in separate blots and probed with anti-actin and anti-transferrin,
respectively. A band for actin was detected between 50 kDa and 37 kDa in HB
homogenates, and a band for transferrin was detected around 75 kDa in human
serum. These bands progressively became smaller and weaker with decreasing
protein load (Figure 2-4). Based on this blot, 30 µg of HB homogenate and 50 µg
of human serum were used for future analysis.
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Figure 2-5
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Figure 2-5. Detection of internal control proteins in dilutions of human
brain (HB) homogenates and serum. 40-1 µg of HB homogenate (A) and 1253.9 µg of human serum were run in separate blots and probed with anti-actin and
anti-transferrin, respectively. A band for actin was detected between 50 kDa and
37 kDa in HB homogenates, and a band for transferrin was detected around 75
kDa in human serum. These bands progressively became weaker and smaller
with decreasing protein load, suggesting that control protein saturation has not
been reached.
Anti-BDNF (ANT-010) and anti-proBDNF (ANT-006) antibodies were
purchased from Alomone Labs (Jerusalem, Israel). The specificity of the ANT010 (Figure 2-5) and the ANT-006 (Figure 2-6) antibodies were tested by the
company. The anti-BDNF antibody is specific for human mBDNF and proBDNF
but does not detect closely related nerve growth factor (NGF) or neurotrophin-3
(NT-3). The anti-proBDNF antibody is specific for human proBDNF, and not
human mature BDNF, NGF, or NT-3.
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Figure 2-6

Alomone Anti-BDNF (ANT-010)

Figure 2-6. Specificity of Alomone anti-BDNF. The anti-BDNF antibody from
Alomone (ANT-010) detects both mBDNF and proBDNF isoforms but does not
detect nerve growth factor (NGF) or neurotrophin-3 (NT-3). Figure adapted from
the Alomone website (www.alomone.com).
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Figure 2-7

Alomone Anti-proBDNF (ANT-006)

Figure 2-7. Specificity of Alomone anti-proBDNF. The anti-proBDNF antibody
form Alomone (ANT-006) detects proBDNF but does not detect mBDNF,
proNGF, or NT-3. Figure adapted from the Alomone website
(www.alomone.com).

The sensitivity of the Alomone antibodies to mBDNF and proBDNF was
tested by running dilutions of mBDNF protein (Alomone, B-250) and of proBDNF
protein (Alomone, B-245) from 100 to 0.3 ng in a western blot. Mature BDNF was
detected around 15 kDa, and proBDNF was detected around 25 kDa. The limit of
detection for mBDNF was 10 ng and for proBDNF was 0.3 ng using the Alomone
antibodies (Figure 2-8).
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Figure 2-8
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Figure 2-8. Sensitivity of Alomone antibodies to different dilutions of
mBDNF and proBDNF proteins. 100-0.3 ng of mBDNF and proBDNF were run
in separate blots and probed with the anti-BDNF (ANT-010) or the anti-proBDNF
(ANT-006) antibodies from Alomone. Greater than 10 ng of mBDNF protein was
reliably detected around 15 kDa (A), and greater than 0.3 ng of proBDNF protein
was reliably detected around 25 kDa (B).

Peptide competition was used to test the specificity of the Alomone
antibodies to mBDNF and proBDNF in HB homogenate and human serum
(Figure 2-9). Specific binding of anti-BDNF and anti-proBDNF antibodies was
tested through peptide competition on 30 µg human brain (HB) homogenate and
50 µg of human serum (Ser). For peptide competition, equal amounts of the
peptide (BDNF or proBDNF) was mixed with the antibody (anti-BDNF or antiproBDNF) in blocking buffer and incubated for 30 minutes at RT with agitation
before use in the western blot protocol. A mBDNF band at 15 kDa could be
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detected in HB homogenate but not in human serum. A small proBDNF band
around 25 kDa was detected in HB homogenate while a strong, large proBDNF
band was detected in human serum. The mBDNF and proBDNF bands were not
detectable when the membranes were probed with peptide-blocked antibodies.
Figure 2-9
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Figure 2-9. Specificity of Alomone anti-BDNF and anti-proBDNF in human
brain homogenate and serum. A mBDNF band detected around 15 kDa (black
arrows) and a proBDNF band detected around 25 kDa (white arrows) did not
appear in membranes probed with peptide-blocked antibodies.

2.4.5 Western Blot Protocol
All cases of each sample type (serum, BA46, ENT, HIP) were run at the
same time on 4 gels using the mini-PROTEAN® Tetra Cell with Precision Plus
Protein Dual Color ladder (Bio-Rad #161-0374), 120 ng of recombinant human
mature BDNF protein (Alomone Labs #B-250), and 2 ng of recombinant human
proBDNF protein (Alomone Labs #B-257) included in every gel. Briefly, Any kD™
Mini-PROTEAN® TGX™ Precast Protein gels (Bio-Rad #456-9036) were used to
Page 60

separate 0.5 µL of serum or 30 µg of human brain homogenate at 150 V for 45
minutes. Separated gel proteins were then transferred onto a 0.2 µm
nitrocellulose membrane (Bio-Rad #162-0112) in transfer buffer (25 mM BisTris,
25 mM Bicine, 0.1mM EDTA, 10% methanol) using a Thermo Scientific Pierce
G2 Fast Blotter with constant voltage (25 V) for 30 minutes. Blots were then
incubated in blocking buffer (0.1% casein in phosphate-buffered saline) at RT for
1 hour with agitation. Next, serum blots were cut at the 20 kDa and 75 kDa
bands, and the top blot was incubated in anti-transferrin antibody, the middle blot
was incubated in anti-proBDNF antibody, and the bottom blot was incubated in
anti-mature BDNF antibody. Brain homogenate blots were cut at the 20 kDa
band, and the top blot was incubated with anti-β-actin and anti-proBDNF
antibodies, and the bottom blot was incubated with anti-mature BDNF antibody.
Blots were incubated with primary antibodies (Table 2-3) diluted in blocking
buffer with 0.1% Tween 20 overnight at 4oC with agitation. The next day, after
washing in TBS-T buffer (2 mM Tris base, 150 mM NaCl, 0.1% Tween 20, pH
7.6), the membrane was incubated in blocking buffer containing IRDye®
secondary antibody targeting the host of the primary antibody (Table 2-3) for 1
hour at RT with agitation. After washing in TBS-T buffer, protein expression in
blots was assessed using the 700 nm and 800 nm channels in Odyssey ® FC
Imaging Systems (LI-COR) and Image Studio 5.x (LI-COR). Internal controls,
mBDNF, and proBDNF were quantified on the same blots using the same
exposure at the same time for each sample type (i.e., serum, BA46, ENT, and
HIP).
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Similar to previous studies between AD and Control post mortem samples
(Connor et al. 1997, Michalski and Fahnestock 2003, Peng et al. 2005), β-actin
and transferrin levels were not significantly different between AD and Control
(p>0.05) and therefore served as ICP in western blots quantification.
Quantification of the target protein (i.e., mBDNF and proBDNF) and the ICP (i.e.,
β-actin for brain tissue and transferrin for serum) was completed using Image
StudioTM Software (licor.com/islite) according to LI-COR’s Housekeeping Protein
Normalization Protocol. Briefly, the Lane Normalization Factor (LNF) for each
lane was calculated by the ratio of (ICP signal for each lane)/(the highest ICP
signal). Then the normalized target protein value was calculated by the ratio of
(target band signal)/(LNF), and this value was used in subsequent analysis.
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Table 2-4

Table 2.4. Advantages and limitations of ELISA, westerns, and
immunohistochemistry. IHC = Immunohistochemistry; mBDNF = Mature
BDNF; tBDNF = Total BDNF.
Method

Primary
Purpose

Sample
Type

Advantages

ELISA

Quantitative
measurement
of protein
levels

Fluid or
tissue
homogenate

 High sensitivity for
 Contested
tBDNF (pg range)
specificity
 Requires low
for mBDNF
sample volume

Fluid or
tissue
homogenate

 High specificity for
 Low
mBDNF and
sensitivity
proBDNF
(µg range)
 Semi-quantitative
measurement of
protein levels

Qualitative
Western measurement
Blots
of protein
levels

IHC

Frozen or
Localization of Paraffinproteins
embedded
tissue

 High-resolution
localization of
proteins in
histological
context

Limitations

 Sensitive to
poor
handling
and/or
fixation of
tissue

2.6 Cytokine Quantification
Serum levels of cytokines and chemokines (GM-CSF, IFNy, IL-1β, IL-2, IL-4, IL5, IL-6, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-23, TNF-α) were determined using
the 14-plex Human High Sensitivity T-Cell Discovery Array (HDHSTC14) by Eve
Technologies (Canada) in Aims 1-3. This assay, run by Eve Technologies,
measures all fourteen biomarkers simultaneously in 75 uL of serum using a kit
from Millipore MILLIPLEX on a BioPlex 200 system (Mineyko et al. 2012, Kim et
al. 2018). In Aims 1 and 2, levels of the pro-inflammatory cytokine IL-1β in the
hippocampus were quantified using a commercial ELISA kit (R&D Systems,
Minneapolis, USA) following manufacturer’s instructions. IL-1β levels in tissue
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homogenates are expressed per mg of protein as determined by a BCA protein
assay (Thermo Scientific, Rockford, IL, USA).
In Chapters 3 and 5, a composite serum cytokine score was calculated
as follows. Standard z-scores were calculated for IL-1β and IL-10 based on the
mean and standard deviation of each measurement in all the samples. IL-10 has
anti-inflammatory properties and was reversed coded so that a high z-score
represented low IL-10 levels. IL-1β z-score and IL-10 reversed z-score were
averaged into a composite score to estimate a serum cytokine score where a
positive score represents a proinflammatory status in serum.
There are many different methods reported in the literature on how to
make a composite inflammation score. Many assign scores based on cutoffs
(e.g., percentile) and then add the scores together for a composite (Boelen 1995,
Wakelkamp et al. 2003, Xu et al. 2013). The serum cytokine score used in this
dissertation is based on a previously published composite cytokine score
(Osuchowski et al. 2010, Osuchowski et al. 2012, Stevens et al. 2017). However,
there are some important differences between the composite cytokine score and
the serum cytokine score. For the composite cytokine score, cytokine levels are
normalized to the median, and composite scores for proinflammatory cytokines
and anti-inflammatory cytokines are either kept as distinct, separate scores or a
ratio of proinflammatory cytokines scores and anti-inflammatory cytokines scores
are calculated. In contrast, the serum cytokine score used in this dissertation
uses the mean to normalize cytokine levels and averages the scores for
proinflammatory cytokines and the reverse-coded score for anti-inflammatory
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cytokines to make one value to reflect inflammation. The serum cytokine score is
similar to the composite cytokine score and is calculated to make better
conceptual sense in relation to serum BDNF levels.
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CHAPTER 3. SERUM BDNF LEVELS POSITIVELY CORRELATE
WITH PHOSPHORYLATED TAU IN ALZHEIMER’S DISEASE

CHAPTER 3.

SERUM BDNF LEVELS POSITIVELY CORRELATE WITH
PHOSPHORYLATED TAU IN ALZHEIMER’S DISEASE

This chapter is being prepared for publication:
Bharani, K. L., A. Ledreux, A. Gilmore, S. L. Carroll, and A. C. Granholm.
“Serum brain-derived neurotrophic factor (BDNF) levels positively
correlate with phosphorylated tau in Alzheimer’s disease.” Planned
submission to Acta Neuropathologica
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3.1 Introduction
Previous literature on BDNF levels in serum, brain, and CSF is discussed
in Chapter 1 Section 1.6. The relationship between BDNF levels in serum, CSF,
and brain tissue has not been fully investigated and represents an important step
to validate the use of blood levels of BDNF as a brain health biomarker.
Measures of BDNF levels in brain tissue or serum have led to mixed
results (see Appendix 1 and 2). Measurements of BDNF in CSF have also led to
mixed results with the added difficulty of limited detection levels (Laske et al.
2006, Soderquist et al. 2009). Furthermore, investigations of BDNF levels in the
CSF have thus far been limited to ante mortem lumbar CSF. BDNF levels in post
mortem cranial and lumbar CSF was unknown when this project was initiated,
and the relationship between BDNF levels in the CSF and brain tissue had not
been reported either.
Methodological issues or the disease stage of AD are likely reasons for
this discrepancy (Balietti et al. 2018). BDNF levels in serum have been proposed
to vary with disease severity, where higher BDNF levels are found in those with
MCI or mild AD compared to controls, and lower BDNF levels are found in those
with severe AD (Laske et al. 2006, Angelucci et al. 2010, Laske et al. 2011,
Forlenza et al. 2015, Kim et al. 2017). Another yet to be resolved issue is the
relationship between serum BDNF levels and brain BDNF levels. Although
significant correlations have been found between serum and brain BDNF levels
in animal models (Karege et al. 2002, Sartorius et al. 2009, Elfving et al. 2010,
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Klein et al. 2011), this relationship has not been directly investigated in humans,
and was therefore one of the aims in the current study.
In addition to the complexity of brain/blood BDNF levels, the interaction
between BDNF and biomarkers of AD (Aβ and pTau) is also complex (Diniz and
Teixeira 2011, Zhang et al. 2012, Rosa and Fahnestock 2014, Budni et al. 2015).
Lee et al. (2005) reported a weak correlation between the loss of BDNF and the
accumulation of neuritic amyloid plaques in AD patients. BDNF has been shown
to have direct dose-dependent protective effects against the toxicity induced by
Aβ peptide in animal models (Arancibia et al. 2008), and reduced high-affinity
BDNF receptor tropomyosin-related kinase B (TrkB) exacerbates hippocampal
signaling dysfunction in AD transgenic mice (Devi and Ohno 2015). TrkB
receptors have also been found to be trapped in senile plaques (Connor et al.
1996) which could contribute to loss of neurotrophic support from BDNF due to
reduced BDNF binding to its high-affinity receptor. Lower TrkB receptor
expression in AD hippocampi has been consistently reported (Connor et al. 1996,
Allen et al. 1999, Ferrer et al. 1999, Ginsberg et al. 2006). However, p75NTR
receptor expression in AD hippocampi has been reported as higher (Hu et al.
2002, Chakravarthy et al. 2012) or not different (Ginsberg et al. 2006) compared
to control, suggesting that a shift between the high-affinity receptor and the
p75NTR receptor may contribute to or be causative in AD neuropathology. Aβ
peptides have been shown to bind to the p75NTR receptor (Sotthibundhu et al.
2008) and positively correlate with p75NTR receptor expression (Chakravarthy et
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al. 2012), providing indirect evidence for a role of BDNF in protection against AD
pathology.
Despite these previous findings, no cohesive examination of BDNF, TrkB,
and AD pathology had been undertaken prior to our study. The aims of the
current study were to examine total BDNF, proBDNF, and mBDNF levels in post
mortem CSF, serum, and brain tissue samples. We aimed to assess the
relationship between BDNF levels in CSF and serum and BDNF levels in brain
tissue (BA46, ENT, HIP), as well as the relationship between BDNF levels and
the distribution of BDNF receptors, Aβ, pTau, and neuroinflammation in the
hippocampus to characterize the role of BDNF in the pathology of AD.

3.2 Methods and Materials
3.2.1 Human Cases
Post mortem human brain tissue and fluids were obtained from the Carroll
A. Campbell, Jr. Neuropathology Laboratory at the Medical University of South
Carolina (MUSC). Thirty-one post mortem cases (20 AD, 11 non-cognitively
impaired controls) were selected for this study. The neuropathological diagnoses
of AD and control cases were assessed by a board-certified neuropathologist at
MUSC. Bielschowsky silver staining, Amylo-Glo (Schmued et al. 2012) and pTau
immunostaining were used to confirm staging of AD pathology in the
hippocampus.
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3.2.2 Human Brain and Fluids Collection
Post mortem blood was collected into BD Vacutainer Serum Separator
Tubes® and allowed to clot for 60 minutes at room temperature (RT) before
being centrifuged for 20 minutes at 1,500 x g. Serum was then carefully
collected, aliquoted, and stored in a -80oC freezer until analysis. Cranial (CSF-C)
and lumbar (CSF-L) cerebrospinal fluid were collected at autopsy and centrifuged
for 20 minutes at 1,500 x g before being aliquoted and stored in a -80oC freezer.
The left hemisphere was cut into 1 cm coronal slabs and placed into clear plastic
bags for storage in a -80oC freezer. Right hemisphere 1 cm slabs were fixed freefloating in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 48-72
hours at 4oC. The paraformaldehyde-fixed slabs, were then transferred to a 0.1
M phosphate buffer solution (pH 7.4) containing 30% sucrose for at least 24
hours at 4oC. Subsequently, samples were transferred into cyroprotectant and
stored at -20oC. Frozen pieces of the prefrontal cortex (Brodmann area 46;
BA46), the entorhinal cortex (ENT), and the hippocampus (HIP) were isolated
from the left hemisphere and stored at -80oC before homogenization and use in
further assays. Fixed pieces of the 16 areas identified by Montine et al. (2012)
were embedded in paraffin, and 5 µm thick sections were used for
immunohistochemistry and for hematoxylin and eosin (H&E) stain, and
Bielschowsky silver stains. Paraffin sections (5 µm thick) of BA46, ENT, and HIP
were used for analysis of AD-related and inflammation-related markers with IHC.
Brain homogenates were prepared as described in Chapter 2 Section 2.3.3.
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3.2.3 Cytokine and Chemokine Quantification
Serum cytokines were measured, and a serum cytokine score was
calculated as described in Chapter 2 Section 2.6. The serum cytokine score
was not different between AD and Control (M-W U=69, p-0.561), did not correlate
with any of the measurements in this analysis, and consequently was not
considered a confounder.

3.2.4 Total BDNF Quantification
Total BDNF levels in undiluted CSF-C, undiluted CSF-L, and serum
samples (diluted 1:20 with manufacturer’s provided diluent, RD6P) were
measured in duplicates using the Human Free BDNF Quantikine ELISA Kit
(DBD00, R&D Systems, Minneapolis, USA), as described in Chapter 2 Section
2.4.2. Total BDNF levels in brain homogenates (BA46, ENT, HIP; each diluted
1:2 with manufacturer-provided Block & Sample buffer) were measured in
duplicate using the BDNF Emax® ImmunoAssay System (G7610, Promega,
Madison, WI) as described in Chapter 2 Section 2.4.3.

3.2.5 Mature BDNF and proBDNF Quantification
Western blotting was used to differentiate further and quantify mBDNF
(14-16 kDa) and proBDNF (28-32 kDa) as described in Chapter 2 Section 2.4.4.
Internal controls, mBDNF, and proBDNF were quantified on the same blots using
the same exposure at the same time for each sample type (i.e., serum, BA46,
ENT, and HIP). Representative blots for serum and brain homogenates are
Page 71

presented in Figure 3-1. Serum blots had strong proBDNF bands but
undetectable mBDNF bands. This is consistent with Carlino et al. (2011) where
western blot analysis of BDNF isoforms in ante mortem human serum samples
resulted in strong proBDNF bands and weak mBDNF bands using an anti-BDNF
antibody from Santa Cruz Biotechnology (N-20/sc-546). Conversely, brain
homogenate blots had strong mBDNF bands and weak proBDNF bands.
Figure 3-1
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Figure 3-1. ProBDNF and mBDNF representative western blots of serum (A)
and brain homogenate (B) samples. The first three lanes in both blots contain
Precision Plus Protein Dual Color ladder, 120 ng of recombinant human mature
BDNF protein (mBDNF), and 2 ng of recombinant human proBDNF protein. The
last three lanes contain 0.5 µL of serum (A) or 30 µg of human brain homogenate
(B) from three different cases. Strong proBDNF bands can be seen in serum
samples (A). Weak proBDNF and strong mBDNF bands can be seen in brain
samples (B).
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3.2.6 Immunohistochemistry
Five-micron paraffin-embedded sections were baked at 60oC for 1 hour
before deparaffinization in xylene twice for 5 minutes each followed by serial
rehydration in graded ethanol [100%, 95%, 70%, and phosphate-buffered saline
(PBS; 137 mM NaCl, 2.7 mM KCl, 43 mM Na2HPO4, 14.7 mM KH2PO4)] for 5
minutes at each step. Sections were then submerged in Tris-EGTA buffer (10mM
Tris, 0.5 mM EGTA) and heated in a microwave for 9 minutes at 80% power and
15 minutes at 40% power. After cooling on the bench for 15 minutes, sections
were blocked in 2% normal goat serum (NGS) in PBS for 30 minutes and then
incubated in 2% NGS-PBS with primary antibody (see Table 3-1) overnight at
4oC with agitation. The next day, sections were washed with PBS and incubated
with 1% bovine serum albumin solution made in PBS containing Alexa Fluor®
568 secondary antibodies targeting the host of the primary antibody (see Table
3-1) for 1 hour at RT with agitation. Sections were incubated in 0.04 ug/mL
bisbenzamide for 10 minutes and then incubated in 0.3% Sudan Black B
(ab146284) in 70% ethanol for 10 minutes before being washed and
coverslipped with ProLong® Diamond Antifade (Thermo Fisher Scientific
P36961).
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Table 3-1

Table 3-1. Antibodies used for immunohistochemistry. CNPase = 2',3'Cyclic-nucleotide 3'-phosphodiesterase; GFAP = Glial fibrillary acidic protein;
HLA-DR = Human Leukocyte Antigen – antigen D Related; pTau (AT8) =
Phosphorylated tau (Ser202, Thr205); TrkB = Tropomyosin receptor kinase B.
Target

Host

Dilution

Source

Identifier

Astroglia
(GFAP)

Rabbit

1:1,000

Agilent

DAKO 20334

Microglia
(HLA-DR)

Mouse

1:100

Thermo Fisher
Scientific

MA5-11966

Neurons
(NeuN)

Mouse

1:500

Millipore Sigma

MAB377

Oligodendrocytes Mouse
(CNPase)

1:200

Abcam

ab6319

p75NTR

Mouse

1:100

R&D Systems

MAB367

pTau (AT8)

Mouse

1:750

Thermo Fisher
Scientific

MN1020

TrkB

Rabbit

1:100

Alomone

ANT-019

Ms IgG (H+L)

Goat

1:1,500

Thermo Fisher
Scientific

Alexa Fluor® 568
A11004

Rb IgG (H+L)

Donkey

1:1,500

Thermo Fisher
Scientific

Alexa Fluor® 568
A10042

Amyloid staining was completed using Amylo-Glo® RTD™ “Ready to
Dilute” Staining reagent (Biosensis #TR-300-AG) following the manufacturer
provided protocol. Briefly, rehydrated sections were placed in 70% ethanol for 5
minutes at RT, distilled water for 2 minutes, manufacturer provided Amylo-Glo®
RTD™ solution for 10 minutes, 0.9% saline solution for 5 minutes, manufacturerprovided ethidium bromide (EtBr RTD™) solution for 3 minutes, 0.9% saline
solution for 5 minutes, and then rinsed briefly in distilled water before being
coverslipped with ProLong® Diamond Antifade.
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Images of the Cornu Ammonis (CA1) area of the hippocampus were
captured using a 40x objective on an Olympus BX53 microscope attached to an
Olympus DP80 camera. Images were analyzed using Fiji ImageJ (version 1.50i,
Schindelin et al. 2012). The background was subtracted using a rolling ball radius
of 50.0 pixels, and thresholding was used to isolate positive staining from
background staining by an experimenter blinded to the neuropathological status
of each case. The percent area of positive staining (% area) was quantified using
the Particle Analyzer feature in Fiji ImageJ with the size inclusion set to 200Infinite pixels to exclude smaller punctate staining with no apparent anatomical
pattern. This procedure was adapted from previous studies (Ubhi et al. 2009,
Ihara et al. 2010, Holleran et al. 2017, Woerman et al. 2018), and this technique
was further validated by a recent study (Holleran et al. 2017) where the
investigators reported a high correlation between stereology count of pTau sites
per area volume and the automated % area of pTau staining obtained using the
above described ImageJ-based workflow. Quantification of positive staining was
reported as an average % area from 3 non-overlapping images by an investigator
blinded to the groups.

3.2.7 Statistics
Outliers were identified using the Robust regression and Outlier removal
(ROUT) method in GraphPad Prism for Windows, version 6 (GraphPrism
Software, La Jolla, California, USA, www.graphpad.com). All other statistics were
run in IBM SPSS Statistics for Windows, version 24 (IBM Corp., Armonk, N.Y.,
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USA). BDNF has been widely reported to have a non-normal distribution
(Ziegenhorn et al. 2007, Balietti et al. 2018). In this study, a non-normal
distribution was confirmed by inspecting the histogram plot of the data for
skewness and by using the Shapiro-Wilk test. Equality of variance across groups
was assessed using Levene’s F-test. Accordingly, non-parametric pairwise
comparison between two groups was assessed using a Mann-Whitney (M-W) Utest for measures with equal variance between groups or a Kolmogorov-Smirnov
(K-S) Z-test for measure with unequal variance between groups. Relationships
between two continuous variables were assessed using nonparametric
Spearman’s rank-order correlation, and relationships between categorical
variables were assessed using the two-sided Fisher’s exact test.

3.3 Results
3.3.1 Demographics and characteristics of AD and Control groups
Summary data of age, gender, brain weight, APOE genotype, and post
mortem interval (PMI) is presented in Table 3-2. The mean age of the AD group
(76.5 ± 2.3 years) was statistically higher (t29=2.117, p=0.043) than the Control
group (66.2 ± 5.1 years). Previous studies have indicated that BDNF levels
decrease with increasing age (Laske et al. 2007, Ziegenhorn et al. 2007,
Erickson et al. 2010, Forlenza et al. 2015, Hakansson et al. 2017); however, in
this cohort, age did not significantly correlate with any of our measurements due
to our narrow age range (see Table 3-3 for correlations). No significant
differences were found in the ratio of females to males between the AD group
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(13/20 females, 65.0%) and the Control group (5/11 females, 45.5%; p=0.449,
two-sided Fisher’s exact test). However, brain weight in males (1316.7 ± 38.5
grams) were found to be significantly higher (t28=5.113, p<0.001) than in females
(1111.2 ± 20.6 grams), but not significantly different (t 28=1.002, p=0.325)
between the AD group and the Control group. The AD group (15/18, 83.3%
APOE ε4 carriers) had significantly more (p<0.001, two-sided Fisher’s exact test)
APOE ε4 alleles than the Control group (0/10, 0.0% APOE ε4 carrier). PMI was
statistically higher (t28=2.560, p=0.016) in the Control group (15.4 ± 1.9 hours)
than the AD group (10.1 ± 1.1 hours), but the PMI for all samples were under 24
hours. PMI also did not significantly correlate (p>0.05) with any measurements
used in this analysis, suggesting that PMI was not a confounder in this study.
Table 3-2

Table 3-2. Demographics of human brain samples. Mean ± SEM. NA= Not
Available; PMI = Post Mortem Interval.
Total

AD

Control

Age (years)

72.8 ± 2.5

76.5 ± 2.3

66.1 ± 5.2

Sex (female / male)

18 / 13

13 / 7

5/6

Brain weight (g)

1193±26.9

1174±36.5

1232±33.4

PMI (hours)

11.8 ± 1.1

10.1 ± 1.1

15.4 ± 1.9

ε2/ε3

2

0

2

ε3/ε3

11

3

8

ε3/ε4

9

9

0

ε4/ε4

6

6

0

NA

3

1

2

APOE status:

Table 3-3
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Table 3-3. Summary statistics of BDNF measurements from AD and Control
samples. Summary statistics are reported as median (Q3-Q1). Normality was
assessed using Shapiro-Wilk test. Equality of variances was assessed using
Levene’s F-test. Pairwise comparison was assessed using Mann-Whitney (M-W)
U-test or Kolmogorov-Smirnov (K-S) Z-test. Significance is indicated with * when
p<0.05. ND = Not Detectable (i.e., measurements were under detectable
threshold).
Measure

Equality PairAD vs Correlation
of
Wise
Control
with Age
Variance Test

AD

Control

Serum
(pg/mL)

524.8
(591-463)

496.7
(580-442)

p=0.396

M-W

p=0.547

rs=-0.004
p=0.987

BA46
(pg/mg)

10.6
(16.9-5.8)

12.3
(16.2-7.7)

p=0.724

M-W

p=0.966

rs=0.197
p=0.296

ENT
(pg/mg)

5.9
(10.9-2.8)

6.6
(10.4-5.5)

p=0.126

M-W

p=0.660

rs=-0.208
p=0.307

HIP
(pg/mg)

18.6
(44-10)

15.7
(33.2-11.6)

p=0.457

M-W

p=0.941

rs=-0.238
p=0.231

BDNF (ELISA)

mBDNF (Western Blot)
Serum

ND

ND

BA46

1.3
(2.4-0.7)

1.9
(2.4-1.3)

p=0.629

M-W

p=0.307

rs=0.241
p=0.199

ENT

0.8
(1.1-0.4)

1.2
(1.7-0.7)

p=0.725

M-W

p=0.104

rs=0.205
p=0.286

HIP

1.1
(1.5-0.6)

1.5
(2.2-0.1)

p=0.235

M-W

p=0.769

rs=0.166
p=0.389

proBDNF (Western Blot)
Serum

22.7
15.6
(33.9-12.4) (21.4-12.8)

p=0.024*

K-S

p=0.161

rs=0.297
p=0.149

BA46

0.06
0.1
(0.09-0.04) (0.14-0.07)

p=0.090

M-W p=0.024*

rs=-0.046
p=0.809

ENT

0.02
0.03
(0.03-0.01) (0.05-0.02)

p=0.903

M-W p=0.045*

rs=0.266
p=0.163

HIP

0.04
0.05
(0.04-0.02) (0.08-0.02)

p=0.042*

K-S

rs=-0.033
p=0.868
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p=0.106

3.3.2 Detection rate of BDNF in CSF-C was lower in the AD group
To test whether BDNF was detected at a lower rate in AD CSF (CSF-C
n=13, CSF-L n=6) than in Control CSF (CSF-C n=8, CSF-L n=8), we compared
the detection rate (number of samples with BDNF detected/total samples tested)
between the two groups. The detection rate of BDNF in undiluted CSF-C was
lower (p=0.007, two-sided Fisher’s exact test) in the AD group (5/13, 38.5%,
median of detected=11.2 pg/mL, Interquartile Range - IQR= 22.0-8.6 pg/mL) than
the Control group (8/8, 100%, median of detected=11.3 pg/mL, IQR= 12.7-9.8
pg/mL). In undiluted CSF-L, there was no difference (p=0.627, two-sided Fisher’s
exact test) in the ratio of BDNF detected in the AD group (4/8, 50.0%, median of
detected =27.9 pg/mL, IQR= 310.0-11.5 pg/mL) compared to the Control group
(4/6, 66.7%, median of detected=14.6 pg/mL, IQR= 106.2-9.3 pg/mL). Detectable
BDNF levels were not significantly different between the AD and Control groups
in both CSF-C (M-W U=19.0, p=0.943) and CSF-L (M-W U=6.0, p=0.686) and
did not significantly correlate (p>0.05) with any serum or brain BDNF
measurements, potentially due to the low number of samples with detectable
BDNF in CSF in the two cohorts.

3.3.3 Serum proBDNF levels were inversely related to HIP tBDNF and
proBDNF levels
To test the relationship between serum and brain tissue levels of BDNF, a
Spearman correlation table was generated to compare tBDNF and proBDNF
from serum with tBDNF, proBDNF, and mBDNF from BA46, ENT, and HIP frozen
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tissue samples. Serum proBDNF levels negatively correlated with HIP tBDNF
(rs=-0.435, p=0.043) and HIP proBDNF levels (rs=-0.432, p=0.040; Figure 3-2),
while serum tBDNF levels measured by ELISA did not correlate with any brain
measurement of BDNF, suggesting either that protein levels of mBDNF or
proBDNF may deteriorate more rapidly in serum than in brain tissue post
mortem, or that levels observed in the blood are not entirely mirroring the levels
observed in the CNS at the same time.

HIP tBDNF (pg/mg)

Figure 3-2

80

60

40

20

0

0

0 .1 0

HIP proBDNF

Figure 3-2. Correlations
between serum proBDNF
measurements and HIP
tBDNF and proBDNF
measurements. Nonparametric Spearman
correlations were used to
compare peripheral serum
measurements of BDNF to
central brain measurements
20
40
60
8 0 of BDNF. Total BDNF
(tBDNF) was assessed
Serum proBDNF
through commercial ELISA
while proBDNF was
quantified through western
rs (23)=-0.432
blotting after normalizing to
p=0.040*
internal control protein
transferrin for serum and βactin for HIP brain
homogenates.
rs (23)=-0.435
p=0.043*
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3.3.4 BA46 and ENT proBDNF levels were lower in AD
In line with previous findings in the parietal cortex (Michalski and
Fahnestock 2003, Peng et al. 2005), proBDNF in BA46 (M-W U=49.0, p=0.024)
and in ENT (M-W U = 51.0 p=0.045) was found to be statistically lower in the AD
group compared to the Control group. ProBDNF in the HIP was not significantly
different between the AD group and the Control group (K-S Z=1.266, p=0.106);
however, HIP proBDNF was negatively correlated with HLA-DR (rs=-0.498,
p=0.011) and positively correlated with p75NTR in the hippocampus (rs=0.480,
p=0.018) across groups, suggesting that higher neuroinflammation was
associated with lower proBDNF and that lower proBDNF was associated with
lower p75NTR receptor density.
Considering that the ENT has direct and indirect inputs into CA1 of the
HIP and the majority of BDNF synthesized in the ENT is transported to the HIP
(Scharfman and Chao 2013), we tested if BDNF levels in the ENT correlated with
IHC measures of AD pathology, BDNF receptors, neurons, and glia in the CA1.
ENT tBDNF levels were found to be positively correlated with NeuN staining in
CA1 (rs=0.419, p=0.041) and negatively correlated with amyloid staining in CA1
(rs=-0.418, p=0.047), suggesting that BDNF from the ENT provide trophic support
for mature neurons and perhaps ameliorates plaque burden in the CA1 region of
the HIP. Western blot measurement of mBDNF and ELISA measurement of
tBDNF levels in any of the brain regions did not differ between AD and Control
(M-W, p>0.05), likely due to high variability.
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3.3.5 TrkB, but not p75 staining, is inversely correlated with amyloid
and pTau accumulation
Frequent diffuse and neuritic plaques were apparent in all AD
hippocampal sections with increased number and size in the CA1 region.
Similarly, numerous NFTs and dystrophic neurites were found in all AD
hippocampal sections with increased number of intracellular and ghost tangles
found in the CA1 region. Control hippocampal sections presented with few to no
positive amyloid plaques or tangles. These observations were supported by
statistical analysis of % area measurements of Amylo-Glo® and pTau (AT8)
staining where the AD group had statistically higher % area staining for amyloid
(K-S Z=1.976, p=0.001) and pTau (K-S Z=1.824, p=0.003) compared to the
Control group (Figure 3-3).
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Figure 3-3
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Figure 3-3. Representative images of amyloid plaques (A, B) and
phosphorylated tau (D, E) in the CA1 region of the hippocampus. Bar graphs
(C, F) depict median and interquartile range of the % area stained by AmyloGlo® and pTau antibody in the AD and Control groups. The AD group had
statistically higher % area staining for amyloid (K-S Z=1.976, p=0.001) and pTau
(K-S Z=1.824, p=0.003) compared to the Control group. (AT8) = Phosphorylated
tau (Ser202, Thr205). **p<0.001.

Microscopic evaluation of the high-affinity BDNF receptor TrkB and lowaffinity BDNF receptor p75NTR revealed diffuse staining across the hippocampal
regions with increased immunoreactivity in cell bodies compared to processes.
Additionally, TrkB staining was not found in the nucleus, unlike p75NTR, and was
found in fewer neurons in the CA1 of the AD cases compared to Control cases.
Statistical analysis of % area measurements of these stains confirmed that the
AD group had lower % area staining of the BDNF receptor TrkB (M-W U=39.0,
p=0.009) than the Control group, but the AD group did not differ from the Control
group in % area staining of p75NTR (M-W U=58.0, p=0.148, Figure 3-4). TrkB %
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area staining negatively correlated with amyloid (r s=-0.386, p=0.042) and pTau
(rs=-0.383, p=0.044) immunoreactivity, while p75NTR % area staining did not
correlate with either amyloid (rs=0.251, p=0.207) or pTau (rs=0.215, p=0.282),
suggesting that amyloid and pTau pathology may downregulate or interfere with
TrkB but not p75NTR density.
Figure 3-4
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Figure 3-4. Representative images of neurotrophin receptors p75
(A, B)
and TrkB (D, E) in the CA1 region of the hippocampus. Bar graphs (C, F)
depict median and interquartile range of the % area stained by TrkB and p75NTR
antibodies in the AD and Control groups. The AD group had lower % area
staining of the BDNF receptor TrkB (M-W U=39.0, p=0.009) than the Control
group, but the AD group did not differ from the Control group in the % area
staining of p75NTR (M-W U=58.0, p=0.148). TrkB = Tropomyosin receptor kinase
B; p75NTR = p75 neurotrophin receptor. **p<0.001.

3.3.6 HLA-DR staining positively correlated with amyloid and pTau
staining
Microscopic evaluation of astrocytes, microglia, oligodendrocytes, and
mature neurons in the hippocampus was highly variable across cases in both the
AD and the Control groups. AD cases tended to have an increase in the density
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of GFAP-stained astrocytes with overlapping processes and enlarged cell bodies
compared to the Control cases, indicating increased astrogliosis in AD
hippocampi. Similarly, ramified microglia with slender extrusions and reactive
microglia with rounded cell bodies and fewer extrusions were observed more
often in the AD hippocampi than in the Controls. However, % area
measurements of GFAP (K-S Z=1.161, p=0.135, Figure 3-5A-C) and HLA-DR
(K-S Z=0.912, p=0.376, Figure 3-5D-F) in the CA1 region of the hippocampus
was not significantly different between the AD and the Control groups,
presumably due to the high variability observed between the different cases.
HLA-DR staining was positively correlated with amyloid staining (rs=0.371,
p=0.057) and pTau staining (r s=0.383, p=0.049), although the former did not
reach statistical significance at p<0.05. This result suggests that increased HLADR positive microglia is associated with increasing AD pathology. Mature, small,
round oligodendrocytes and their long thin processes were observed equivalently
between AD and Control hippocampi which was supported by statistical analysis
of % area measurements of CNPase staining (M-W U=92.0, p=0.135, Figure 5GI). Consistent with previous findings that hippocampal atrophy and not
necessarily neuronal loss distinguishes AD from controls (Simic et al. 1997, Jin et
al. 2004), the density of mature neurons was not decreased in the CA1 region of
AD hippocampi compared to Control hippocampi. This observation was further
supported by statistical analysis of % area measurements of NeuN staining (M-W
U=83.0, p=0.492, Figure 3-5J-L).
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Figure 3-5
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Figure 3-5. Representative images of astrocytes (GFAP; A, B), activated
microglia (HLA-DR; D, E), oligodendrocytes (CNPase; G, H), and mature
neurons (NeuN; J, K) in the CA1 region of the hippocampus. Bar graphs (C,
F, I, L) depict median and interquartile range of the percent area stained of each
marker in the AD and Control groups. The AD and Control groups did not
significantly differ in % area measurements of GFAP (K-S Z=1.161, p=0.135),
HLA-DR (K-S Z=0.912, p=0.376), CNPase staining (M-W U=92.0, p=0.135), or
NeuN staining (M-W U=83.0, p=0.492). CNPase = 2',3'-Cyclic-nucleotide 3'phosphodiesterase; GFAP = Glial fibrillary acidic protein; HLA-DR = Human
Leukocyte Antigen – antigen D Related; NeuN = Neuronal nuclei.
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3.3.7 Serum proBDNF positively correlated with pTau staining
As an exploratory analysis to see if serum tBDNF or serum proBDNF
levels were correlated with hippocampal pathology, a Spearman correlation table
between serum BDNF levels (tBDNF and proBDNF) and IHC density measures
of amyloid, pTau, BDNF receptors, and glia in the CA1 was analyzed. Serum
tBDNF levels were positively correlated with HLA-DR staining density (rs=0.593,
p=0.007), and serum proBDNF levels were positively correlated with pTau
staining density (rs=0.435, p=0.043), suggesting that serum BDNF may be
upregulated

with

increasing

neuroinflammation

and

AD

pathology.

No

correlations reached significance (p>0.05).

3.3.8 High and Low AD subgroups differed in amyloid, pTau, and
GFAP staining
To investigate the effects of severity, z-scores were calculated for each
stain using the mean and standard deviation of the control group. A positive zscore is interpreted as higher % area staining compared to controls, and a
negative z-score is interpreted as lower % area staining compared to controls.
Two AD subgroups could be distinguished by density of GFAP staining. One AD
subgroup (High AD) had intense GFAP staining, and the other subgroup (Low
AD) was more similar to the Control group with low GFAP staining. Accordingly,
AD subgroups were defined based on GFAP % area z-scores where cases with
z-scores greater than 2 was classified as High AD (n=7), and cases with z-scores
less than 1 were classified as Low AD (n=10). Visualization of these stains by
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subgroups (Figure 3-6A) suggests that the High AD subgroup had higher
amyloid, higher pTau, and higher GFAP staining than the Low AD subgroup.
Statistical analysis between High AD and Low AD confirmed this observation in
in terms of GFAP staining (M-W U=0.0, p<0.001) while only a marginally
significant difference was found between High AD and Low AD in amyloid (M-W
U=15.0, p=0.055) and pTau (M-W U=16.0, p=0.070). The High AD and Low AD
subgroups did not differ in staining for p75NTR (M-W U=23.0, p=0.475), TrkB (MW U=26.0, p=0.417), HLA-DR (M-W U=29.0, p=0.958), CNPase (M-W U=28.0,
p=0.536), or NeuN (M-W U=27.0, p=0.475). Visualization of brain tBDNF zscores by subgroup (Figure 3-6B) suggests that the Low AD subgroup had
higher tBDNF in the ENT and HIP than the High AD subgroup and the Control
group, suggesting a possible compensatory increase in BDNF in AD compared to
Control when AD pathology is low. In addition, proBDNF levels seem to be higher
in both the AD subgroups compared to the Control group only in serum (Figure
3-6C), and mBDNF was lower in all three brain regions in both the AD subgroups
(Figure 3-6D). Although mechanistically interesting, these observations were not
found to be statistically significant (p>0.05). Interestingly, the AD case which had
the highest HLA-DR staining area for CA1 also exhibited very high % staining for
GFAP, pTau, and among the lowest levels of BDNF, suggesting a correlation
between inflammatory activation, AD pathology, and BDNF expression at the
individual level. This will have to be further examined using early and late Braak
stage cases in the future.
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Figure 3-6
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Figure 3-6. Profiles of staining (A), total BDNF (B), proBDNF (C), and mature
BDNF (D) in Control and AD subgroups. Mean and standard error of Z-scores
for % area of each stain and total BDNF levels for the Control group, High AD
subgroup, and Low AD subgroup are plotted. Z-scores were calculated using the
mean and standard deviation of the Control group. The AD subgroup was
defined by GFAP % area staining where a case with a z-score greater than 2
was classified as High AD and a case with a z-score less than 1 was classified
as Low AD. A significant difference between the High AD and Low AD subgroups
was found in z-scores of GFAP (M-W U=0.0, p<0.001) while a marginally
significant difference was found in z-scores of amyloid (M-W U=15.0, p=0.055)
and pTau (M-W U=16.0, p=0.070). Total BDNF levels in the dorsolateral
prefrontal cortex (BA46), entorhinal cortex (ENT), hippocampus (HIP) and serum
and proBDNF in serum were not significantly (p>0.05) different between the High
AD and Low AD subgroups. However, trends can be observed in BDNF levels in
brain regions where the Low AD subgroup seems to have had higher total BDNF
levels than the High AD subgroup in the ENT and HIP. Similarly, trends can be
observed in proBDNF and mature BDNF between groups; however, these
relationships were not significantly different (p>0.05).
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3.4 Discussion
To our knowledge, this is the first investigation of BDNF in serum, CSF,
and brain tissue from the same AD and Control cases. We measured the levels
of tBDNF, proBDNF, and mBDNF in post mortem CSF, serum, and frozen brain
tissue regions and correlated these findings with staining densities of amyloid,
pTau, BDNF receptors (TrkB and p75NTR), and glia (astrocytes, activated
microglia, oligodendrocytes) in the CA1 region of the HIP to investigate the
relationship between peripheral BDNF levels, central BDNF levels and pathology.
We found that 1) BDNF in CSF was detected at a lower ratio in the AD group
than in the Control group, 2) BDNF in serum was inversely related to BDNF in
HIP, and 3) HIP AD pathology was correlated with decreased TrkB staining,
increased neuroinflammation, and decreased HIP proBDNF levels, as measured
by western blots. Further exploratory data analysis showed that serum BDNF
levels were correlated with the % area of staining of HIP CA1 microglia and pTau
and suggested that a low pathology AD subgroup expressed lower levels of
astrogliosis and higher BDNF levels than the high pathology AD subgroup,
although further in-depth analysis is warranted in future studies.
We showed that tBDNF was not reliably detected in post mortem CSF
samples, similar to studies using ante mortem lumbar CSF (Blasko et al. 2006,
Laske et al. 2006, Laske et al. 2007, Jiao et al. 2016). However, tBDNF was
above the detection limit in cranial CSF more often in Control cases than in AD
cases, suggesting reduced tBDNF levels in AD samples. This is consistent with
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previous reports of lower BDNF levels in ante mortem lumbar CSF from AD
patients compared to age-matched Controls (Laske et al. 2007, Zhang et al.
2008, Li et al. 2009, Forlenza et al. 2015). In the samples where BDNF was
above the detection limit, we found that CSF BDNF levels did not correlate with
serum BDNF levels (tBDNF or proBDNF), confirming findings by Laske et al.
(2007) who reported a similar finding in ante mortem lumbar CSF and serum.
These findings are unique in that neither CSF-C nor CSF-L BDNF levels
correlated with BDNF levels (tBDNF, proBDNF, or mBDNF) in BA46, the ENT, or
the HIP. These results underscore the difficulty in measuring and interpreting the
significance of BDNF levels in CSF, which has also been pointed out previously
by others (Blasko et al. 2006, Laske et al. 2006, Laske et al. 2007, Jiao et al.
2016).
Previous investigations have reported lower proBDNF levels in AD
compared to Control only in the parietal cortex and not in the frontal cortex (BA9)
or hippocampus (Michalski and Fahnestock 2003, Peng et al. 2005, Michalski et
al. 2015). In the current study, we investigated proBDNF levels in the dorsolateral
prefrontal cortex (BA46), the ENT, and the HIP, and we found lower levels of
proBDNF in BA46 and ENT but not in the HIP of the AD group compared to the
Control group. Similar to Michalski and Fahnestock (2003), we found no
differences in mBDNF levels between the AD and Control groups in any of the
three brain regions investigated (BA46, ENT, HIP). We also found no difference
between tBDNF levels measured by ELISA between the AD and Control groups
in any of the three brain regions investigated (BA46, ENT, HIP). This
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preservation of hippocampal BDNF levels in AD compared to Control has been
reported before (Connor et al. 1997, Murer et al. 1999), and may be due to the
highly interconnected nature of the hippocampus which may facilitate
compensatory anterograde transport of BDNF from other brain regions to the
hippocampus (Scharfman and Chao 2013). Indeed, in this study, we found that
tBDNF levels in the ENT positively correlated with NeuN staining density and
negatively with Amylo-Glo staining in the hippocampal CA1 area, suggesting that
ENT input in to CA1 through the perforant pathway may provide trophic support
and mitigate amyloidosis, as suggested in tissue culture and animal models of
AD (Arancibia et al. 2008). We also found that although tBDNF, proBDNF, and
mBDNF levels were not significantly different between the AD and Control
groups in the HIP, proBDNF levels in the HIP were inversely related to HLA-DR
staining. HLA-DR staining, in turn, was positively correlated with amyloid and
pTau staining. HLA-DR is an major histocompatibility (MHC)-Class II marker for
microglial activation and indiactes increased inflammatory processes in the brain,
which have been shown to induce and increase AD neuropathology (Busse et al.
2015, Hendrickx et al. 2017). This result highlights the antagonistic relationship
between BDNF and inflammation and the potential benefit of inc/reasing BDNF
levels to reduce inflammation or to compensate for downregulated BDNF
expression due to inflammation as reported in previous studies (Patterson 2015,
Di Benedetto et al. 2017).
We further found that high-affinity BDNF TrkB receptor staining was
downregulated in AD CA1 compared to staining observed in the control cases.
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Previous studies have shown that TrkB receptors may be trapped in senile
plaques, leading to reduced BDNF signaling in patients with AD (Connor et al.
1996) and our finding of a negative correlation between TrkB expression and
amyloid and pTau expression further supports this finding. Overall, our finding of
equivalent BDNF levels but decreased TrkB receptor expression in the HIP
suggests that stimulation of TrkB expression should be considered along with
BDNF supplementation therapy. A recent manuscript by Zhang et al. (2018) has
shown that Tau phosphorylation negatively controls BDNF-TrkB receptor
activation in AD mouse brains, demonstrating a strong connection between the
development of AD pathology and down-regulation of BDNF expression or
receptor activation. Targeting both BDNF and TrkB expression will be interesting
for future pharmaceutical investigations and will complement current trials
focused on AAV delivery of BDNF to aged non-human primates and humans with
AD (Nagahara et al. 2018).
Moreover, p75NTR receptor staining densities in the hippocampus were not
different between the AD and Control groups, which is consistent with the
Ginsberg et al. (2006) study where they found a downregulation in TrkB but not
p75NTR expression in cholinergic basal forebrain neurons in patients with AD.
Although we find a preservation of p75NTR receptor expression in the AD
hippocampus compared to controls, it has been proposed that the increase of
p75NTR expression in relation to TrkB may reflect cell fate towards apoptosis and
death (Meeker and Williams 2014). Amyloid has also been shown to interact with
p75NTR receptors to induce neuronal damage (Perini et al. 2002, Zeng et al.
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2011), and a positive correlation between p75NTR and amyloid (Chakravarthy et
al. 2012) and pTau (Hu et al. 2002) staining in the hippocampus has been
previously reported. Although we found a positive correlation between p75NTR
staining densities in CA1 of the hippocampus and proBDNF levels in the
hippocampus, this result was difficult to interpret because p75NTR is a
promiscuous receptor with several different ligands and functions (Zeng et al.
2011), and because reports of p75NTR expression in AD brains compared to
control has been mixed with some reports of increased expression in AD (Hu et
al. 2002, Chakravarthy et al. 2012) or not different between AD and control
(Ginsberg et al. 2006). There is thus a complicated relationship between the
expression of this pan-neurotrophin receptor and the progression of AD
neuropathology.
Two subgroup within our AD cases were identified by separating AD
subjects by degree of GFAP staining. The Low AD subgroup, which is
characterized by low GFAP immunoreactivity, also presented with lower amyloid
and pTau staining than did the High AD subgroup despite having equivalent
HLA-DR staining. AD pathology has been shown to upregulate GFAP and trigger
reactive astrogliosis (Heneka et al. 2015, Hol and Pekny 2015, Osborn et al.
2016). Reactive astrocytes often accumulate around senile plaques (Medeiros
and LaFerla 2013) and are thought to aid with neuroprotection and degradation
of amyloid (Wyss-Coray et al. 2003). However, an interesting study in the
APP/PS1 mouse model of AD showed that AAV suppression of astrogliosis led to
improved cognition and decreased amyloid aggregation (Furman et al. 2012). In
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the current study, the Low AD subgroup also had higher tBDNF levels in the ENT
and HIP compared to both the High AD subgroup and the Control group,
although this was not statistically significant. Our observation of low AD
pathology and higher BDNF levels in the Low AD subgroup supports the notion
of a compensatory increase in serum, brain, and CSF BDNF levels in MCI or
early AD compared to controls (Durany et al. 2000, Laske et al. 2006, Konukoglu
et al. 2012, Kim et al. 2017). Once a compensatory increase in BDNF fails to
ameliorate the pathology, the patient is thought to be at a higher risk for cognitive
and clinical decline, suggesting that failure to compensate with higher BDNF
expression may lead to a conversion from MCI to AD.
Unique to this study is the measurements of BDNF levels in serum and
brain tissue from the same human donors to investigate the correlation between
serum BDNF levels and brain BDNF levels. A positive correlation between blood
and brain BDNF levels has been consistently reported in rats, mice, and pigs
(Karege et al. 2002, Sartorius et al. 2009, Klein et al. 2011, Bharani et al. 2017),
but the relationship between blood and brain BDNF is unknown in humans to
date. In a rat model of aging and cognitive impairment, we recently demonstrated
a significant correlation between serum and brain tissue levels of BDNF and also
found that lower BDNF levels in aged rats were associated with increased
inflammatory markers, at least following an acute neurodegenerative lesion
(Bharani et al. 2017). Both in our previous work and in the current study, we used
commercially available ELISA kits that are frequently used in the assessment of
serum BDNF in various clinical populations as well as semi-quantitative western
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blotting techniques to measure tBDNF, proBDNF, and mBDNF in serum and in
three brain regions from the same donor (BA46, ENT, HIP). We hypothesized
that a positive correlation between blood and brain BDNF levels would validate
the use of blood BDNF levels to infer the expression of BDNF in brain tissue.
However, we found a negative correlation between serum proBDNF levels and
hippocampal total BDNF levels as well as hippocampal proBDNF levels. This
result parallels the findings reported by Elfving et al. (2010) where a negative
correlation was found between serum and hippocampal BDNF in a genetic rat
model of depression and may suggest that peripheral sources of BDNF could
interfere with interpretations of BDNF levels in serum as a biomarker for
neurological conditions affecting the brain.
One interpretation of a negative correlation between blood and brain
BDNF is that increasing pathology disrupts the blood-brain barrier such that
BDNF is trapped in one compartment. However, this is highly unlikely
considering that blood-brain barrier integrity has been shown to decrease with
increasing AD pathology (Yamazaki and Kanekiyo 2017, Zenaro et al. 2017).
Alternatively, BDNF is produced in peripheral tissues (e.g., endothelial cells and
smooth muscles) (Donovan et al. 1995, Fujimura et al. 2002, Michalski and
Fahnestock 2003), and peripheral BDNF levels might be upregulated to
compensate for pathology-associated downregulation of BDNF levels in the
brain. Further interventional studies in animal models need to be undertaken to
understand the role of peripheral BDNF levels and its relationship with brain
BDNF levels and function in the context of pathologic aging.
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When studying post mortem tissues, one has to consider many different
factors that can influence the outcomes and interpretation. Clinical factors known
to modulate BDNF levels such as ante mortem medication (Leyhe et al. 2008,
Leyhe et al. 2009) and comorbidities (Bus et al. 2011, Bus et al. 2012) should
also be carefully considered for any analysis. In addition, as a post mortem
cross-sectional investigation, inherent limitations exist in regards to inferring
causation and so longitudinal studies need to be undertaken to investigate
whether BDNF dysfunction in AD is a primary pathological event. However, the
strengths of our study include using conservative statistical testing to avoid false
positives, measuring different forms of BDNF (tBDNF, mBDNF, and proBDNF)
with both commercial ELISA kits and western blot analyses to increase
reproducibility, and uniquely relating levels of peripheral BDNF (serum and CSF)
to central BDNF in three different regions of the brain (BA46, ENT, HIP). Our
results thus define the relationship between serum BDNF levels, brain BDNF
levels and hippocampal pathology. Our results indicate that proBDNF may be
significantly associated with both amyloid load and pTau-positive NFTs in the
hippocampus, and that future therapeutic strategies for AD should consider
targeting both BDNF and TrkB expression.
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4.1 Introduction
Aging and aging-related disorders such as Alzheimer’s disease (AD) and
Parkinson’s disease (PD) are characterized by a subclinical chronic inflammatory
status (Tansey and Goldberg 2010, Holmes 2013, Amor et al. 2014, Heneka et
al. 2015) and by increased pro-inflammatory markers in the brain (Franceschi et
al. 2000). Additionally, existing neuropathology can be exacerbated by systemic
inflammation via a spread of pro-inflammatory cytokines across the blood-brain
barrier (BBB) and subsequent activation of microglial cells in the brain (Perry et
al. 2007, Perry 2010, Bettcher and Kramer 2014, Heneka et al. 2015). Systemic
inflammation induced by the bacterial endotoxin lipopolysaccharide (LPS) is welldocumented to cause neuroinflammation in animal models (Qin et al. 2007,
Jeong et al. 2010) despite the fact that the endotoxin does not readily cross the
BBB (Banks and Erickson 2010, Banks and Robinson 2010). Instead, circulating
pro-inflammatory cytokines induced by systemic LPS cross the BBB, activate
microglia, and directly inhibit crucial transcription factors in hippocampal neurons
to induce neurodegeneration secondary to neuroinflammation (Laflamme and
Rivest 1999, Perry et al. 2007, Perry 2010, Bettcher and Kramer 2014, Heneka
et al. 2015, Patterson 2015). Several clinical and epidemiological studies suggest
that pro-inflammatory cytokines can increase the susceptibility to cognitive
impairment in older adults (Perry et al. 2007, Cunningham et al. 2009, Simen et
al. 2011, Holmes 2013, Franceschi and Campisi 2014, Cunningham and
Hennessy 2015). Accordingly, factors that further damage the BBB and increase
its permeability, such as aging and noradrenergic degeneration (Wolburg and
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Lippoldt 2002, Kalinin et al. 2006), can exacerbate the detrimental neuronal
effect of LPS-induced systemic inflammation.
Noradrenergic degeneration has been shown to occur early in AD
progression and is found in amnestic mild cognitive impairment patients (Kelly et
al. 2017). Understanding effects of systemic inflammation in an aged model with
locus coeruleus noradrenergic (LC-NE) dysfunction will be essential for
developing therapies to mitigate cognitive decline in older adults, but a combined
examination of LPS and LC-NE degeneration has not been undertaken to date.
LC-NE neurons have extensive innervations of cortical and subcortical brain
regions and modulate cognitive functions including memory and attention
(Uematsu et al. 2015). In particular, the LC-NE influences cognitive flexibility,
working memory, and attentional processes (Lockrow et al. 2011). LC-NE
neurons have also been shown to degenerate in normal aging, and, to a greater
extent, in both AD and PD early in the disease process (Tomlinson et al. 1981,
Feinstein et al. 2016, Vermeiren and De Deyn 2017). In addition to its role as a
neurotransmitter, NE also has potent anti-inflammatory effects via adrenergic
receptors on astrocytes and microglia to suppress the expression of proinflammatory cytokines and chemokines (Heneka et al. 2002, Heneka et al. 2010,
Lockrow et al. 2011). Accordingly, LC-NE degeneration leads to the loss of the
anti-inflammatory state in the brain (Marien et al. 2004, Grudzien et al. 2007,
Lockrow et al. 2011), and elevated neuroinflammation due to LC-NE pathway
degeneration has been linked to early neuronal dysfunction and aggravated AD
pathophysiology including increased amyloid accumulation in AD mouse models
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(Heneka et al. 2010). Because of adrenoreceptors located on endothelial cells in
the brain, the degeneration of LC-NE innervation is implicated in the disruption of
tight junction assembly (Kalinin et al. 2006) and increased BBB permeability
(Wolburg and Lippoldt 2002), which is likely to make the central nervous system
more susceptible to systemic insults. Although these findings individually
implicate LC-NE pathway degeneration and systemic inflammation in pathologies
of aging, the interaction between LC-NE degeneration and systemic inflammation
in the aged brain remains to be explored.
Systemic inflammation induced by LPS may also affect neurotrophic
support. For example, brain-derived neurotrophic factor (BDNF) is broadly
important for regulating neuronal growth, differentiation, and survival and is
necessary for neuronal plasticity along with counteracting amyloid toxicity in cell
culture (Counts and Mufson 2010, Liu et al. 2015, Begni et al. 2017). Systemic
inflammation was shown to reduce BDNF gene expression in certain areas of the
rodent brain (Guan and Fang 2006), and pro-inflammatory cytokines interfere
with BDNF’s neuroprotective effects in rat brain tissue cultures (Tong et al. 2008,
Tong et al. 2012). Inflammatory disruption of BDNF synthesis and function can
lead to dysfunctions in rat hippocampal-dependent memory (Barrientos et al.
2004, Patterson 2015). LC-NE activity and BDNF seem to have an intricate
relationship. Indeed, exogenous BDNF infusion into the frontal cortex protects
against age-related LC-NE degeneration in rats (Nakai et al. 2006). Because LCNE activity regulates the expression of BDNF (Willis et al. 2005, Mello-Carpes et
al. 2016), we wanted to explore whether a combined systemic inflammation and
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LC-NE degeneration would affect BDNF levels in serum or in brain tissue in aged
rats.
The neurotoxin DSP4 (N-(2-chloro ethyl)-N-ehtyl-bromo-benzyl amine)
readily crosses the BBB to cause selective degeneration of the rat LC-NE system
by first inhibiting the noradrenaline transporter, depleting intracellular NE, and
finally inducing degeneration of noradrenergic terminals. Although peripheral
administration of DSP4 decreases NE levels in the peripheral sympathetic
system, this effect is temporary and is resolved within one week (for review, see
Ross and Stenfors (2015)). Our lab has previously shown that LC-NE
degeneration induced by DSP4 significantly promotes neuroinflammation and
behavioral deficits in the Ts65Dn mouse model of Down syndrome, but has no
neuroinflammatory and minimal behavioral effects on normosomic mice (Lockrow
et al. 2011). Similarly, DSP4 treatment on rats has had minimal to no effect on
behavioral performance in the open field test (Srinivasan and Schmidt 2004),
elevated plus maze (Lapiz et al. 2001), water maze (Abe et al. 1997), and Cogitat
holeboard paradigm (Hauser et al. 2012). Thus, the overall purpose of the
current study is to examine whether a DSP4-induced LC-NE lesion would
potentiate neuroinflammation and behavioral impairment specifically in aged rats
subjected to LPS-induced systemic inflammation. We hypothesized that aged
rats with pronounced LC-NE degeneration would develop an exacerbated
response to LPS-induced systemic inflammation in terms of inflammatory
markers, glial activation, and neuronal deterioration and that this would be
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related to a reduction in BDNF expression and reduced performance in a novel
object recognition task.

4.2 Methods
4.2.1 Animals
Twenty-month-old male Fischer 344 (F344) rats (weighing 434 ± 34 g)
from the aging colony of National Institute on Aging (NIA) at Charles River were
pair-housed in an Association for Assessment and Accreditation of Laboratory
Animal Care accredited animal care facility at the Medical University of South
Carolina (MUSC). All animals were maintained on a 12-h light/dark cycle
according to NIA guidelines for aged rats and received food and water ad libitum.
All experimental procedures were approved by the Institutional Animal Care and
Use Committee (IACUC) at MUSC and complied with NIH guidelines.

4.2.2 Treatment
Treatment groups consisted of 16 double-saline-injected rats (Ctrl), 18
saline- and lipopolysaccharide- (LPS, from Escherichia coli, serotype O55:B5,
Sigma-Aldrich) injected rats (LPS), and 19 DSP4- [N-(2-chloroethyl)-N-ethyl-2bromobenzylamine, Sigma-Aldrich] and LPS-injected rats (DSP4+LPS). Rats first
received one dose of DSP4 (25 mg/kg, dissolved in sterile saline 0.9%, i.p.),
known to be capable of crossing the BBB and toxic to norepinephrine (NE)
neurons (Kalinin et al. 2006, Lockrow et al. 2011, Ross and Stenfors 2015) or
saline (i.p.). Two weeks following the DSP4 or saline injection, rats were injected
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with LPS (0.75 mg/kg, dissolved in sterile saline 0.9%) or saline (i.p.). After four
hours, a subgroup of rats was sacrificed by an overdose of isoflurane (short-term
subgroup). The remaining subgroup of rats underwent behavioral assessment
seven days after LPS injection and was then sacrificed (long-term subgroup).

4.2.3 Novel object recognition task (NORT)
Seven days following the LPS injection, the long-term subgroup of rats
completed a three-day novel object recognition task. On Day 1, rats were
habituated to an empty circular testing arena (80 cm wide) for 5 minutes. On Day
2, rats were first exposed to two identical objects (A, A) for a 5-minute period
(Trial 1). After a 90-minute break, rats were exposed to one familiar and one
novel object (A, B) and rats were free to explore for another 5 minutes (Trial 2).
On Day 3, one of the objects was replaced with a new object (A, C), and rats
explored for 5 minutes (Trial 3). After a 90-minute break, the novel object (C) was
moved 90o clockwise, and rats were placed in the testing arena for another 5
minutes (Trial 4). Each trial was recorded and analyzed through an automated
tracking system (Panlab SMART v3.0, Harvard Apparatus, USA).

4.2.4 Blood and brain collection
Rats were anesthetized deeply with isoflurane, and blood was collected by
cardiac puncture into BD Vacutainer® SST tubes. Blood was allowed to clot for 1
hour at room temperature before being centrifuged for 20 minutes at 1,500 x g.
Serum was aliquoted and stored in -80°C freezer until further analysis. The right
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frontal cortex and right hippocampus were snap frozen on dry ice and stored at 80oC until homogenization.

4.2.5 Preparation of brain homogenates
Brain homogenates were prepared in the Lab buffer as described in
Chapter 2 Section 2.3.2.

4.2.6 Quantification of cytokines and chemokines
Quantification of serum levels of cytokines (IL-1β, IL-6, IL-10, IL-17A,
TNFα, and IFNγ), serum chemokine (IP-10), and hippocampal IL-1β are
described in Chapter 2 Section 2.6.

4.2.7 Quantification of BDNF
BDNF levels in serum samples and brain homogenates were measured in
duplicates by ELISA using the human BDNF Quantikine kit (R&D Systems,
Minneapolis, USA), as described in Chapter 2 Section 2.4.

4.2.8 Immunohistochemistry
Rats were anesthetized deeply with isoflurane gas (Novaplus) and the
brain was rapidly removed and dissected. The left hemisphere was fixed in 4%
paraformaldehyde for 48 hours and transferred to 30% sucrose in phosphatebuffered saline (PBS) at 4°C. Sections of hippocampus (40 µm) were sectioned
using a cryostat (Microm) and processed for immunohistochemistry as previously
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published (Granholm et al. 1992, Ledreux et al. 2016) using the following
antibodies: TH (tyrosine hydroxylase, Abcam, 1:250), GFAP (Glial fibrillary acidic
protein, Dako, 1:100) and Iba1 (ionized calcium-binding adapter molecule 1,
Wako, 1:500). Briefly, free-floating sections were washed 4 times in TBS (Trisbuffered saline 0.01M, pH = 7.4) and then blocked for 1 hour at room
temperature with 10% normal donkey serum in TBS-T (TBS with 0.2 % Triton-X
100). Sections were incubated with primary antibodies for 24 hours at 4°C,
washed with TBS, and then incubated with secondary antibodies (Alexa 594 or
Alexa 488, Life Technologies, 1:250) directed against the appropriate species for
1 hour at room temperature. Sections were washed with TBS, mounted on glass
slides, air-dried, and cover-slipped with ProLong Gold antifade reagent
(Molecular Probes). Photomicrographs were generated using a Nikon Eclipse 80i
microscope (Nikon Instruments, Inc., Melville, NY) equipped with a QImaging
Fast 1394 digital camera (QImaging, Surrey, Canada).

4.2.9 Densitometry
Semiquantitative densitometric measurements were performed in Fiji
(version 1.51h, http://imagej.nih.gov/ij) using the region of interest (ROI) feature
(Schindelin et al. 2012). Measurements were performed blind by one
experimenter and are reported as an average of 3-4 sections per brain.
Immunofluorescence staining density was obtained when background staining
was subtracted from ROI staining intensities for each section. For TH and GFAP
densitometry measurements, the ROI included the tip of the dentate gyrus of the
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hippocampus, as shown in the insert at the top of Fig. 1. For Iba1 densitometry
measurements, the ROI included a portion of the stratum radiatum, just below
the stratum pyramidale in the CA1 of hippocampus.

4.2.10 Statistical analysis
Data were reported as a mean ± standard error of the mean (SEM).
Grubb’s method was used to check for outliers. Two-way ANOVA (treatment x
time) were used to detect significant interactions between treatment and time
after injection on relevant measurements. Tukey’s post hoc multiple comparison
tests were used to explore, within each exposure time, which groups were
significantly different. Behavior results were analyzed using one-way ANOVA
with Tukey’s post hoc multiple comparison tests to detect changes between the
three treatment groups. Pearson’s correlations were used when assessing
relations between two variables. Statistical significance was set at p < 0.05.
GraphPad Prism version 6.0 (GraphPad Software, Inc., La Jolla, CA) was used
for all statistical analyses.

4.3 Results
4.3.1 DSP4 treatment caused degeneration of NE fibers in the
hippocampus
As expected based on previous work (Lockrow et al. 2011), DSP4 lesions
gave rise to a loss of tyrosine hydroxylase (TH) immunoreactivity in the
hippocampus (Figure 4-1A). A two-way ANOVA analysis confirmed a significant
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effect of the treatment on TH immunoreactive fibers in the dentate gyrus (F 2,15 =
18.52, p < 0.0001). Subsequent Tukey’s post hoc tests showed that DSP4+LPStreated rats had significantly reduced TH immunoreactivity compared to the
Control group (short-term: p = 0.004, long-term: p = 0.005) and LPS-treated rats
(short-term: p = 0.003, long-term: p = 0.014; Figure 41B), thus demonstrating the
loss of NE fibers resulting specifically from the DSP4 treatment with no effect
observed from LPS alone.
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Figure 4-1

Figure 4-1. Hippocampal TH immunofluorescence. TH immunofluorescence
staining shown in the hippocampal dentate gyrus (A) and densitometry (B;
expressed as percent of the Ctrl group) in the short-term and long-term
subgroups. The histograms demonstrate a significant reduction in TH-positive
neurites in the DSP4-lesioned group, both short- and long-term, compared to the
other two groups demonstrating a successful administration of the NE toxin
DSP4. Densitometry confirmed observed changes, with highly significant
reductions in TH density in both DSP4 groups and no changes observed in either
Ctrl or LPS groups. Scale bar represents 250 μm.
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4.3.2 Astroglial and microglial activity
hippocampus after DSP4+LPS treatment

was

elevated

in

the

Effects of DSP4 and LPS treatments on astrocytic activation in the
hippocampus were assessed through glial fibrillary acidic protein (GFAP)
immunoreactivity (Figure 4-2). Both DSP4+LPS and LPS treatments gave rise to
significantly increased staining with GFAP antibody in this brain region, with the
most intense increase observed in the dentate gyrus of the DSP4+LPS-treated
rats in the short-term subgroup (Figure 4-2A). A two-way ANOVA on GFAP
densitometry measurements (expressed as percent of controls) showed
significant effects of the treatment (F 2,33 = 8.92, p = 0.001) and time after LPS
administration (F1,33 = 11.36, p = 0.002) as well as a significant interaction
between treatment and time (F2,33 = 3.80, p = 0.033). Tukey’s post hoc test
revealed that in the short-term subgroup, the DSP4+LPS-treated rats had
significantly higher GFAP immunoreactivity than the Control (p < 0.0001) and
LPS (p = 0.016, Figure 4-2B) groups. GFAP immunoreactivity in the LPS group
was also elevated compared to the Control group (p = 0.045; see Fig 2B). Seven
days following the LPS treatment, no significant difference was observed in
reactive astrogliosis in the dentate gyrus between the three groups, suggesting
that the astrocytic activation following LPS and DSP4+LPS treatment had
subsided at this point in the long-term group.
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Figure 4-2

Figure
4-2.
Hippocampal
GFAP
immunofluorescence.
GFAPimmunofluorescent staining in the hippocampal dentate gyrus (A) and
densitometry (B; expressed as percent of the Ctrl group) in the short-term and
long-term subgroups. The histograms demonstrate a significant increase in
GFAP-positive astroglia in the DSP4+LPS-treated rats in the short-term subgroup
but not in the long-term subgroup. Densitometry confirmed observed changes
with a highly significant increase in GFAP density in the DSP4+LPS group
compared to Ctrl and LPS groups in the short-term subgroup. No significant
differences were found between treatment groups in the long-term subgroup.
Scale bar represents 250 µm.
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Microglial activation was assessed with Iba1 immunoreactivity in the
hippocampus (Figure 4-3). Both DSP4+LPS and LPS treatments resulted in
increased Iba1 immunoreactivity in the CA1 of the hippocampus in the short-term
group. A two-way ANOVA on Iba1 densitometry measurements (expressed as
percent of controls) showed significant effects of the treatment (F 2,32 = 14.76, p <
0.0001) and time after LPS administration (F1,32 = 15.24, p = 0.0005), with
Tukey’s post hoc tests revealing that the DSP4+LPS-treated rats had significantly
higher Iba1 immunoreactivity compared to the Control (p < 0.0001) and LPS (p =
0.012, Fig 3B) groups. No significant difference was found in the long-term
group.
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Figure 4-3

Figure 4-3. Hippocampal Iba1 immunofluorescence. Iba1-immunofluorescent
staining in the CA1 (A) and densitometry (B; expressed as percent of the Ctrl
group) in the short-term and long-term subgroups. Densitometry measurements
demonstrate a significant increase in Iba1-microglia in the DSP4+LPS-treated
rats compared to Ctrl and LPS groups in the short-term subgroup but not in the
long-term subgroup. Scale bar represents 250 μm.
Page 114

4.3.3 Serum cytokines and chemokines levels were increased in
response to DSP4+LPS treatment
In order to determine whether treatment or time after the LPS injection
affected peripheral inflammatory markers, two-way ANOVA followed by Tukey’s
post hoc multiple comparison tests were conducted on serum IL-1β, IL-6, IL-10,
IL-17A, IFNγ, TNFα, and IP-10 levels. A significant statistical interaction was
found between the effect of treatment and time after LPS injection, as well as a
main effect of treatment and a main effect of time, as shown in Table 4-1.
Table 4-1

Table 4-1. Two-way ANOVA results for serum cytokines and chemokine levels
Serum
Cytokine/
Chemokine

Treatment

Time

Interaction

IL-1β

F2,43 = 3.84, p = 0.029

F1,43 = 9.80, p = 0.003

F2,43 = 4.34, p = 0.019

IL-6

F2,46 = 3.94, p = 0.026

F1,46 = 6.23, p = 0.016

F2,46 = 3.93, p = 0.027

IL-10

F2,43 = 3.71, p = 0.033

F1,43 = 12.89, p = 0.001 F2,43 = 3.89, p = 0.028

IL-17A

F2,47 = 6.63, p = 0.003

F1,47 = 6.64, p = 0.013

IFNγ

F2,47 = 6.39, p = 0.004

F1,47 = 24.0, p < 0.0001 F2,47 = 7.54, p = 0.001

TNFα

F2,46 = 12.3, p < 0.0001 F1,46 = 43.7, p < 0.0001 F2,46 = 11.6, p < 0.0001

IP-10

F2,46 = 11.8, p < 0.0001 F1,46 = 29.8, p < 0.0001 F2,46 = 11.9, p < 0.0001

F2,47 = 4.96, p = 0.011

In the short-term subgroup, Tukey’s post hoc multiple comparisons tests showed
consistently, significant differences between the Control and DSP4+LPS groups
for all the aforementioned cytokines, revealing that NE lesions due to DSP4
treatment and peripheral inflammation caused by LPS resulted in elevated serum
cytokines and chemokine levels when compared to the Control group (see
Figure 4-4 for p values). The NE lesion caused by the DSP4 toxin exacerbated
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the immune response caused by the LPS challenge, which increased cytokine
levels in the DSP4+LPS group compared to the LPS group. However, further
statistical analysis (Tukey’s post hoc test) revealed significant differences
between these two groups only for IL-6 and IL-17A (p = 0.011 and p = 0.002,
respectively) while a difference trending towards significance was found for IFNγ
(p = 0.067), most likely because of the high variability observed within the 3
short-term treatment groups for this cytokine. Similarly, the LPS treatment
resulted in elevated serum cytokines relative to the Control group, and Tukey’s
post hoc multiple comparison tests showed significant differences for the
cytokines TNFα, IL-10, IFNγ (p < 0.0001, p = 0.045, and p = 0.011, respectively)
and chemokine IP-10 (p < 0.0001; see Figure 4-4).
In the long-term subgroup, it is noteworthy that serum cytokine levels for
LPS and DSP4+LPS groups were returned to levels similar to those of the
Control group and were approximately one order magnitude lower when
compared to the short-term subgroup (Figure 4-4). Overall, the absence of
differences in serum cytokine levels between the 3 treatment groups 7 days after
LPS treatment suggests that the cytokine and chemokine response to the LPSinduced systemic inflammation was resolved after 7 days.
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Figure 4-4

Figure 4-4. Serum cytokines/chemokine levels in the short-term and longterm subgroups for the Control, LPS-, and DSP4+LPS-treated rats. All levels
are expressed in pg/mL ± SEM. In the short-term subgroup, serum cytokine
levels including IL-1β, IL-6, IL-10, IL-17A, TNFα, IFNγ, and the chemokine IP-10
were significantly different between the three groups. Tukey’s post hoc test
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suggest that the NE lesion caused by the DSP4 toxin exacerbated the immune
response caused by the LPS challenge in the short-term, with increased cytokine
levels in the DSP4+LPS group compared to the LPS group. The absence of
differences in serum cytokine levels between the 3 treatment groups in the longterm suggests that the acute cytokine response to the LPS-induced systemic
inflammation was resolved after 7 days.

4.3.4 Hippocampal levels of IL-1β were transiently elevated after LPS
challenge in DSP4-treated rats
Elevated levels of IL-1β in the hippocampus have been repeatedly shown
to impair hippocampal-dependent memory by affecting the long-term potentiation
(Hauss-Wegrzyniak et al. 1998, Murray and Lynch 1998, Pugh et al. 1998,
Hauss-Wegrzyniak et al. 1999, Pugh et al. 1999, Vereker et al. 2000, HaussWegrzyniak et al. 2002, Barrientos et al. 2004, Barrientos et al. 2009). In order to
determine if the LPS and DSP4+LPS treatments resulted in exacerbated
neuroinflammation, the levels of IL-1β were quantified by ELISA in the
hippocampus of Control, LPS-treated, and DSP4+LPS-treated rats in the shortterm and long-term subgroups. Our data showed that there was a significant
interaction between treatment and time after LPS injection (two-way ANOVA:
F2,44 = 3.38, p = 0.043), as wells as a significant main effect of time (F 1,44 = 10.30,
p = 0.003). In the short-term subgroup, Tukey’s multiple comparison tests
showed that the DSP4+LPS-treated rats exhibited higher hippocampal IL-1β
levels relative to the Control group (p = 0.019; Figure 4-5). In the long-term
subgroup, hippocampal IL-1β levels were not affected by the treatment and were
similar to levels measured in the Control group (Figure 4-5).
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Figure 4-5

Figure 4-5. IL-1β levels in the hippocampus as determined by ELISA in
short-term and long-term subgroups. Levels are expressed in pg/mg protein ±
SEM. A significant increase in hippocampal IL-1β levels in DSP4+LPS-treated
rats compared to the Control rats suggests an exacerbated neuroinflammatory
response caused by the LPS challenge in the short-term subgroup, an effect that
is not seen in the long-term subgroup.

4.3.5 Serum and hippocampal BDNF levels were modulated by LPS
and DSP4+LPS treatments
In order to examine whether the NE lesion caused by the DSP4 toxin had
further effects on BDNF levels compared to LPS effects alone, BDNF levels were
assessed in serum, hippocampus, and frontal cortex by ELISA. Two-way
ANOVAs were conducted to examine the effect of treatment and time after LPS
injection on BDNF levels.
We found a significant interaction between the effect of treatment and time
after LPS injection for serum BDNF levels (F2,45 = 5.40, p = 0.008). In the shortterm group, Tukey’s post hoc test showed that serum BDNF levels were
significantly lower in the DSP4+LPS group relative to the Control group (p =
0.012) and were decreased relative to the LPS-treated group although it did not
reach significance (p = 0.069, Figure 4-6A). In the long-term group, serum BDNF
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levels appeared increased in the DSP4+LPS group compared to the LPS,
although not significantly (Tukey’s post hoc test: p = 0.144; see Figure 4-6A).
A significant interaction between treatment and time after LPS injection
was found in hippocampal BDNF levels (two-way ANOVA: F2,45 = 4.395, p =
0.018, Fig 6B) but not in frontal cortex BDNF levels (data not shown). In the
short-term group, hippocampal BDNF levels in the DSP4+LPS group were
significantly lower relative to the Control group (Tukey’s post hoc test: p = 0.032)
and trended towards significance when compared to the LPS-treated group (p =
0.066, Fig 6B). A Pearson correlation revealed a statistically significant positive
correlation between BDNF levels in the hippocampus and serum (r = 0.492, p =
0.015), possibly indicating that the elevated BDNF levels in serum observed in
the short-term subgroup could reflect adaptive changes in the brain. Interestingly,
in the short-term group, GFAP immunoreactivity in the dentate gyrus correlated
negatively with the hippocampal BDNF levels (r = -0.762, p = 0.001) and
positively with hippocampal IL-1β levels (r = 0.549, p = 0.042) and Iba1
immunoreactivity (r = 0.499, p = 0.058), suggesting that lower BDNF levels and
higher IL-1β levels, as well as stronger microglia activation, were related to
increased activation of astrocytes in the hippocampus. No significant treatment
effect was observed in the long-term group (Figure 4-6B).
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Figure 4-6

Figure 4-6. BDNF levels in
serum (A) and hippocampus (B)
as determined by ELISA after
short-term
or
long-term
exposure to LPS. Serum levels
are expressed in pg/mL ± SEM
and hippocampal levels are
expressed in pg/mg protein ±
SEM. BDNF levels in serum and
hippocampus were significantly
reduced in DSP4-lesioned animals
after LPS challenge in the shortterm subgroup compared to Ctrl.

4.3.6 Behavior
Reduced spontaneous locomotion after DSP4+LPS treatment
DSP4+LPS-treated rats exhibited a significant deficit in total distance
traveled (Figure 4-7A). A one-way ANOVA showed significant effects of LPS and
DSP4+LPS treatment (F2,22 = 5.998, p = 0.008) on spontaneous locomotion.
Tukey’s post hoc analysis revealed that DSP4+LPS-treated rats performed
significantly worse than LPS-treated rats (p = 0.009) and Control rats (p = 0.047),
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suggesting that NE lesions gave rise to reduced spontaneous movement in the
aged rats.

Novel object recognition task
The novel object recognition task (NORT) was administered 7 days after
the LPS injection in DSP4-lesioned and non-lesioned rats. NORT is indicative of
exploratory behavior as well as memory function (Antunes and Biala 2012). The
discrimination index (DI) was calculated as the amount of time spent exploring
the novel object relative to the familiar object, divided by the total amount of time
exploring both objects (Lockrow et al. 2011, Antunes and Biala 2012). In order to
get a more robust estimate of the discrimination index, we collapsed the data
across the 3 testing phases. A one-way ANOVA showed an overall significant
difference between the treatment groups (F2,21 = 4.48, p = 0.024, Figure 4-7B).
Tukey’s post hoc comparison revealed that the DSP4+LPS-treated group
performed worse on this task compared to the Control group (p = 0.049) and the
LPS group (p = 0.033), suggesting that these rats were not able to discriminate
between a familiar object and a novel object. We found that the discrimination
index results were negatively correlated to Iba1 immunoreactivity (r = -0.520, p =
0.027) and to GFAP immunoreactivity (r = -0.625, p = 0.017), suggesting that rats
with poorer performance had increased microglial and astroglial activation.
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Figure 4-7

Figure 4-7. Spontaneous locomotion and discrimination index. The novel
object recognition task (NORT) was administered 7 days after the LPS injection
in control and DSP4-lesioned and non-lesioned rats. Spontaneous locomotion
(A) indicates a reduction in movement in the DSP4-lesioned rats compared to
both Ctrl and LPS groups. The discrimination index (B) was calculated as the
amount of time spent exploring the novel object relative to the familiar object,
divided by the total amount of time exploring both objects, and collapsed across
all three testing phases. DSP4+LPS-treated rats performed worse on this task
compared to the Ctrl group and the LPS group, suggesting that these rats were
not able to discriminate between a familiar object and a novel object.

4.4 Discussion
Neuroinflammation induced by systemic inflammation has been implicated
in the onset and progression of neurodegenerative diseases including AD, PD,
and Down syndrome (Jeong et al. 2010, Tansey and Goldberg 2010, Holmes
2013, Trager and Tabrizi 2013, Heneka et al. 2015). Previous studies have
shown

that

a

peripheral

immune

challenge

in

animal

models

of

neurodegeneration exacerbates pathology and cognitive deficits and implicates
the immune system’s disease modifying role (Qin et al. 2007, Cunningham et al.
2009, Schreuder et al. 2017). The results of the present study add to this
literature and show that neuroinflammation induced by systemic inflammation is
exacerbated by LC-NE lesion. Specifically, in aged rats, we found that a loss of
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LC-NE neurons induced by the neurotoxin DSP4 combined with peripheral
inflammation caused by LPS led to transiently increased astrogliosis and
microglial activation in the hippocampus, increased accumulation of proinflammatory cytokines both in the hippocampus and in serum, and reduced
exploratory behavior. BDNF levels were initially reduced in both serum and
hippocampus following the LPS challenge in NE-lesioned rats. Similar to
previous reports on LPS-treated rats, we did not find significant differences in
hippocampal BDNF levels in the LPS group alone compared to the control (Shaw
et al. 2001, Zhu et al. 2014). However, in the short-term subgroup, BDNF levels
in the DSP4+LPS-treated rats were significantly reduced compared to Control
and recovered to control levels after the long-term exposure. These results
suggest that neuronal damage due to DSP4 in addition to LPS inflammation may
disrupt BDNF synthesis. Thus, our results show that degeneration of the LC-NE
pathway results in an exacerbated but transient systemic and neural response to
a peripheral immune challenge including increased cytokine production,
astrogliosis, microglial activation, and modulated BDNF levels.
We found that systemic LPS injection stimulates the release of proinflammatory cytokines IL-1β, IL-6, IL-17A, and TNFα in the peripheral
circulation. These effects of systemic LPS administration in aged rats have also
been reported by others (Nolan et al. 2005, Kohman et al. 2007, Donoso et al.
2008, Culley et al. 2014, Fu et al. 2014, Kawano et al. 2014, Sun et al. 2015). In
vitro, LPS has also been shown to induce the anti-inflammatory cytokine IL-10 in
a negative feedback manner to mitigate excessive inflammation (Iyer et al. 2010).
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In our study, although an elevation of the aforementioned cytokines and
chemokines was found in the short-term LPS-treated group relative to the Control
group, this elevation was only statistically significant from control for TNFα, IL-10,
IFNγ, and IP-10. However, we found a robust significant elevation of these
cytokines and chemokine in the short-term DSP4+LPS group, suggesting that
LC-NE degeneration by DSP4 potentiates the inflammatory response to LPS.
This potentiation may be due to a transient neurotoxic effect of DSP4
(approximately seven days) on the peripheral sympathetic system in addition to
the central nervous system (Bortel 2014, Ross et al. 2015). In the long-term
group, cytokine and chemokine levels in LPS-treated and DSP4+LPS-treated
rats were returned to control levels, suggesting a resolution of inflammation after
seven days. While previous studies showed increased hippocampal IL-1β levels
after LPS exposure in rats (Fu et al. 2014, Kawano et al. 2014), this was not the
case under our experimental conditions, possibly due to differences in animal
models or incubation period between LPS administration and sample collection.
It is also noteworthy that the LPS dose used in our study (0.75 mg/kg) was lower
than the ones used in the Fu et al. (2014) (2 mg/kg) and Kawano et al. (2014) (5
mg/kg) studies. However, we found that the NE lesion caused by the DSP4 toxin
resulted in significantly elevated hippocampal IL-1β levels 4 hours after the LPS
administration. Similar to previous reports showing that systemic inflammation by
itself does not induce neurodegeneration (Jeong et al. 2010), our results show
that a peripheral immune challenge in aged rats resolves within seven days and
does not induce long-term cognitive deficits despite inducing neuroinflammation.
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Our findings showed that the LPS group did not exhibit any statistically significant
changes in either spontaneous locomotion or in exploratory behavior. However,
we report lasting cognitive deficits in the DSP4+LPS group, potentially due to the
reduction of NE levels in hippocampus caused by the DSP4 administration in the
DSP4-treated rats (Srinivasan and Schmidt 2004). The lack of behavioral effects
in the LPS group differs from Haba et al. (2012) who showed that LPS
administration reduced novel object exploration in mice for at least 24 hours after
injection, but this difference can be explained by our use of a different animal
model and our extended time between LPS administration and cognitive testing.
Indeed, Czerniawski et al. (2015) report that LPS administration does not impair
novel object recognition in rats 6 hours after LPS administration, suggesting that
there are still conflicting results in animal models regarding short- or long-term
effects of LPS on behavioral measures.
LPS influence on neuroinflammation has been largely attributed to the
upregulation of cytokines that cross the BBB and interact with CNS tissue (Banks
and Erickson 2010). These LPS-induced pro-inflammatory cytokines can
suppress the expression or release of BDNF (Guan and Fang 2006), which is
important for the survival of LC-NE neurons. Our results indicate that LPS
treatment combined with DSP4 in aged rats can further reduce BDNF levels in
the hippocampus, at least initially. The reduction of hippocampal BDNF protein
levels was negatively correlated with the extent of neuroinflammation induced by
the LPS administration. Interestingly, after the resolution of inflammation (i.e.,
seven days post-LPS administration), both serum and hippocampal BDNF levels
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in the DSP4+LPS-treated group were returned to levels similar to the control
group. This reduction suggests that after the inflammatory state is resolved and
pro-inflammatory cytokines are no longer suppressing BDNF, BDNF levels are
upregulated both centrally and peripherally as a compensation to return function
to normal. A similar compensatory increase in BDNF levels has been observed in
other neuronal lesion models (Li et al. 2001), lending support to the notion of
BDNF increase due to lesions in the brain. It is possible that the relative
reduction in BDNF levels in serum acutely after DSP4+LPS treatment result from
the systemic administration of the NE neurotoxin affecting the sympathetic
nervous system and therefore cause degenerative changes in BDNF in serum.
As shown by Ross and Stenfors (Ross et al. 2015), NE levels in the periphery
were reduced as well after systemic DSP4 lesions but recovered fully within a
week of injection, which could explain why peripheral cytokines and BDNF levels
are affected by the NE neurotoxin. Similar to the pro-inflammatory effects of NE
degeneration in the brain (Kalinin et al. 2006), the peripheral sympathetic system
acts to suppress inflammatory reactions in the peripheral nervous system
(Roggero et al. 2016). It is therefore not unlikely that the DSP4 lesions could
have given rise to sympathetic changes in the short term which would have
affected the expression of BDNF and initiated peripheral inflammation,
aggravated by LPS. An interaction between the peripheral and central NE
transmitter systems may be important especially with aging, since studies have
shown not only age-related degeneration of the LC-NE nucleus but also reduced
sympathetic nervous system innervation in target tissues in the periphery with
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aging (Rengo et al. 2016). This interesting connection between aging effects in
peripheral versus central NE afferents will be pursued in future studies. In
conclusion, our results indicate that NE depletion increases susceptibility to
neuroinflammation induced by systemic inflammation in aged rats. This result is
relevant to the aging community where NE levels are decreased due to natural
and pathology-associated degeneration of the LC-NE pathways (Mann 1983,
Grudzien et al. 2007). An age-related reduced LC-NE function leading to an
increased inflammatory reaction both in the periphery and in the brain could
aggravate severe effects of immune challenges in the elderly (Bardou et al.
2014). Epidemiological studies have shown strong influence of peripheral
inflammation on cognitive performance in elderly subjects (Duarte et al. 2017,
Handing et al. 2017, Kesse-Guyot et al. 2017). For example, Kesse-Guyot et al.
(2017) suggested that a pro-inflammatory diet at midlife might be associated with
subsequent lower cognitive functioning. Our findings in aged rats support this
previous suggestion and also point to a complicated relationship between
inflammation and NE innervation that affects both peripheral and central
systems. Our findings suggest future treatment options, such as using NEenhancing drugs that may affect not only neuronal components of the brain but
may also mitigate ongoing inflammatory processes both in the brain and
peripherally.
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5.1 Introduction
Part of the challenge in AD research is identifying the mechanistic shift
from healthy brain aging to neurodegeneration, which may occur decades before
the development of symptoms (Dubois et al. 2007, Sperling et al. 2011, Jack et
al. 2013). In this chapter, my goal is to investigate whether serum BDNF can
predict subtle changes in neuropsychological performance and neuroimaging
measures related to AD over time in healthy older adults. There are many
possible confounders of the relationship between BDNF and our measures of
interest that need to be accounted for when interpreting our results. Other than
age and level of education which are commonly examined in interpreting
neuropsychological performance, we paid special attention to inflammatory
markers based on our results in Chapters 3 and 4. We also look into differences
between women and men in our cohort based on a wealth of literature supporting
sex differences in incidence of AD and in BDNF levels. The following is a review
of literature specific for this chapter.

5.1.1 Sex differences in AD and BDNF
AD disproportionately affects women, but a definitive biological reason for
this finding remains elusive (Carter et al. 2012, Hebert et al. 2013, Association
2018). One possible reason AD prevalence is higher in women than men is due
to the fact that women live longer than men on average (Hebert et al. 2001,
Chene et al. 2015). However, women with AD also have greater impairment
across a range of cognitive domains than men, and this finding may be attributed
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to hormonal differences (Mielke et al. 2014, Laws et al. 2016). Estrogen loss
adversely affects cognition in both postpartum and postmenopausal women, and
estrogen therapy improves cognitive performance in women with AD (Laws et al.
2016). Estrogen also has neuroprotective properties that can drive APP
processing by α-secretase instead of β-secretase to reduce amyloid plaque
production and prevent hyperphosphorylation of tau to reduce tangle formation
(Wharton et al. 2009). In addition, several studies have shown that women with
the ε4 allele of the APOE gene have an increased risk of progressing from MCI
to AD and experience a more precipitous clinical and pathologic decline than
men with the same allele (Mielke et al. 2014, Kim et al. 2015). Furthermore, a
recent meta-analysis showed that the Val66Met genetic variation on the BDNF
gene conferred increased susceptibility to AD in women but not men (Fukumoto
et al. 2010). This dimorphic sexual effect is paralleled in blood BDNF protein
levels which have been found to be higher in women than in men (Trajkovska et
al. 2007, Bus et al. 2011, Shimada et al. 2014), and women with BDNF levels in
the top quintile were less likely to develop dementia and AD (Weinstein et al.
2014). These reports all support the concept that women with AD may have a
different disease course than men due to a) estrogen effects on AD pathology
and b) differential production and function of BDNF. Further research is needed
into how serum BDNF levels differentially predict subtle AD-related
changes between sexes in healthy older adults.
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5.1.2 Neurocognitive correlates of BDNF
A wide range of studies has shown that serum BDNF levels affect
cognitive function in various populations (Gunstad et al. 2008, Erickson et al.
2010, Nettiksimmons et al. 2014, Shimada et al. 2014, Dols et al. 2015,
Piepmeier and Etnier 2015, Buchman et al. 2016). BDNF is highly concentrated
in the hippocampus and has been shown to be vital for memory processes
(Tapia-Arancibia et al. 2008, Cunha et al. 2010). In older adults, lower BDNF
levels have been linked to poorer memory and smaller hippocampal size
(Erickson et al. 2010, von Bohlen und Halbach 2010, Dols et al. 2015). A
carefully performed mediation analysis on cross-sectional data from older adults
between 59 and 81 years old additionally revealed that age-related decline in
BDNF levels partially contributes to volumetric shrinkage of the hippocampus
associated with advancing age (Erickson et al. 2010). Evidence also indicates
that associations between hippocampal volume, memory, and blood BDNF levels
are different in men and women. Women with lower serum BDNF levels were
associated with greater decline in memory (Weinstein et al. 2014). These results
strongly suggest a link between BDNF, memory, and hippocampal volume, and,
in this study, we tested whether serum BDNF levels are correlated with
changes in memory performance and hippocampal volume. In addition, a
recent study found that lower BDNF expression in post mortem human
dorsolateral prefrontal cortex (DLPFC) has also been related to greater ante
mortem cognitive decline in AD patients compared to controls (Buchman et al.
2016). The prefrontal cortex is associated with executive function (Yuan and Raz
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2014), and, to parallel our investigation of BDNF levels in BA46 in Chapter 3, we
tested whether serum BDNF levels are correlated with changes in executive
function performance and DLPFC thickness.

5.1.3 Associations between BDNF and white matter
While volumetric shrinkage represents neuronal loss in the region of
interest, subtle changes in the brain associated with astrocytic gliosis and myelin
loss are better detected through diffusion analysis (Larsson et al. 2004,
Hugenschmidt et al. 2008), and diffusion metrics are more sensitive in studying
healthy populations where early signs of pathology are not easily detectable
(Fellgiebel and Yakushev 2011). Although several studies (Montag et al. 2010,
Chiang et al. 2011, Tost et al. 2013) have investigated the relationship between
diffusion metrics of the brain and the Val66Met variant in the BDNF gene, which
is associated with lower secretion of BDNF (Egan et al. 2003), there are a limited
number of studies relating blood BDNF levels to diffusion metrics in older adults.
In one study, investigators found that higher plasma BDNF levels reflected a
higher degree of white matter lesions and lower white matter integrity (i.e.,
fractional anisotropy) in a manually defined prefrontal region (Dalby et al. 2013).
In another study, it was found that serum BDNF levels negatively associated with
mean diffusivity in the hippocampus (Manna et al. 2015). However, the
relationship between serum BDNF and the white matter microstructure of
the limbic system, which highly interconnects the prefrontal cortex and the
hippocampus, has not been reported and was investigated in this study.
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5.1.4 Diffusion tensor imaging
To study the white matter microstructure of the limbic system, we used a
magnetic resonance imaging (MRI) modality called diffusion tensor imaging
(DTI). DTI characterizes the microstructure properties of tissue by detecting the
micro-scale displacement of water (Basser and Pierpaoli 1996). Fractional
anisotropy (FA) and mean diffusivity (MD) are the most commonly reported DTI
metric. FA describes the degree of directional variability of water diffusion in a
voxel. FA ranges from a score of 0 to 1, where a score of 0 indicates unrestricted
(or equally restricted) diffusion such that a molecule can diffuse equally in all
directions (i.e., isotropic), and a score of 1 indicates restricted diffusion in a
certain axis (i.e., anisotropic). Values closer to 1 are commonly found in white
matter fiber bundles where diffusion in certain directions is restricted by myelin.
MD is the average of the magnitude of diffusion in three orthogonal directions.
MD is highest in CSF where there are few barriers to diffusion. In older adults, FA
decreases and MD increases with increasing age, and these changes are
thought to be due to myelin loss (Falangola et al. 2008).

5.1.5 Current investigation
In this study, we complement the aforementioned research by
investigating the potential of baseline serum BDNF to predict changes in
neuropsychological

performance

(executive

function

and

memory)

and

neuroimaging measures (cortical thickness of the DLPFC, hippocampal volume,
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and white matter microstructure of the limbic tracts) in a cohort of healthy older
adults with particular attention to sex differences. This study is similar to the
study done by Driscoll et al. (2012), which found that lower baseline plasma
BDNF levels were associated with steeper frontal white matter volume decline in
women but not men (n=59). In contrast to Driscoll’s study, we used different
neuroimaging regions of interest, and we used serum BDNF levels instead of
plasma BDNF levels for reasons explained in Chapter 1 Section 1.6.1. We
hypothesized that lower baseline serum BDNF levels were related to lower
cognitive functioning, thinner DLPFC, smaller hippocampal volume, and
abnormal white matter microstructure in limbic tracts as well as declines in these
measures over time and that these effects will be more pronounced in women
than men. As previously described in Chapter 1 and supported in the results of
Chapters 3 and 4, inflammation and BDNF are highly interconnected, and
measures of inflammation along with age, education, and sex were accounted for
when

assessing

the

relationship

between

serum

BDNF

levels

and

neuropsychological performance or neuroimaging measures.

5.2 Methods
5.2.1 Participants
The MR Imaging of Neurodegeneration (MIND) study at the Medical
University of South Carolina recruited cognitively healthy older adults (ages 6085) to participate in annual neuropsychological tests, MRI scans, and a fasting
blood draw. Neuropsychological testing was performed under the supervision of
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a board-certified neuropsychologist. Brain MRI was obtained the same day as
neuropsychology testing and was stored in an encrypted and de-identified
database for subsequent analysis. No more than 50 ml of blood was extracted
and stored from each participant by the South Carolina Translation Research
(SCTR) Nexus. The Institutional Review Board at the Medical University of South
Carolina approved this study (Pro00028302), and all participants gave written
informed consent. A total of 65 participants were enrolled from October 2013 to
April 2015, and 39 of these participants returned for a follow-up after 15.2  3.2
months. This report is based on the baseline and follow-up data from these 39
subjects.

5.2.2 Quantification of BDNF
BDNF levels in serum samples were measured in duplicates by ELISA
using the human BDNF Quantikine kit (R&D Systems, Minneapolis, USA), as
described in Chapter 2 Section 2.4.

5.2.3 Quantification of cytokine and chemokine
Quantification of serum levels of cytokines IL-1β and IL-10 were
determined using the 14-plex Human High Sensitivity T-Cell Discovery Array
(HDHSTC14) by Eve Technologies (Canada) and a serum cytokine score for the
first time point (referred to as basal inflammation) was calculated as described in
Chapter 2 Section 2.6.
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5.2.4 Neuropsychological assessment
A

trained

neuropsychologist

or

technician

administered

neuropsychological testing on the same day as MRI scanning. Raw scores from
nine neuropsychological measures were each converted into standard z-scores
based on the group mean and standard deviation at each time point. Average zscore composites were calculated for the following two neuropsychological
domains: Executive Function (WMS-R Logical Memory – Digit Span Backward
Total, Trail Making B, F-A-S Verbal Fluency) and Memory (WMS-R Logical
Memory IIa, RAVLT – Long Delay Recall).

5.2.5 MRI acquisition
Scanning was performed on a 3T TIM Trio MR system (Siemens Medical
Solutions, Erlangen, Germany) with the parameters previously reported
(Fieremans et al. 2013). The following protocols were used 1) 3D T1-weighted
imaging

using

an

MPRAGE

sequence

with

these

parameters:

TR/TI/TE=1900/900/2.26 ms, FOV=256x256 mm2, a generalized auto-calibrating
partially parallel acquisition (GRAPPA) factor of 2, 1 x 1 x 1 mm3 voxels, scan
duration 4 min, 26 s. 2) T2-FLAIR sequence with these parameters: TR/TI/TE =
9000/2500/79.0 ms, FOV=220x220 mm2, a GRAPPA factor of 2, voxel size 0.9 x
0.9 x 3 mm3, scan duration 4 min, 14 s. 3) DKI was acquired using single-shot,
twice-refocused echo planar imaging, with these parameters: 3 b-values (0,
1000, 2000 s/mm2) along 64 diffusion-encoding directions, one average, TR/TE =
8300/103 ms, FOV=220x220 mm2, a GRAPPA factor of two, scan duration 18
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min, 17 s. There were a total of 25 separate acquisitions with the b-value set to
zero and identical image parameters (scan duration 3 min, 46 s).

5.2.6 Imaging processing
Cortical thickness and hippocampal volume values were estimated in both
hemispheres using the Freesurfer package (surfer.nmr.mgh.harvard.edu).
Bilateral hippocampal volumes were averaged together and normalized for
intracranial volume (ICV) through proportion (i.e., hippocampal volume / ICV).
DLPFC thickness was estimated as the average of gray matter thickness of
regions labeled as middle frontal gyrus, middle frontal sulcus, superior frontal
sulcus, inferior frontal sulcus, and superior frontal gyrus as previously described
(Yamagishi et al. 2016).
Raw diffusion images were first visually inspected for image quality and
then de-noised with a principal components analysis technique (Veraart et al.
2016). Gibbs ringing artifact reduction (Kellner et al. 2016) was then applied prior
to additional processing utilizing in-house software (diffusional kurtosis estimator,
DKE, (Tabesh et al. 2011) that was used for motion correction and registration
and for estimating the diffusion and diffusional kurtosis tensors. The tensors were
then used to derive the DKI-acquired parametric maps for diffusivity metrics (i.e.,
Fractional Anisotropy [FA] and Mean Diffusivity [MD]). Non-brain tissue was
removed using the Brain Extraction Tool from FSL (FMRIB Software Library,
Oxford, UK, http://www.fmrib.ox.ac.uk/fsl/). A fractional intensity threshold of 0.3
resulted in optimum non-brain tissue extraction, verified via visual inspection.
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Region of interest (ROI) analysis was conducted on maps normalized via
FSL’s tract-based spatial statistics pipeline (TBSS). In TBSS, all subject FA
images were non-linearly registered into standard FMRIB58_FA space, and a
mean FA image was generated and thresholded to create the mean FA skeleton.
All other parametric maps of each subject were then projected onto this FA
skeleton with a threshold of FA=0.2. The TBSS-processed maps were then
subjected to ROI analyses, extracting metric values using the Johns Hopkins
ICBM-DTI-81 atlas (Mori, Wakana, Nagae-Poetscher, & van Zijl, 2005). A
composite limbic tract variable was created by averaging the metric values of
three tracts bilaterally: cres of the fornix, uncinate fasciculus, and cingulum
[hippocampus]).

5.2.7 Statistical analysis
Statistical analysis was completed in IBM SPSS Statistics for Windows,
version 24 (IBM Corp., Armonk, N.Y., USA). Serum BDNF measurements have
been previously reported to have a non-normal distribution (Ziegenhorn et al.
2007, Balietti et al. 2018); however, visualization of BDNF levels in the data set
used in this study indicated a reasonably normal distribution, and transformation
to normalize the distribution of BDNF levels was not done to make interpretations
of our results easier. Differences between sexes in demographics and baseline
serum BDNF levels were tested using independent-samples t-tests. Differences
between sexes and changes over time in neuropsychological performance and
neuroimaging measures were tested using a mixed ANOVA with sex as a
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between-subject factor (women and men) and time as a within-subject factor
(baseline and follow-up). To assess whether baseline serum BDNF levels can
predict changes over time in neuropsychological performance and neuroimaging
measures, first, annualized change scores for our variables of interest were
calculated by dividing the difference of the follow-up (FU) score, and baseline
(BL) score by the follow-up interval measured in years (i.e., [FU – BL]/Interval).
Then, multiple linear regressions were used to test whether BDNF at baseline
interacts with sex to predict changes in neuropsychological performance or
neuroimaging measures over time. Based on previous studies, BDNF levels are
affected by age, education, and inflammation, and these terms were included in
our model (Ziegenhorn et al. 2007, Bus et al. 2011, Bus et al. 2012, Calabrese et
al. 2014). Six regression models were created with the change score in
neuropsychological domains (executive function or memory) or neuroimaging
measures (DLPFC thickness, hippocampal volume, limbic FA, and limbic MD) as
the dependent variable (DV). Independent variables included age, education,
sex, basal inflammation, baseline DV score, baseline BDNF, and an interaction
term for BDNF and sex. A two-tailed p-value <0.05 was regarded as a significant
result.

5.3 Results
5.3.1 Baseline serum BDNF levels were higher in women than in men
Baseline sample characteristics (Means ± SD) are reported in Table 5-1.
Serum BDNF and cytokine values, neuropsychological performance scores, and
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neuroimaging measures from 39 older adults (28 women) were used in this
study. Results from independent-sample t-tests indicated that there were no
statistical differences between women and men for age, education and basal
inflammation. Baseline serum BDNF levels were statistically higher (t33.2=2.075,
p=0.045) in women (21.3 ± 8.3 ng/ml) than in men (17.1 ± 4.5 ng/ml). This finding
of sex differences in baseline serum BDNF levels further supported our rationale
to investigate differences between sex in our neuropsychological and
neuroimaging measures of interest.
Table 5-1

Table 5-1. Summary of baseline variables. Data represented as Mean (SD).
Differences between women and men were calculated through independentsamples t-test, and p-values from this test are reported under the significance
(Sig) column.
Characteristic

Total

Women

Men

Sig

Sample Size

39

28

11

Age (years)

67.7 (5.2)

68 (5.6)

66.9 (4.2)

0.564

Education (years)

16.5 (2.5)

16.3 (2.5)

17.2 (2.2)

0.295

Basal Inflammation

0.00 (0.61)

0.05 (0.66)

-0.13 (0.48)

0.409

Serum BDNF (ng/ml)
*p<0.05

20.1 (7.6)

21.3 (8.3)

17.1 (4.5)

0.046*

Demographics
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5.3.2 Neuropsychological performance differed by sex over time
Mixed ANOVAs were used to investigate the sex differences in
neuropsychological performance over time. The results of this mixed ANOVA on
neuropsychological performance showed that there was a marginally significant
interaction between sex and time on

executive function performance

(F1,37=3.072, p=0.098, ηp2=0.077) and a significant interaction between sex and
time (F1,37=6.166, p=0.018, ηp2=0.143) on memory performance (Figure 5-1). For
women, executive function performance increased and memory performance
decreased between baseline and follow-up. In men, the opposite trend was
found: men exhibited decreased executive function performance and increased
memory performance between baseline and follow-up. However, it is important to
note that these changes in composite z-scores were less than 1 SD and are
unlikely to be clinically significant.
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Figure 5-1
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Figure 5-1. Interaction between sex and time in neuropsychological
performance. Mean values of baseline and follow-up neuropsychological
performance scores in women and men are graphed. Results from a mixed
ANOVA indicated a marginally significant interaction between sex and time on
executive function performance and a significant interaction between sex and
time on memory performance. In executive function performance, composite zscores for women increased while z-scores for men decreased between baseline
and follow-up. In memory performance, z-scores for women decreased while
scores for men z-increased between baseline and follow-up.

5.3.3 White matter microstructure decreased over time
Mixed ANOVAs were used to investigate the sex differences in
neuroimaging measures over time. The results of the mixed ANOVA on
neuroimaging measures showed that there was no significant interaction
between sex and time on all four neuroimaging measures (all p>0.5). This result
suggests that sex did not affect the change of these neuroimaging measures
between baseline and follow-up. A significant main effect was found in limbic FA
(F1,37=7.500, p=0.009, ηp2=0.169) and limbic MD (F1,37=4.977, p=0.032,
ηp2=0.119), but not in DLPFC thickness (F1,37=0.287, p=0.595, ηp2=0.008) or
hippocampal volume (F1,37=0.125, p=0.725, ηp2=0.003). Visualization of these
results indicates that, for both women and men, limbic FA decreased and limbic
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MD increased between baseline and follow-up (Figure 5-2), but DLPFC
thickness and hippocampal volume did not significantly change between baseline
and follow-up.
Figure 5-2
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Figure 5-2. Changes in limbic white matter microstructure over time.
Results from a mixed ANOVA indicated a significant main effect of time for limbic
fractional anisotropy (FA) and limbic mean diffusivity (MD). For both women and
men, limbic FA significantly decreased, and limbic MD significantly increased
between baseline and follow-up.

5.3.4 Serum BDNF levels are marginally significant as predictors of
changes in neuroimaging measures
Results from the multiple linear regression models are reported in Table
5-2. Overall, our models failed to reject the null hypothesis that none of the
independent variables are related to change scores of neuropsychological
domain or neuroimaging measures (all p>0.05). Our model for memory change
scores was marginally significant (F7,31= 2.261, p=0.056); however, only age was
statistically related to the change in memory score, and our variables of interest,
BDNF and sex*BDNF, were not significantly related to memory change scores. A
negative β value for age in this model suggests that increasing age was
associated with steeper declines in memory over time. The interaction between
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baseline BDNF and sex were found to be marginally significant as a predictor for
changes in hippocampal volume (p=0.085) and limbic FA (p=0.070). Visualization
of the relationship of baseline BDNF levels and the change in hippocampal
volume and limbic FA by sex suggests that higher serum BDNF levels are related
to greater declines in hippocampal volume and limbic FA in men, but not women
(Figure 5-3). However, it is important to note that these z-score changes were
less than 1 SD and are unlikely to be clinically significant.
Table 5-2

Table 5-2. Results from multiple linear regression models. Data represented
as β (SE). BL = Baseline; DLPFC = Dorsolateral Prefrontal Cortex Thickness; DV
= dependent variable; Educ = Education. EF = Executive Function; FA =
Fractional Anisotropy; HIP = Hippocampus Volume; Inflam = Basal Inflammation;
MD = Mean Diffusivity.
IV

EF

Memory

HIP

DLPFC

Limbic
FA

Limbic
MD

Constant

0.915
(1.097)

1.857
(1.424)

-0.015
(0.036)

0.191
(0.298)

-0.026
(0.034)

0.014
(0.119)

Age

-0.016
(0.013)

-0.039*
(0.016)

0.000
(0.000)

-0.001
(0.002)

0.000
(0.000)

0.000
(0.001)

Educ

0.031
(0.022)

0.023
(0.036)

0.001
(0.001)

0.003
(0.003)

0.000
(0.000)

0.002
(0.002)

Sex

-0.226
(0.433)

0.281
(0.619)

0.016
(0.01)

-0.07
(0.069)

0.018†
(0.01)

-0.056
(0.049)

Inflam

0.013
(0.093)

-0.077
(0.134)

0.000
(0.002)

0.001
(0.014)

0.002
(0.002)

-0.006
(0.009)

BL DV

-0.164†
(0.088)

-0.107
(0.112)

-0.049
(0.077)

-0.032
(0.076)

0.023
(0.053)

-0.005
(0.09)

BL BDNF

0 (0.027)

0.002
(0.04)

0.001†
(0.001)

-0.005
(0.004)

0.001
(0.001)

-0.003
(0.003)

Sex*BL
BDNF

-0.001
(0.024)

-0.001
(0.035)

-0.001†
(0.001)

0.004
(0.004)

-0.001†
(0.001)

0.003
(0.003)

R2

0.225

0.338

0.115

0.075

0.195

0.107

F
1.283
†
*p<0.05, p<0.10

2.261

0.557

0.359

1.074

0.533

Page 146

Figure 5-3
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Figure 5-3. Relationship between baseline BDNF levels and changes in
neuroimaging measures over time by sex. Although the overall linear
regression model was not significant, the interaction between baseline BDNF and
sex was found to be marginally significant as a predictor for changes in
hippocampal volume (p=0.085) and limbic FA (p=0.070). Visualization of the
relationship between baseline BDNF and changes in hippocampal volume (A)
and limbic FA (B) suggest that higher baseline BDNF levels are associated with
greater declines in these neuroimaging measures in men but not women.

5.4 Discussion
In our healthy older adult cohort, we found that baseline serum BDNF
levels were higher in women compared to men, that executive function scores
declined in men over time, and that memory scores declined in women over time.
In addition, we found marginally significant relationships between baseline serum
BDNF levels and changes in hippocampal volume and limbic FA indicating that
higher serum BDNF levels in men were associated with greater declines in
hippocampal volume and limbic FA. Our results are contrary to Driscoll et al.
(2012) where higher BDNF levels in plasma were associated with slower
changes in white matter volume in women but not in men. Nonetheless, our
results suggest that sex differences in the relationship between BDNF
neuropsychological performance, and neuroimaging measures should be
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investigated further. Consideration of sex differences in BDNF and AD research
is especially important considering that older adult women with mild cognitive
impairment decline faster than men (Lin et al. 2015), and interventions to
increase BDNF levels, such as exercise, may have a lower effect in women than
in men (Szuhany et al. 2015).
We examined whether serum BDNF levels correlated with three
neuroimaging measures sensitive to aging and dementia: cortical thickness of
the DLPFC, hippocampal volume, and white matter microstructure of the limbic
tracts. Based on previous literature, we hypothesized that lower serum BDNF
levels would indicate to smaller hippocampal volumes, thinner DLPFC, and
abnormal white matter microstructure in the limbic tracts and that this association
would be greater in women than men. We did not find a significant relationship
between serum BDNF levels and changes in these neuroimaging measures
changes over time. Our results instead indicated that higher serum BDNF levels
in men are associated with abnormal changes in neuroimaging measures (i.e.,
greater declines in hippocampal volume and limbic FA) which is the opposite
relationship we hypothesized. On the one hand, this result may be interpreted as
these men having a compensatory increase of serum BDNF to help ameliorate
some underlying pathology that is affecting the volume of their hippocampus.
Further follow-up on these men as they possibly convert to MCI could support
this theory. In addition, this relationship between higher blood BDNF levels and
abnormal neuroimaging findings is mirrored by Dalby et al. (2013) findings of
higher plasma BDNF levels reflecting higher prefrontal white matter lesions and
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lower white matter integrity (FA). On the other hand, there are important
limitations to this study, including a small sample size, which make our result
difficult to interpret.
Major strengths of our study include the use of neuropsychological
domains composed of scores from several neuropsychological tests, the use of
multiple neuroimaging techniques to assess subtle changes in the brain, and the
use of a longitudinal design to assess prospective change. Although we did not
find a significant change in DLPFC thickness and hippocampal volume between
timepoints, it is remarkable that we found changes in white matter microstructure
in our cohort despite the short time interval. This suggests that changes in white
matter microstructure may be more sensitive than measures of DLPFC thickness
and hippocampal volume to aging. Our finding of a marginal relationship between
baseline serum BDNF levels and limbic FA support the rationale to further
investigate serum BDNF levels and white matter structure with more advanced
techniques.
In addition to its major strengths, this study has some limitations.
Participants were volunteers recruited by the University and may not be
representative for the general older adult population. Our study also has a small,
unbalanced sample size with more women than men which may have biased our
results. The changes between baseline and follow-up visits we noted in
neuropsychological performance and neuroimaging measures over time were
subtle and did not have clinical significance or affect activities of daily lviing in
these healthy older adults. In addition, serum BDNF levels assessed from an
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ELISA can be difficult to interpret since they represent a mixture of mature and
proBDNF (Michalski and Fahnestock 2003, Yoshida 2012, Lim et al. 2015,
Polacchini et al. 2015). Although both forms of BDNF are decreased in AD
(Michalski and Fahnestock 2003, Peng et al. 2005), they act on different
receptors (mature BDNF on TrkB and proBDNF on p75) to drive neuronal
survival vs death (Teng et al. 2005, Tapia-Arancibia et al. 2008), and we could
not assess the contribution of either form to our measure of total BDNF. In
addition, BDNF is produced in peripheral tissue (e.g., endothelial cells and
smooth muscles), and BDNF measured in serum reflect BDNF from neuronal
and non-neuronal sources (Donovan et al. 1995, Fujimura et al. 2002, Michalski
and Fahnestock 2003). Nevertheless, the association between serum BDNF
levels and brain BDNF levels is supported by reports demonstrating changes in
BDNF levels in blood from people with various psychiatric and neurological
disorders (Carlino et al. 2011, Yoshida 2012, Fernandes et al. 2015) and by a
human study where BDNF levels were found to be higher in blood from the
internal jugular vein compared to blood from the brachial arterial, suggesting that
BDNF levels in venous blood are supplemented by BDNF produced in the brain
(Dawood et al. 2007). Finally, our multiple linear regression models were found to
not significantly predict our dependent variables, suggesting optimization of our
predictor variables is needed to assess better the relationship between serum
BDNF levels and our variable of interest.
Overall our results suggest that a relationship between serum BDNF
levels and both neuropsychological performance and neuroimaging measures
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are limited in healthy older adults. This result somewhat differs with the literature
where lower blood BDNF levels are related to smaller hippocampi, cognitive
decline, and associations with AD status (Connor et al. 1997, Laske et al. 2006,
Yasutake et al. 2006, Erickson et al. 2010, Nettiksimmons et al. 2014). Our result
may differ from the literature due to our use of healthy older adults, and further
follow-up on these older adults as they age may further differentiate serum BDNF
levels and neuropsychological performance or neuroimaging measures more
apparent between those with MCI and healthy controls. In this study, we found
interesting differences between men and women in serum BDNF levels, in
changes of neuropsychological scores over time, and in the relationship between
serum BDNF levels and changes in neuroimaging measures over time. These
results serve to support rationale to investigate sex differences in future studies
relating BDNF to longitudinal changes in older adults. Understanding the
differential role of BDNF between women and men can also inform future
interventional

studies

that

modulate

BDNF

pharmaceutical intervention.
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6.1 Overview of results
The primary goal of my studies was to investigate the biomarker potential
of BDNF in the context of AD. Because of the many different, sometimes
conflicting results in the literature regarding BDNF levels in serum and their
relationship to AD pathology, there was a need to clarify this issue in order to
move the field forward. This is especially important in light of a recent clinical
Phase I trial focused on replacing BDNF levels in the brain of patients with AD
using viral vectors (Tuszynski 2017, Tuszynski et al. 2017). I hypothesized that
BDNF fluctuates with disease course with high levels of BDNF in early stages of
the disease course and low levels of BDNF in late stages of disease course. In
order to examine this hypothesis, I utilized three different systems: A) post
mortem brain tissue and blood, B) an aged rat model with and without LC
degeneration, and C) blood, neuropsychological scores, and neuroimaging
measures from healthy older adults. Each of these models contributed
significantly to the overall goals of my thesis.
In Chapter 3, I describe the results of the first aim of my dissertation
where I investigated whether serum BDNF levels were correlated with brain
BDNF levels and AD pathology using post mortem human samples. I found that
serum proBDNF levels were inversely related to hippocampal levels of total
BDNF (tBDNF) and proBDNF. I also identified subgroups of AD cases with high
pathology (High AD) and low pathology (Low AD). The Low AD subgroup had
lower amyloid and tau pathology than the High AD subgroup, as well as less
GFAP immunostaining. In addition, the Low AD subgroup had higher tBDNF
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levels compared to the control and High AD subgroups, indicating a
compensatory increase in BDNF to ameliorate neuropathology. I also discovered
that the high-affinity BDNF TrkB receptor was negatively correlated with both
amyloid and pTau staining in post mortem sections of the hippocampus. This
result underscores the disruption of the neuroprotective effects of BDNF by AD
pathology.
In Chapter 4, I sought to investigate whether BDNF levels were altered,
either in serum or brain tissue, with an inflammatory challenge in aged rats with
and without a selective degeneration of the LC-NE neurons. The rationale for
investigating the combination of LPS and LC-NE degeneration was that LC-NE
neurons degenerate early in the AD disease process and aged rats with LC-NE
degeneration may model older adults at the beginning stages of MCI and AD
{Ross, 2015 #550}. I found that an LPS challenge in aged rats resulted in
increased peripheral and hippocampal inflammation and decreased serum and
hippocampal BDNF levels after 4 hours. These acute effects were more severe
in rats with an LC-NE lesion, presumably due to the loss of anti-inflammatory
protection of NE. Protective effects of NE innervation against glial activation has
been shown by others in both AD mouse models and aged rats and mice by us
and others (Kalinin et al. 2006, Kalinin et al. 2007, Fortress et al. 2015). Seven
days after the LPS challenge, inflammation in serum and the hippocampus had
been resolved, but aged rats with an LC-NE lesion had increased serum BDNF
levels when compared with aged rats without an LC-NE lesion, suggesting a
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protective compensatory increase in peripheral BDNF in the LC-NE lesioned
group.
These two aims established that serum BDNF levels can reflect pathology
due to chronic AD neurodegeneration (Chapter 3) and can be sensitive to acute
challenges in aged rats (Chapter 4). These results indicate that serum BDNF
levels can reflect AD pathology and can be modified by acute neuropathological
insults, features that support the rationale of using serum BDNF levels as a
biomarker. My next goal was to test how sensitive serum BDNF levels are to
subtle changes in older adult neuropsychological performance and neuroimaging
measures.
In Chapter 5, I investigated whether serum BDNF levels could predict
changes in neuropsychological performance and neuroimaging measures in
cognitively normal older adults who completed two visits approximately 15
months apart. In this cohort, serum BDNF levels were higher in women than
men, memory scores declined in men over time, and executive function declined
in women over time. Although we did not find significant declines in DLPFC
thickness and hippocampal volume over time in our cohort, it was remarkable
that we found significant changes in white matter microstructure of the limbic
system even during this short 15-month interval. To address our main goal of
assessing

the

ability

of

serum

BDNF

levels

to

predict

changes

in

neuropsychological performance and neuroimaging measures, linear regression
models were used which controls for possible confounders: age, education, and
serum cytokine score. Although our models were not found to be statistically
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significant overall, we found marginally significant interactions between BDNF
and sex in predicting changes in hippocampal volume and limbic FA. This result
suggested that higher baseline BDNF levels were associated with greater
declines in hippocampal volume and limbic FA in men, but not in women. Results
from this aim overall support the rationale of further investigating how serum
BDNF levels reflect changes in white matter microstructure differently in women
and men using advance MRI modalities and longer time course in future studies.
In summary, my dissertation work demonstrates that serum BDNF levels are
related to the severity of AD pathology, inversely fluctuate with inflammation in an
aged rat model with LC-NE neurodegeneration, and have potential to predict
hippocampal and limbic white matter changes in cognitively normal older adults.

6.2 Measuring BDNF in Fluids
Several different peripheral fluid sources were considered for biomarker
analysis in this dissertation. Measuring BDNF in saliva samples was an attractive
objective considering the ease of obtaining saliva compared to obtaining blood or
CSF. However, Mandel et al. (2009) found that not every sample collected
contained both pro- and mature forms of BDNF, and BDNF in saliva was
considered to be too unreliable. In Chapter 3, we showed for the first time that
BDNF levels in post mortem CSF samples were not reliably detectable using a
commercially available ELISA from R&D Systems. Although we were able to
detect BDNF levels in the CSF more often in control samples compared to AD
samples, our findings highlight the difficulty of measuring and interpreting the
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significance of BDNF levels in CSF, which has also been pointed out previously
by others using pre mortem CSF (Blasko et al. 2006, Laske et al. 2006, Laske et
al. 2007, Jiao et al. 2016). BDNF measurement in plasma and whole blood was
also considered, but we ultimately decided to focus on BDNF levels in serum for
reasons described in Chapter 1 Section 1.6.1.

6.3 Brain and Serum BDNF
In Chapter 4, we found that serum BDNF levels positively correlated with
brain BDNF levels in our aged rat model, reproducing results from studies done
by others (Karege et al. 2002, Sartorius et al. 2009, Klein et al. 2011). In Chapter
3, we uniquely investigated the relationship between brain and serum BDNF
levels in human samples. A positive correlation between human brain and serum
BDNF levels was expected due to results found in other animal models (Karege
et al. 2002, Sartorius et al. 2009, Klein et al. 2011), due to several reports
relating blood BDNF to various psychiatric and neurological diseases (Carlino et
al. 2011, Yoshida 2012, Fernandes et al. 2015), and due to an interesting study
completed by Dawood et al. (2007) where BDNF levels in venous blood from the
jugular vein were higher than arterial blood from the brachial artery, suggesting
that BDNF levels in venous blood were supplemented by BDNF produced in the
brain. We used two of the most commonly used commercial ELISA to measure
total BDNF levels, one from R&D Systems and one from Promega. As discussed
in Chapter 2 section 2.4.1, the R&D BDNF ELISA kit was not appropriate to use
on human brain samples due to tissue matrix interference, and the Promega
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BDNF ELISA kit was used to quantify brain BDNF levels. Although we did not
find a correlation between serum and brain BDNF levels in human samples, this
may be due to the fact that we used the R&D ELISA kit to measure serum BDNF
levels and the Promega ELISA kit to measure brain BDNF levels. We did find a
positive correlation between serum total BDNF levels and hippocampal staining
of HLA-DR, suggesting that peripheral BDNF levels increased to compensate for
increasing neuroinflammation. To the best of my knowledge, this is the first study
to investigate directly the relationship between brain and serum BDNF levels in
humans, and our results warrant further replication in larger and more diverse
sample sizes. One of the possible reasons this study may have not been done
before is due to the limited availability of post mortem human brain and fluid
samples, and increased support to human brain banks will make studies like
these more possible.
We recognize that BDNF levels measured from ELISA represent total
BDNF composed of both proBDNF and mBDNF, and interpretation of total BDNF
may be convoluted by the disease prejudicially altering levels of either proBDNF
or mBDNF. The importance of carefully interpreting results from BDNF ELISA is
further highlighted in Chapter 2 Section 2.4.1 where I show that high levels of
proBDNF levels in biological samples can influence quantification of BDNF using
the R&D BDNF ELISA kit such that one can overestimate the amount of mature
BDNF in a sample if they adopt the assumption that the kit only measures mature
BDNF. Accordingly, we referred to BDNF levels measured by ELISA as total
BDNF, made up of both mature and proBDNF. In Chapter 3, we further
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investigated the different forms of BDNF using western blots and found a
negative correlation between serum proBDNF levels and hippocampal total
BDNF levels as well as hippocampal proBDNF levels although we had
hypothesized a positive correlation between brain and serum mature BDNF
levels. Possible reasons for this counterintuitive result are discussed in further
detail in Chapter 3. The fact that we found a) serum BDNF levels positively
correlated with brain BDNF levels in rats but not in humans and b) human serum
proBDNF levels negatively correlated with brain BDNF levels, further
underscores the difficulty of using serum BDNF levels as a clinical biomarker
without consideration of both the forms of BDNF: proBDNF and mBDNF. A
recent report indicated that serum BDNF isoforms may also differ across ethnic
backgrounds (Hashimoto 2016). These results warrant further investigation
specifically into the differences between mature and proBDNF across
demographic factors and clinical status. In addition, quantification of factors that
process proBDNF into mature BDNF and/or facilitate the production or clearance
of mature and proBDNF may further facilitate interpretation of how the disease
course affects total BDNF levels. Innovations into multiplex assays that can
accurately measure BDNF isoforms and relevant modifier molecules in small
amounts of samples would greatly facilitate progress in this area. Although
several multiplex systems currently exist, it is unclear whether these systems are
tested for use in human brain samples, and validation experiments similar to the
ones completed in Chapter 2 on the R&D BDNF ELISA kits will be important for
the future of biomarker studies with human brain samples.
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6.4 BDNF and Inflammation
In addition to considering the pro- versus mature forms of BDNF, the
strong antagonistic relationship between BDNF and inflammation should also be
considered when interpreting BDNF measurements in a clinical setting. In
Chapter 3, we found that staining for activated microglia increased with
increasing AD pathology (amyloid and pTau) and that the AD case with the
highest activated microglia staining had the lowest levels of BDNF, suggesting
that BDNF plays a protective role against pTau and amyloid accumulation.
Furthermore, in Chapter 4, we found that higher hippocampal IL-1β levels and
lower BDNF levels in aged rats were correlated with increased activation of
astrocytes in the hippocampus and that aged rats with the highest microglial and
astroglial activation in the hippocampus had the poorest cognitive performance.
These findings have been supported by others, showing a strong correlation
between neuroinflammation and cognitive performance, both with aging and in
AD (Bettcher and Kramer 2014). In Chapter 5, we analyzed the relationship
between serum BDNF levels and changes in neuropsychological performance
and neuroimaging measures while controlling for basal inflammation status
assessed by cytokine levels in serum. In this chapter, our linear regression
models did not indicate that inflammation was an important predictor for changes
in neuropsychological scores or neuroimaging measures. However, this was
most likely due to our use of healthy older adults.
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6.5 BDNF as a Biomarker
A summary of major questions and answers addressed in my dissertation
is presented in Figure 6-1. In Chapter 3, I predicted that inflammation would be
higher and serum BDNF levels would be lower in AD compared to control. In the
brain, we found increased neuroinflammation and decreased BDNF levels in the
High AD subgroup compared to control. In serum, however, we did not find a
significant difference in serum cytokines and BDNF levels between AD and
control. This finding in serum most likely is due to the high variability in cytokines
measurements in post mortem samples. In addition, others have shown that
BDNF levels deteriorate in blood even when stored at -80oC (Trajkovska et al.
2007, Zuccato et al. 2011), and this may have influenced our findings. We did
find a slight decrease in mean serum total BDNF levels in the High AD subgroup
compared to control, but this was found to be not statistically significant, possibly
due to our small sample size. Interestingly, we found that serum proBDNF levels
were increased in AD compared to control which complements several studies
that found increased serum total BDNF levels in AD compared to control (Laske
et al. 2006, Angelucci et al. 2010, Konukoglu et al. 2012, Sonali et al. 2013). We
additionally found that serum proBDNF levels were negatively correlated with
BDNF levels in brain tissue, suggesting either a compensatory increase in serum
proBDNF to replace depleting brain BDNF or disease-related interference of
processing of proBDNF to mBDNF. Although the cleavage of proBDNF to the
mature form has not been examined in AD patients previously, to our knowledge,
our group recently showed a deficient cleavage of proNGF to its mature form in
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patients with Down syndrome and AD, suggesting that the cleavage process of
neurotrophins may be affected by the AD pathology (Iulita et al. 2014).
Interestingly, we found an increase of brain BDNF levels in the Low AD
subgroup compared to both the High AD subgroup and control, suggesting an
upregulation of brain BDNF to theoretically compensate and counteract the early
effects of the pathology. Increased BDNF levels in serum were previously
reported in early AD compared to control and late AD (Laske et al. 2006,
Konukoglu et al. 2012), and increased total BDNF and proBDNF levels were
reported in the hippocampus of AD compared to control (Durany et al. 2000, Lim
et al. 2015). Our results support the hypothesis first proposed by Laske et al.
(2006) that BDNF has a dynamic relationship with disease course characterized
by an early compensatory increase and subsequent reduction of BDNF levels as
the disease progresses. These results in human samples are further supported
by our findings from Chapter 4 where after an inflammatory challenge causes an
immediate drop in serum BDNF in aged rats, a compensatory increase in serum
BDNF is found in aged rats with an AD-related neurodegeneration. These results
are depicted in the proposed model in Figure 6-1.
In Chapter 5, we tested whether serum BDNF levels can predict changes
in neuropsychological performance and neuroimaging measures in cognitively
healthy older adults while controlling for inflammation. In this preliminary
investigation with a modest sample size, we found significant differences
between women and men in their baseline serum BDNF levels and in the
progression of memory and executive function performance over the course of
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15 months. In addition, high serum BDNF levels in men were associated with
steeper declines in hippocampal volume and white matter microstructure of the
limbic system. Although these relationships were marginally significant due to our
small and unbalanced sample size, this study lays the foundation for follow up
studies to investigate further how serum BDNF levels predict changes over time
in older women and men especially in more at-risk populations such as patients
with MCI or AD.
Overall, our results indicate that serum BDNF is sensitive to AD pathology
and has some predictive ability for changes related to AD pathology; however,
our results do not assess whether changes in BDNF are specific to AD pathology
since we did not include other neurodegenerative pathologies (e.g., PD or HD) in
our comparison. Changes in serum BDNF may be due to changes related to AD
pathology, as supported by this dissertation, or due to changes in diet, exercise,
infection, or other neuropsychiatric disorders. Nevertheless, serum BDNF levels
reflect clinically-relevant changes in older adults and should be considered to be
included in routine blood workup in a clinical setting. Ideally, dramatic changes in
serum BDNF levels in older adults will prompt the clinician to ask relevant
questions about lifestyle changes or neuropsychological changes to determine
whether additional testing or intervention is needed.
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Figure 6-1

Biomarker Abnormality

High

Low

Aim 3

Aim 2

Aim 1

Longitudinal

Experimental

Cross-sectional

Aβ Levels
pTau Levels
Brain Structure
Memory Function
Clinical Function
Inflammation
BDNF Levels

Detection
Threshold

Cognitively Healthy

Cognitively Impaired

AD

Can BDNF levels
predict changes in
neuropsychological
performance and
neuroimaging
measures in healthy
older adults?

How do BDNF
levels fluctuate with
inflammation in an
aged rat model?

What is the
relationship
between serum
BDNF levels, brain
BDNF levels, and
AD pathology?

Higher BDNF levels
marginally predict
steeper declines in
the hippocampus and
in white mater
microstructure of the
limbic system in
older men and not
older women over 15
months

BDNF has an
inverse relationship
with inflammation,
and a peripheral
compensatory
increase of BDNF
occurs after an
acute inflammatory
challenge is
resolved

The High AD
subgroup had
higher
neuroinflammation
and lower brain
BDNF levels but
similar serum BDNF
levels compared to
control

Figure 6-1. Framework of major dissertation questions and answers.
Answers to major dissertation questions based on aims are added to the model
and questions presented in Figure 1-5. Only results from Aim 1 did not support
the hypothetical changes of BDNF and inflammation plotted in the model. Results
from Aim 1 indicate that the High AD subgroup had higher neuroinflammation
and lower brain BDNF levels compared to control but equivalent serum tBDNF
levels and cytokine levels compared to control. This is contrary to our expected
finding of high inflammation and low BDNF in serum in AD compared to
cognitively healthy control.
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Figure 6-2

6.6 Future Directions
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sources would theoretically better reflect
neurocognitive
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or

Exosomes

neuropathological
are

extra-cellular

microvesicles found in biological fluids that
are

produced

endocytic

by

pathway.

cells

through

Using

a

the
novel

technique developed by Dr. Granholm’s
collaborator, Dr. Ed Goetzl, we were able
to isolate specific exosomes of neuronal
origin from plasma, referred to as Neuron- Figure 6-2. Representative BDNF
western blot on human serum
Derived Exosomes or NDEs (Fiandaca et and neuron-derived exosomes.
Two proteins with higher molecular
al. 2015, Goetzl et al. 2015, Hamlett et al. mass (~50 kDa, ~100 kDa) and a
doublet (>25 kDa) are seen in 20 μg
2018). The Granholm laboratory has of neuronal-derived exosome but
not in 20 μg of human serum after
utilized this method to track AD probing with anti-BDNF antibody
(Alomone, ANT-010). The identity of
biomarkers in NDEs in individuals with the higher molecular weight proteins
in exosomes may be dimers or
Down syndrome (DS), a condition with a tetramers of BDNF species.
high incidence of early-onset AD (Hamlett
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et al. 2018). Considering that serum BDNF may reflect non-neuronal BDNF,
BDNF levels in NDEs may better reflect BDNF levels in the human brain and
better correlate with neuropathological changes. In a preliminary study, I purified
NDEs from older adult blood samples and performed a western blot analysis of
BDNF in serum and exosomes. These studies show remarkable differences in
BDNF species, with two higher molecular weight bands (~50 kDa and ~100 kDa)
found in exosomes but not in serum (Figure 6-2). These bands may represent
dimers or higher order organization of proBDNF, which are normally digested by
proteases present in serum. These preliminary results suggest that BDNF
composition in NDEs is more complex than those found in serum and is
worthwhile investigating further to understand the function of BDNF in NDEs and
their possible biomarker potential, since the neuronal origin of the purified NDEs
may be better predictors of what is going on in the brain.

6.7. BDNF as a neuroprotective therapy for AD
In addition to having potential as a biomarker for AD, several investigators
have suggested that elevating BDNF levels in the brain may have value as a
preventative or interventional drug for AD patients. For example, Alvarez et al.
(2016) recently demonstrated that a combination treatment consisting of
Cerebrolysin and Donepezil gave rise to synergistic increases in serum BDNF
levels in patients with AD. The combination therapy was more effective than each
drug alone, and BDNF serum levels were investigated at weeks 16 and 28. In
addition, this group showed an increased BDNF response in apolipoprotein E
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epsilon-4 allele carriers, and higher BDNF levels were also associated with better
cognitive improvements in apolipoprotein E epsilon-4 allele patients treated with
Cerebrolysin and the combined therapy. There are other drugs with proven
positive effects on serum BDNF levels, including memantine (Amidfar et al. 2017)
and caffeine (Lao‐Peregrín et al. 2017), suggesting that drug administration or
intake of caffeine can increase BDNF systems in the brain and lead to protection
against AD pathology. Another way to increase BDNF levels and/or expression is
via exercise. Multiple studies, both from others and from our group, have shown
that moderate levels of exercise increase BDNF levels which, in turn, increase
cognitive performance (Rasmussen et al. 2009, Lafenetre et al. 2010, Heijnen et
al. 2015, Hakansson et al. 2017). Finally, a more extreme way to significantly
increase BDNF expression in the brain is to administer intracranial AAV-BDNF
vectors. This is now in Phase I clinical trials lead by Dr. Mark Tusczynski at
UCSD (Tuszynski 2017, Tuszynski et al. 2017). Gene therapy experiments will
finally confirm whether BDNF plays a major role in protecting the brain from AD
pathology. These kinds of findings could motivate the population to engage in life
style changes that may prove to be protective for dementia.

6.8 Conclusion
This dissertation led to significant observations of the biomarker potential
of serum BDNF in post mortem human brain samples, in aged rat models with
neurodegeneration, and in a longitudinal study on older adults. Through the
experiments conducted in this dissertation, I have had the unique opportunity to
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collaborate with experts across disciplines and learn about the strengths and
challenges

of

techniques

used

in

neuropathology,

neuroimaging,

and

neuropsychology. In addition to developing a professional network at MUSC, my
work and training has allowed me to travel to Boston, Chicago, Denver, and D.C.,
where I received additional training and guidance from leaders in the aging and
AD research field including Drs. Cynthia Lemere, Dean Hartley, and Sangram
Sisodia. I do not doubt that the skills and connections I have developed through
this

dissertation

will

guide

my

career

neuropathologist.
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as

a

physician-scientist
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APPENDIX 1. BDNF LEVELS IN AD HUMAN SERUM SAMPLES
AD = Alzheimer's disease, Con = Control, ELISA
immunosorbent assay, MCI = Mild Cognitive Impairment

=

Enzyme-linked

Appendix 1. Studies on serum BDNF levels in AD
Result

Author

Year

Origin

Sample Method
Size

Decreased
BDNF
levels in
AD
compared
to Con

Borba et
al.

2016

Brazil

13 AD ELISA kit (R&D AD and MCI
10 MCI Systems)
had lower
10 Con
BDNF levels
than Con

Curto et
al.

2014

Italy

30 AD Emax
16 Con ImmunoAssay
System
(Promega)

Forlenza
et al.

2010

Brazil

30 AD ELISA (DuoSet AD and MCI
71 MCI R&D Systems) had similar
59 Con
BDNF levels
that were
lower than
Con

Forlenza
et al.

2015b Brazil

26 AD ELISA (DuoSet AD and MCI
62 MCI R&D Systems) had lower
46 Con
BDNF levels
than Con
and MCI with
lower BDNF
levels
progressed
to AD

Gezen-Ak 2013
et al.

Turkey

76 AD ELISA
30 MCI (ChemiKineTM,
50 Con CYT306,
Millipore)
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Notes

AD had
lower BDNF
levels than
Con

Early and
late-onset
AD had
lower BDNF
levels
compared to
Con and
MCI

Appendix 1. Studies on serum BDNF levels in AD
Result

Author

Year

Origin

Sample Method
Size

Jiao et al. 2016

China

44 AD ELISA (Abexa) AD had
54 Con
lower BDNF
levels than
age- and
sex-matched
Con

Laske et
al.

2007

Germany 27 AD ELISA (R&D
28 Con Systems)

AD had
lower BDNF
levels
compared to
Con in
elderly

Laske et
al.

2011

Germany 40 AD

ELISA (R&D
Systems)

AD patients
with fast
cognitive
decline
(n=12) had
lower BDNF
levels than
those with
slow
cognitive
decline
(n=28)

Laske et
al.

2006b Germany 28 AD ELISA (R&D
10 Con Systems)

AD had
lower BDNF
levels than
Con

Lee et al.

2009

AD and MCI
had similar
BDNF levels
which was
lower than
Con

Korea

47 AD ELISA (Emax
41 MCI Promega)
39 Con
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Notes

Appendix 1. Studies on serum BDNF levels in AD
Result

Author

Year

Origin

Sample Method
Size

Leyhe et
al.

2008

Germany 19 AD ELISA (R&D
20 Con Systems)

AD had
lower BDNF
levels than
Con which
was rectified
by 15
months of
donepezil

Leyhe et
al.

2009

Germany 27 AD ELISA (R&D
15 Con Systems)

AD had
lower BDNF
levels than
Con which
was rectified
by 6 weeks
of lithium
treatment

Liu et al.

2015

China

110
AD
120
Con

Raybio human AD had
BDNF ELISA
lower BDNF
levels than
Con in
elderly Han
Chinese

Ventriglia
et al.

2013

Italy

266
AD
169
Con

ELISA
AD had
(Quantikine
lower BDNF
R&D Systems) levels than
Con

Wang et
al.

2015

China

64 AD ELISA (R&D
68 MCI Systems)
90 Con
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Notes

AD and MCI
had lower
BDNF levels
than Con
and MCI with
lower BDNF
levels
progressed
to AD

Appendix 1. Studies on serum BDNF levels in AD
Result

Author

Year

Origin

Sample Method
Size

Weinstein 2014
et al.

USA

2131
Con

Yasutake
et al.

Japan

60 AD ELISA
AD had
33 Con (Quantikine
lower BDNF
R&D Systems) levels than
Con and
vascular
dementia

Italy

89 AD ELISA (R&D
54 MCI Systems)
27 Con

AD and MCI
had higher
BDNF levels
compared to
Con

Turkey

12 AD ELISA (Emax
20 Con Promega)

Early AD
had higher
BDNF level
than Con
and late AD

2006

Increased Angelucci 2010
BDNF
et al.
levels in
AD
compared
to Con
Konukoglu 2012
et al.

ELISA (R&D
Systems)

Laske et
al.

2006a Germany 15 AD ELISA (R&D
10 Con Systems)

Sonali et
al.

2013

India

Notes
Higher
BDNF in
Con
associated
with lower
risk to
develop AD
or dementia

Early AD
had higher
BDNF level
than Con
and late AD

63 AD Raybio human AD and MCI
15 MCI BDNF ELISA
had higher
63 Con
BDNF levels
compared to
Con
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Appendix 1. Studies on serum BDNF levels in AD
Result

Author

Year

No
Alvarez et 2014
difference al.
in BDNF
levels
between
AD and
Con
Konukoglu 2012
et al.

Origin

Sample Method
Size

Notes

Spain

252
ELISA (R&D
AD 48 Systems)
MCI 62
Con

BDNF levels
were not
different
between AD,
MCI and
Con

Turkey

10 AD ELISA (Emax
20 Con Promega)

Late AD had
similar
BDNF levels
to Con but
both were
lower than
early AD

Laske et
al.

2006a Germany 15 AD ELISA (R&D
10 Con Systems)

Late AD had
similar
BDNF levels
to Con but
both were
lower than
early AD

O'Bryant
et al.

2009

USA

98 AD Multi-Analyte
98 Con Profile (Rule
Based
Medicine)

BDNF levels
were not
different
between AD
and Con

O'Bryant
et al.

2011

USA

198
AD
201
Con

Multi-Analyte
Profile (Rule
Based
Medicine)

BDNF levels
were not
different
between AD
and Con

Woolley et 2012
al.

USA

34 AD ELISA (R&D
30 MCI Systems)
38 Con

BDNF levels
were not
different
between AD,
Con, and
MCI
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APPENDIX 2. BDNF LEVELS IN AD HUMAN BRAIN SAMPLES
AD = Alzheimer's disease, BA = Brodmann Area, BF = Basal forebrain, BG =
Basal Ganglia, CBL = Cerebellar cortex, CG = Cingulate gyrus, Con = Control,
DG = Dentate gyrus, ELISA = Enzyme-linked immunosorbent assay, ENT =
Entorhinal cortex, FC = Frontal cortex, HIP = Hippocampus, IHC =
Immunohistochemistry, mBDNF = mature BDNF, MC = Motor Cortex, MCI = Mild
Cognitive Impairment, OC = Occipital cortex, PC = Parietal cortex, PUT =
Putamen, TC = Temporal cortex, THL = Thalamus, WB = Western Blot
Appendix 2. Studies on brain BDNF levels in AD
Result

Author Year Region

Method

Notes

HIP (9 AD 8 Con)
TC (9 AD 8 Con)

IHC
(Amgen)

AD had lower
BDNFimmunopositive cell
bodies in the HIP
CA1 region and TC

FC (4 AD 4 Con)
HIP (6 AD 4 Con)

IHC
AD had reduced
(sc N-20) BDNF
immunoreactivity in
FC and HIP
neurons

Hock et 2000 HIP (9AD 9 Con)
al.
PC (8 AD 5 Con)

ELISA
AD had lower
(Emax
levels of BDNF in
Promega) HIP and PC but not
FC or CBL

Jiao et
al.

2016 PC (12 AD 12 Con)

WB
AD had ~50%
(ab72439) lower BDNF levels
in PC compared to
ELISA
age- and sex(Abexa) matched controls

Lee et
al.

2005 TC (57 AD 19 Con)

ELISA
AD had ~33%
(R&D
lower BDNF levels
MAB848) in TC but not in FC
or CBL

Decrease Connor 1997
d BDNF
et al.
levels in
AD
compared
to Con
Ferrer
1999
et al.

Lim
al.

et 2015 HIP (10 AD 10 Con)
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WB
(GeneCo
poeia,
and sc N20)

AD had 6-fold lower
mBDNF and 16fold higher
proBDNF levels
than Con

Appendix 2. Studies on brain BDNF levels in AD
Result

Author Year Region

Method

Michals 2003 PC (7 AD 8 Con)
ki et al.

WB
AD had 40% lower
(sc N-20) pro-BDNF levels in
PC

Narisaw 1996 DG (10 AD 10 Con) ELISA
a-Saito
ENT (10 AD 10 Con)
et al.
MC (10 AD 10 Con)
Peng et 2005 PC (17 AD 20 Con
al.
17 MCI)

Increased Durany
BDNF
et al.
levels in
AD
compared
to Con

Lim et
al.

No
Durany
difference et al.
in BDNF
levels
between
AD and
Con

Notes

AD had lower
BDNF level in ENT
but not MC or DG

WB
AD and MCI had
(sc N-20) lower proBDNF and
mature BDNF
levels in PC
compared to Con

2000 HIP (9 AD 9 Con)
PC (12 AD 9 Con)

ELISA
Higher BDNF
(Emax
concentration found
Promega) in AD compared to
Con in HIP and PC
but not CG, FC,
OC, PUT, TC,
THAL

2015 HIP (10 AD 10 Con)

WB
(Gene
Copoeia,
and sc N20)

2000 CG (8 AD 8 Con)
FC (12 AD 12 Con)
OC (9 AD 9 Con)
PUT (8 AD 8 Con)
TC (13 AD 13 Con)
THL (6 AD 6 Con)

ELISA
Higher BDNF
(Emax
concentration found
Promega) in AD compared to
Con in HIP and PC
but not CG, FC,
OC, PUT, TC,
THAL

Hock et 2000 CBL (7 AD 5 Con)
al.
FC (19AD 9 Con)
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AD had 6-fold lower
mBDNF and 16fold higher
proBDNF levels
than Con

ELISA
AD had lower
(Emax
levels of BDNF in
Promega) HIP and PC but not
FC or CBL

Appendix 2. Studies on brain BDNF levels in AD
Result

Author Year Region

Method

Notes

Kao et
al.

2012 HIP (2 AD 1 Con)

IHC
BDNF
(sc N-20) immunoreactivity in
the HIP CA1 region
was similar
between the three
groups: 1) control,
2) early AD with no
cognitive deficit,
and 3) early AD
with mild cognitive
deficit

Lee et
al.

2005 CBL (54 AD 16 Con) ELISA
AD had ~33%
FC (50 AD 13 Con) (R&D
lower BDNF levels
MAB848) in TC but not in FC
or CBL

Michals 2015 PC (28 AD 22 Con)
ki et al.

ELISA
(DuoSet
R&D
Systems)

BDNF levels were
similar between
four groups all
aged 90 years or
older: 1) Con, 2)
Con w/ dementia,
3) AD w/o
dementia, and 4)
AD w/ dementia

Murer et 1999 HIP (3 AD 4 Con)
al.
BG (3 AD 4 Con)
BF (3 AD 4 Con)

IHC

BDNF staining
pattern and labeling
intensity was
similar between AD
and Con
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